<author><surname>Buning</surname> <given-names>H</given-names> </author><author><surname>Perabo</surname> <given-names>L</given-names> </author><author><surname>Coutelle</surname> <given-names>O</given-names> </author><author><surname>Quadt-Humme</surname> <given-names>S</given-names> </author><author><surname>Hallek</surname> <given-names>M</given-names> </author><title>Recent developments in adeno-associated virus vector technology</title><source>J Gene Med</source><year>2008</year><volume>10</volume><fpage>717</fpage><lpage>733</lpage>
<author><surname>Wu</surname> <given-names>Z</given-names> </author><author><surname>Asokan</surname> <given-names>A</given-names> </author><author><surname>Samulski</surname> <given-names>RJ</given-names> </author><title>Adeno-associated virus serotypes: vector toolkit for human gene therapy</title><source>Mol Ther</source><year>2006</year><volume>14</volume><fpage>316</fpage><lpage>327</lpage>
<author><surname>Lebherz</surname> <given-names>C</given-names> </author><author><surname>Maguire</surname> <given-names>A</given-names> </author><author><surname>Tang</surname> <given-names>W</given-names> </author><author><surname>Bennett</surname> <given-names>J</given-names> </author><author><surname>Wilson</surname> <given-names>JM</given-names> </author><title>Novel AAV serotypes for improved ocular gene transfer</title><source>J Gene Med</source><year>2008</year><volume>10</volume><fpage>375</fpage><lpage>382</lpage>
<author><surname>Schmidt</surname> <given-names>M</given-names> </author><author><surname>Voutetakis</surname> <given-names>A</given-names> </author><author><surname>Afione</surname> <given-names>S</given-names> </author><title>Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity</title><source>J Virol</source><year>2008</year><volume>82</volume><fpage>1399</fpage><lpage>1406</lpage>
<author><surname>Blankinship</surname> <given-names>MJ</given-names> </author><author><surname>Gregorevic</surname> <given-names>P</given-names> </author><author><surname>Chamberlain</surname> <given-names>JS</given-names> </author><title>Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors</title><source>Mol Ther</source><year>2006</year><volume>13</volume><fpage>241</fpage><lpage>249</lpage>
<author><surname>Wang</surname> <given-names>L</given-names> </author><author><surname>Herzog</surname> <given-names>RW</given-names> </author><title>AAV-mediated gene transfer for treatment of hemophilia</title><source>Curr Gene Ther</source><year>2005</year><volume>5</volume><fpage>349</fpage><lpage>360</lpage>
<author><surname>Buch</surname> <given-names>PK</given-names> </author><author><surname>Bainbridge</surname> <given-names>JW</given-names> </author><author><surname>Ali</surname> <given-names>RR</given-names> </author><title>AAV-mediated gene therapy for retinal disorders: from mouse to man</title><source>Gene Ther</source><year>2008</year><volume>15</volume><fpage>849</fpage><lpage>857</lpage>
<author><surname>Moss</surname> <given-names>RB</given-names> </author><author><surname>Milla</surname> <given-names>C</given-names> </author><author><surname>Colombo</surname> <given-names>J</given-names> </author><title>Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial</title><source>Hum Gene Ther</source><year>2007</year><volume>18</volume><fpage>726</fpage><lpage>732</lpage>
<author><surname>Manno</surname> <given-names>CS</given-names> </author><author><surname>Pierce</surname> <given-names>GF</given-names> </author><author><surname>Arruda</surname> <given-names>VR</given-names> </author><title>Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response</title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>342</fpage><lpage>347</lpage>
<author><surname>McPhee</surname> <given-names>SW</given-names> </author><author><surname>Janson</surname> <given-names>CG</given-names> </author><author><surname>Li</surname> <given-names>C</given-names> </author><title>Immune responses to AAV in a phase I study for Canavan disease</title><source>J Gene Med</source><year>2006</year><volume>8</volume><fpage>577</fpage><lpage>588</lpage>
<author><surname>Mingozzi</surname> <given-names>F</given-names> </author><author><surname>High</surname> <given-names>KA</given-names> </author><title>Immune responses to AAV in clinical trials</title><source>Curr Gene Ther</source><year>2007</year><volume>7</volume><fpage>316</fpage><lpage>324</lpage>
<author><surname>Erles</surname> <given-names>K</given-names> </author><author><surname>Sebokova</surname> <given-names>P</given-names> </author><author><surname>Schlehofer</surname> <given-names>JR</given-names> </author><title>Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)</title><source>J Med Virol</source><year>1999</year><volume>59</volume><fpage>406</fpage><lpage>411</lpage>
<author><surname>Halbert</surname> <given-names>CL</given-names> </author><author><surname>Miller</surname> <given-names>AD</given-names> </author><author><surname>McNamara</surname> <given-names>S</given-names> </author><title>Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors</title><source>Hum Gene Ther</source><year>2006</year><volume>17</volume><fpage>440</fpage><lpage>447</lpage>
<author><surname>Mingozzi</surname> <given-names>F</given-names> </author><author><surname>Maus</surname> <given-names>MV</given-names> </author><author><surname>Hui</surname> <given-names>DJ</given-names> </author><title>CD8(+) T-cell responses to adeno-associated virus capsid in humans</title><source>Nat Med</source><year>2007</year><volume>13</volume><fpage>419</fpage><lpage>422</lpage>
<author><surname>Zaiss</surname> <given-names>AK</given-names> </author><author><surname>Muruve</surname> <given-names>DA</given-names> </author><title>Immune responses to adeno-associated virus vectors</title><source>Curr Gene Ther</source><year>2005</year><volume>5</volume><fpage>323</fpage><lpage>331</lpage>
<author><surname>Wang</surname> <given-names>Z</given-names> </author><author><surname>Allen</surname> <given-names>JM</given-names> </author><author><surname>Riddell</surname> <given-names>SR</given-names> </author><title>Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy</title><source>Hum Gene Ther</source><year>2007</year><volume>18</volume><fpage>18</fpage><lpage>26</lpage>
<author><surname>Yuasa</surname> <given-names>K</given-names> </author><author><surname>Yoshimura</surname> <given-names>M</given-names> </author><author><surname>Urasawa</surname> <given-names>N</given-names> </author><title>Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products</title><source>Gene Ther</source><year>2007</year><volume>14</volume><fpage>1249</fpage><lpage>1260</lpage>
<author><surname>Cao</surname> <given-names>O</given-names> </author><author><surname>Dobrzynski</surname> <given-names>E</given-names> </author><author><surname>Wang</surname> <given-names>L</given-names> </author><title>Induction and role of regulatory CD4+ CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer</title><source>Blood</source><year>2007</year><volume>110</volume><fpage>1132</fpage><lpage>1140</lpage>
<author><surname>Riviere</surname> <given-names>C</given-names> </author><author><surname>Danos</surname> <given-names>O</given-names> </author><author><surname>Douar</surname> <given-names>AM</given-names> </author><title>Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice</title><source>Gene Ther</source><year>2006</year><volume>13</volume><fpage>1300</fpage><lpage>1308</lpage>
<author><surname>Streilein</surname> <given-names>JW</given-names> </author><title>Ocular immune privilege: therapeutic opportunities from an experiment of nature</title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>879</fpage><lpage>889</lpage>
<author><surname>Yamagami</surname> <given-names>S</given-names> </author><author><surname>Kawashima</surname> <given-names>H</given-names> </author><author><surname>Tsuru</surname> <given-names>T</given-names> </author><title>Role of Fas&#8211;Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants</title><source>Transplantation</source><year>1997</year><volume>64</volume><fpage>1107</fpage><lpage>1111</lpage>
<author><surname>Jorgensen</surname> <given-names>A</given-names> </author><author><surname>Wiencke</surname> <given-names>AK</given-names> </author><author><surname>la</surname> <given-names>CM</given-names> </author><title>Human retinal pigment epithelial cell-induced apoptosis in activated T cells</title><source>Invest Ophthalmol Vis Sci</source><year>1998</year><volume>39</volume><fpage>1590</fpage><lpage>1599</lpage>
<author><surname>Camelo</surname> <given-names>S</given-names> </author><author><surname>Kezic</surname> <given-names>J</given-names> </author><author><surname>McMenamin</surname> <given-names>PG</given-names> </author><title>Anterior chamber-associated immune deviation: a review of the anatomical evidence for the afferent arm of this unusual experimental model of ocular immune responses</title><source>Clin Experiment Ophthalmol</source><year>2005</year><volume>33</volume><fpage>426</fpage><lpage>432</lpage>
<author><surname>Sonoda</surname> <given-names>KH</given-names> </author><author><surname>Sakamoto</surname> <given-names>T</given-names> </author><author><surname>Qiao</surname> <given-names>H</given-names> </author><title>The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation</title><source>Immunology</source><year>2005</year><volume>116</volume><fpage>390</fpage><lpage>399</lpage>
<author><surname>Schlichtenbrede</surname> <given-names>FC</given-names> </author><author><surname>da</surname> <given-names>CL</given-names> </author><author><surname>Stephens</surname> <given-names>C</given-names> </author><title>Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy</title><source>J Gene Med</source><year>2003</year><volume>5</volume><fpage>757</fpage><lpage>764</lpage>
<author><surname>Kjellstrom</surname> <given-names>S</given-names> </author><author><surname>Bush</surname> <given-names>RA</given-names> </author><author><surname>Zeng</surname> <given-names>Y</given-names> </author><author><surname>Takada</surname> <given-names>Y</given-names> </author><author><surname>Sieving</surname> <given-names>PA</given-names> </author><title>Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration</title><source>Invest Ophthalmol Vis Sci</source><year>2007</year><volume>48</volume><fpage>3837</fpage><lpage>3845</lpage>
<author><surname>Bainbridge</surname> <given-names>JW</given-names> </author><author><surname>Smith</surname> <given-names>AJ</given-names> </author><author><surname>Barker</surname> <given-names>SS</given-names> </author><title>Effect of gene therapy on visual function in Leber's congenital amaurosis</title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2231</fpage><lpage>2239</lpage>
<author><surname>Maguire</surname> <given-names>AM</given-names> </author><author><surname>Simonelli</surname> <given-names>F</given-names> </author><author><surname>Pierce</surname> <given-names>EA</given-names> </author><title>Safety and efficacy of gene transfer for Leber's congenital amaurosis</title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2240</fpage><lpage>2248</lpage>
<author><surname>Pang</surname> <given-names>JJ</given-names> </author><author><surname>Chang</surname> <given-names>B</given-names> </author><author><surname>Hawes</surname> <given-names>NL</given-names> </author><title>Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA)</title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>152</fpage><lpage>162</lpage>
<author><surname>Mistry</surname> <given-names>AR</given-names> </author><author><surname>De</surname> <given-names>AM</given-names> </author><author><surname>Feudner</surname> <given-names>E</given-names> </author><author><surname>Ali</surname> <given-names>RR</given-names> </author><author><surname>Thrasher</surname> <given-names>AJ</given-names> </author><title>High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors</title><source>Methods Mol Med</source><year>2002</year><volume>69</volume><fpage>445</fpage><lpage>460</lpage>
<author><surname>Rogers</surname> <given-names>WO</given-names> </author><author><surname>Weaver</surname> <given-names>CT</given-names> </author><author><surname>Kraus</surname> <given-names>LA</given-names> </author><title>Visualization of antigen-specific T cell activation and cytokine expression in vivo</title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>649</fpage><lpage>657</lpage>
<author><surname>Leonard</surname> <given-names>WJ</given-names> </author><author><surname>Kronke</surname> <given-names>M</given-names> </author><author><surname>Peffer</surname> <given-names>NJ</given-names> </author><author><surname>Depper</surname> <given-names>JM</given-names> </author><author><surname>Greene</surname> <given-names>WC</given-names> </author><title>Interleukin 2 receptor gene expression in normal human T lymphocytes</title><source>Proc Natl Acad Sci USA</source><year>1985</year><volume>82</volume><fpage>6281</fpage><lpage>6285</lpage>
<author><surname>Kim</surname> <given-names>HP</given-names> </author><author><surname>Imbert</surname> <given-names>J</given-names> </author><author><surname>Leonard</surname> <given-names>WJ</given-names> </author><title>Both integrated and differential regulation of components of the IL-2/IL-2 receptor system</title><source>Cytokine Growth Factor Rev</source><year>2006</year><volume>17</volume><fpage>349</fpage><lpage>366</lpage>
<author><surname>Sancho</surname> <given-names>D</given-names> </author><author><surname>Gomez</surname> <given-names>M</given-names> </author><author><surname>Sanchez-Madrid</surname> <given-names>F</given-names> </author><title>CD69 is an immunoregulatory molecule induced following activation</title><source>Trends Immunol</source><year>2005</year><volume>26</volume><fpage>136</fpage><lpage>140</lpage>
<author><surname>Testi</surname> <given-names>R</given-names> </author><author><surname>D'Ambrosio</surname> <given-names>D</given-names> </author><author><surname>De</surname> <given-names>MR</given-names> </author><author><surname>Santoni</surname> <given-names>A</given-names> </author><title>The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells</title><source>Immunol Today</source><year>1994</year><volume>15</volume><fpage>479</fpage><lpage>483</lpage>
<author><surname>Boulanger</surname> <given-names>A</given-names> </author><author><surname>Liu</surname> <given-names>S</given-names> </author><author><surname>Yu</surname> <given-names>S</given-names> </author><author><surname>Redmond</surname> <given-names>TM</given-names> </author><title>Sequence and structure of the mouse gene for RPE65</title><source>Mol Vis</source><year>2001</year><volume>7</volume><fpage>283</fpage><lpage>287</lpage>
<author><surname>Bennicelli</surname> <given-names>J</given-names> </author><author><surname>Wright</surname> <given-names>JF</given-names> </author><author><surname>Komaromy</surname> <given-names>A</given-names> </author><title>Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer</title><source>Mol Ther</source><year>2008</year><volume>16</volume><fpage>458</fpage><lpage>465</lpage>
<author><surname>Thomas</surname> <given-names>CE</given-names> </author><author><surname>Ehrhardt</surname> <given-names>A</given-names> </author><author><surname>Kay</surname> <given-names>MA</given-names> </author><title>Progress and problems with the use of viral vectors for gene therapy</title><source>Nat Rev Genet</source><year>2003</year><volume>4</volume><fpage>346</fpage><lpage>358</lpage>
<author><surname>Petry</surname> <given-names>H</given-names> </author><author><surname>Brooks</surname> <given-names>A</given-names> </author><author><surname>Orme</surname> <given-names>A</given-names> </author><title>Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice</title><source>Gene Ther</source><year>2008</year><volume>15</volume><fpage>54</fpage><lpage>60</lpage>
<author><surname>Bennett</surname> <given-names>J</given-names> </author><title>Immune response following intraocular delivery of recombinant viral vectors</title><source>Gene Ther</source><year>2003</year><volume>10</volume><fpage>977</fpage><lpage>982</lpage>
<author><surname>Chen</surname> <given-names>J</given-names> </author><author><surname>Wu</surname> <given-names>Q</given-names> </author><author><surname>Yang</surname> <given-names>P</given-names> </author><author><surname>Hsu</surname> <given-names>HC</given-names> </author><author><surname>Mountz</surname> <given-names>JD</given-names> </author><title>Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX Gene Therapy</title><source>Mol Ther</source><year>2006</year><volume>13</volume><fpage>260</fpage><lpage>269</lpage>
<author><surname>McTiernan</surname> <given-names>CF</given-names> </author><author><surname>Mathier</surname> <given-names>MA</given-names> </author><author><surname>Zhu</surname> <given-names>X</given-names> </author><title>Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts</title><source>Gene Ther</source><year>2007</year><volume>14</volume><fpage>1613</fpage><lpage>1622</lpage>
<author><surname>Vandenberghe</surname> <given-names>LH</given-names> </author><author><surname>Wang</surname> <given-names>L</given-names> </author><author><surname>Somanathan</surname> <given-names>S</given-names> </author><title>Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid</title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>967</fpage><lpage>971</lpage>
<author><surname>Perabo</surname> <given-names>L</given-names> </author><author><surname>Goldnau</surname> <given-names>D</given-names> </author><author><surname>White</surname> <given-names>K</given-names> </author><title>Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism</title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>7265</fpage><lpage>7269</lpage>
<author><surname>Jiang</surname> <given-names>H</given-names> </author><author><surname>Couto</surname> <given-names>LB</given-names> </author><author><surname>Patarroyo-White</surname> <given-names>S</given-names> </author><title>Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy</title><source>Blood</source><year>2006</year><volume>108</volume><fpage>3321</fpage><lpage>3328</lpage>
<author><surname>Wang</surname> <given-names>Z</given-names> </author><author><surname>Kuhr</surname> <given-names>CS</given-names> </author><author><surname>Allen</surname> <given-names>JM</given-names> </author><title>Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression</title><source>Mol Ther</source><year>2007</year><volume>15</volume><fpage>1160</fpage><lpage>1166</lpage>
<author><surname>Swerdlow</surname> <given-names>SH</given-names> </author><author><surname>Campo</surname> <given-names>E</given-names> </author><author><surname>Harris</surname> <given-names>NL</given-names> </author><source>WHO classification of tumours of haematopoietic and lymphoid tissues</source><year>2008</year><other>Lyon</other><publisher>IARC</publisher>
<author><surname>Tefferi</surname> <given-names>A</given-names> </author><author><surname>Thiele</surname> <given-names>J</given-names> </author><author><surname>Orazi</surname> <given-names>A</given-names> </author><author><surname>Kvasnicka</surname> <given-names>HM</given-names> </author><author><surname>Barbui</surname> <given-names>T</given-names> </author><author><surname>Hanson</surname> <given-names>CA</given-names> </author><author><surname>Barosi</surname> <given-names>G</given-names> </author><author><surname>Verstovsek</surname> <given-names>S</given-names> </author><author><surname>Birgegard</surname> <given-names>G</given-names> </author><author><surname>Mesa</surname> <given-names>R</given-names> </author><author><surname>Reilly</surname> <given-names>JT</given-names> </author><author><surname>Gisslinger</surname> <given-names>H</given-names> </author><author><surname>Vannucchi</surname> <given-names>AM</given-names> </author><author><surname>Cervantes</surname> <given-names>F</given-names> </author><author><surname>Finazzi</surname> <given-names>G</given-names> </author><author><surname>Hoffman</surname> <given-names>R</given-names> </author><author><surname>Gilliland</surname> <given-names>DG</given-names> </author><author><surname>Bloomfield</surname> <given-names>CD</given-names> </author><author><surname>Vardiman</surname> <given-names>JW</given-names> </author><title>Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel</title><source>Blood</source><year>2007</year><volume>110</volume><issue>4</issue><fpage>1092</fpage><lpage>1097</lpage>
<author><surname>Thiele</surname> <given-names>J</given-names> </author><author><surname>Kvasnicka</surname> <given-names>HM</given-names> </author><author><surname>Facchetti</surname> <given-names>F</given-names> </author><author><surname>Franco</surname> <given-names>V</given-names> </author><author><surname>Walt</surname> <given-names>J</given-names> </author><author><surname>Orazi</surname> <given-names>A</given-names> </author><title>European consensus on grading bone marrow fibrosis and assessment of cellularity</title><source>Haematologica</source><year>2005</year><volume>90</volume><fpage>1128</fpage><lpage>1132</lpage>
<author><surname>Fend</surname> <given-names>F</given-names> </author><author><surname>Horn</surname> <given-names>T</given-names> </author><author><surname>Koch</surname> <given-names>I</given-names> </author><author><surname>Vela</surname> <given-names>T</given-names> </author><author><surname>Orazi</surname> <given-names>A</given-names> </author><title>Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm</title><source>Leuk Res</source><year>2008</year><volume>32</volume><issue>12</issue><fpage>1931</fpage><lpage>1935</lpage>
<author><surname>Wardrop</surname> <given-names>D</given-names> </author><author><surname>Steensma</surname> <given-names>DP</given-names> </author><title>Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?</title><source>Br J Haematol</source><year>2009</year><volume>144</volume><issue>6</issue><fpage>809</fpage><lpage>817</lpage>
<author><surname>Ades</surname> <given-names>L</given-names> </author><author><surname>Boehrer</surname> <given-names>S</given-names> </author><author><surname>Prebet</surname> <given-names>T</given-names> </author><author><surname>Beyne-Rauzy</surname> <given-names>O</given-names> </author><author><surname>Legros</surname> <given-names>L</given-names> </author><author><surname>Ravoet</surname> <given-names>C</given-names> </author><author><surname>Dreyfus</surname> <given-names>F</given-names> </author><author><surname>Stamatoullas</surname> <given-names>A</given-names> </author><author><surname>Chaury</surname> <given-names>MP</given-names> </author><author><surname>Delaunay</surname> <given-names>J</given-names> </author><author><surname>Laurent</surname> <given-names>G</given-names> </author><author><surname>Vey</surname> <given-names>N</given-names> </author><author><surname>Burcheri</surname> <given-names>S</given-names> </author><author><surname>Mbida</surname> <given-names>RM</given-names> </author><author><surname>Hoarau</surname> <given-names>N</given-names> </author><author><surname>Gardin</surname> <given-names>C</given-names> </author><author><surname>Fenaux</surname> <given-names>P</given-names> </author><title>Efficacy and safety of lenalidomide in intermediate-2-or high risk myelodysplastic syndromes (MDS) with 5q deletion: Results of a phase II study</title><source>Blood</source><year>2009</year><volume>113</volume><issue>17</issue><fpage>3947</fpage><lpage>3952</lpage>
<author><surname>Castro</surname> <given-names>GA</given-names> </author><author><surname>Arntzen</surname> <given-names>CJ</given-names> </author><title>Immunophysiology of the gut: a research frontier for integrative studies of the common mucosal immune system</title><source>Am J Physiol</source><year>1993</year><volume>265</volume><fpage>G599</fpage><lpage>610</lpage>
<author><surname>Jung</surname> <given-names>C</given-names> </author><author><surname>Hugot</surname> <given-names>JP</given-names> </author><author><surname>Barreau</surname> <given-names>F</given-names> </author><title>Peyer's Patches: The Immune Sensors of the Intestine</title><source>Int J Inflam</source><year>2010</year><volume>2010</volume><fpage>823710</fpage>
<author><surname>MacDonald</surname> <given-names>T</given-names> </author><title>The gut is still the biggest lymphoid organ in the body</title><source>Mucosal Immunology</source><year>2008</year><volume>1</volume><fpage>246</fpage><lpage>247</lpage>
<author><surname>Neutra</surname> <given-names>MR</given-names> </author><author><surname>Mantis</surname> <given-names>NJ</given-names> </author><author><surname>Kraehenbuhl</surname> <given-names>JP</given-names> </author><title>Collaboration of epithelial cells with organized mucosal lymphoid tissues</title><source>Nat Immunol</source><year>2001</year><volume>2</volume><fpage>1004</fpage><lpage>1009</lpage>
<author><surname>Rescigno</surname> <given-names>M</given-names> </author><author><surname>Urbano</surname> <given-names>M</given-names> </author><author><surname>Valzasina</surname> <given-names>B</given-names> </author><author><surname>Francolini</surname> <given-names>M</given-names> </author><author><surname>Rotta</surname> <given-names>G</given-names> </author><author><surname>Bonasio</surname> <given-names>R</given-names> </author><author><surname>Granucci</surname> <given-names>F</given-names> </author><author><surname>Kraehenbuhl</surname> <given-names>JP</given-names> </author><author><surname>Ricciardi-Castagnoli</surname> <given-names>P</given-names> </author><title>Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria</title><source>Nat Immunol</source><year>2001</year><volume>2</volume><fpage>361</fpage><lpage>367</lpage>
<author><surname>Gorfu</surname> <given-names>G</given-names> </author><author><surname>Rivera-Nieves</surname> <given-names>J</given-names> </author><author><surname>Ley</surname> <given-names>K</given-names> </author><title>Role of beta7 integrins in intestinal lymphocyte homing and retention</title><source>Curr Mol Med</source><year>2009</year><volume>9</volume><fpage>836</fpage><lpage>850</lpage>
<author><surname>Cunliffe</surname> <given-names>RN</given-names> </author><author><surname>Mahida</surname> <given-names>YR</given-names> </author><title>Expression and regulation of antimicrobial peptides in the gastrointestinal tract</title><source>J Leukoc Biol</source><year>2004</year><volume>75</volume><fpage>49</fpage><lpage>58</lpage>
<author><surname>Plaut</surname> <given-names>AG</given-names> </author><title>Trefoil peptides in the defense of the gastrointestinal tract</title><source>N Engl J Med</source><year>1997</year><volume>336</volume><fpage>506</fpage><lpage>507</lpage>
<author><surname>Kim</surname> <given-names>YS</given-names> </author><author><surname>Ho</surname> <given-names>SB</given-names> </author><title>Intestinal goblet cells and mucins in health and disease: recent insights and progress</title><source>Curr Gastroenterol Rep</source><year>2010</year><volume>12</volume><fpage>319</fpage><lpage>330</lpage>
<author><surname>Cerf-Bensussan</surname> <given-names>N</given-names> </author><author><surname>Gaboriau-Routhiau</surname> <given-names>V</given-names> </author><title>The immune system and the gut microbiota: friends or foes?</title><source>Nat Rev Immunol</source><year>2010</year><volume>10</volume><fpage>735</fpage><lpage>744</lpage>
<author><surname>Macpherson</surname> <given-names>AJ</given-names> </author><author><surname>Hunziker</surname> <given-names>L</given-names> </author><author><surname>McCoy</surname> <given-names>K</given-names> </author><author><surname>Lamarre</surname> <given-names>A</given-names> </author><title>IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms</title><source>Microbes Infect</source><year>2001</year><volume>3</volume><fpage>1021</fpage><lpage>1035</lpage>
<author><surname>Suzuki</surname> <given-names>K</given-names> </author><author><surname>Maruya</surname> <given-names>M</given-names> </author><author><surname>Kawamoto</surname> <given-names>S</given-names> </author><author><surname>Sitnik</surname> <given-names>K</given-names> </author><author><surname>Kitamura</surname> <given-names>H</given-names> </author><author><surname>Agace</surname> <given-names>WW</given-names> </author><author><surname>Fagarasan</surname> <given-names>S</given-names> </author><title>The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut</title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>71</fpage><lpage>83</lpage>
<author><surname>Spencer</surname> <given-names>J</given-names> </author><author><surname>Barone</surname> <given-names>F</given-names> </author><author><surname>Dunn-Walters</surname> <given-names>D</given-names> </author><title>Generation of Immunoglobulin diversity in human gut-associated lymphoid tissue</title><source>Semin Immunol</source><year>2009</year><volume>21</volume><fpage>139</fpage><lpage>146</lpage>
<author><surname>Macpherson</surname> <given-names>AJ</given-names> </author><author><surname>McCoy</surname> <given-names>KD</given-names> </author><author><surname>Johansen</surname> <given-names>FE</given-names> </author><author><surname>Brandtzaeg</surname> <given-names>P</given-names> </author><title>The immune geography of IgA induction and function</title><source>Mucosal Immunol</source><year>2008</year><volume>1</volume><fpage>11</fpage><lpage>22</lpage>
<author><surname>Maizels</surname> <given-names>RM</given-names> </author><author><surname>Yazdanbakhsh</surname> <given-names>M</given-names> </author><title>Immune regulation by helminth parasites: cellular and molecular mechanisms</title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>733</fpage><lpage>744</lpage>
<author><surname>Cella</surname> <given-names>M</given-names> </author><author><surname>Fuchs</surname> <given-names>A</given-names> </author><author><surname>Vermi</surname> <given-names>W</given-names> </author><author><surname>Facchetti</surname> <given-names>F</given-names> </author><author><surname>Otero</surname> <given-names>K</given-names> </author><author><surname>Lennerz</surname> <given-names>JK</given-names> </author><author><surname>Doherty</surname> <given-names>JM</given-names> </author><author><surname>Mills</surname> <given-names>JC</given-names> </author><author><surname>Colonna</surname> <given-names>M</given-names> </author><title>A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity</title><source>Nature</source><year>2009</year><volume>457</volume><fpage>722</fpage><lpage>725</lpage>
<author><surname>Takayama</surname> <given-names>T</given-names> </author><author><surname>Kamada</surname> <given-names>N</given-names> </author><author><surname>Chinen</surname> <given-names>H</given-names> </author><author><surname>Okamoto</surname> <given-names>S</given-names> </author><author><surname>Kitazume</surname> <given-names>MT</given-names> </author><author><surname>Chang</surname> <given-names>J</given-names> </author><author><surname>Matuzaki</surname> <given-names>Y</given-names> </author><author><surname>Suzuki</surname> <given-names>S</given-names> </author><author><surname>Sugita</surname> <given-names>A</given-names> </author><author><surname>Koganei</surname> <given-names>K</given-names> </author><author><surname>Hisamatsu</surname> <given-names>T</given-names> </author><author><surname>Kanai</surname> <given-names>T</given-names> </author><author><surname>Hibi</surname> <given-names>T</given-names> </author><title>Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease</title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>882</fpage><lpage>892</lpage>892 e881-883
<author><surname>Satoh-Takayama</surname> <given-names>N</given-names> </author><author><surname>Vosshenrich</surname> <given-names>CA</given-names> </author><author><surname>Lesjean-Pottier</surname> <given-names>S</given-names> </author><author><surname>Sawa</surname> <given-names>S</given-names> </author><author><surname>Lochner</surname> <given-names>M</given-names> </author><author><surname>Rattis</surname> <given-names>F</given-names> </author><author><surname>Mention</surname> <given-names>JJ</given-names> </author><author><surname>Thiam</surname> <given-names>K</given-names> </author><author><surname>Cerf-Bensussan</surname> <given-names>N</given-names> </author><author><surname>Mandelboim</surname> <given-names>O</given-names> </author><author><surname>Eberl</surname> <given-names>G</given-names> </author><author><surname>Di Santo</surname> <given-names>JP</given-names> </author><title>Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense</title><source>Immunity</source><year>2008</year><volume>29</volume><fpage>958</fpage><lpage>970</lpage>
<author><surname>Shiomi</surname> <given-names>H</given-names> </author><author><surname>Masuda</surname> <given-names>A</given-names> </author><author><surname>Nishiumi</surname> <given-names>S</given-names> </author><author><surname>Nishida</surname> <given-names>M</given-names> </author><author><surname>Takagawa</surname> <given-names>T</given-names> </author><author><surname>Shiomi</surname> <given-names>Y</given-names> </author><author><surname>Kutsumi</surname> <given-names>H</given-names> </author><author><surname>Blumberg</surname> <given-names>RS</given-names> </author><author><surname>Azuma</surname> <given-names>T</given-names> </author><author><surname>Yoshida</surname> <given-names>M</given-names> </author><title>Gamma interferon produced by antigen-specific CD4+ T cells regulates the mucosal immune responses to Citrobacter rodentium infection</title><source>Infect Immun</source><year>2010</year><volume>78</volume><fpage>2653</fpage><lpage>2666</lpage>
<author><surname>Jabri</surname> <given-names>B</given-names> </author><author><surname>Ebert</surname> <given-names>E</given-names> </author><title>Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue</title><source>Immunol Rev</source><year>2007</year><volume>215</volume><fpage>202</fpage><lpage>214</lpage>
<author><surname>Beagley</surname> <given-names>KW</given-names> </author><author><surname>Husband</surname> <given-names>AJ</given-names> </author><title>Intraepithelial lymphocytes: origins, distribution, and function</title><source>Crit Rev Immunol</source><year>1998</year><volume>18</volume><fpage>237</fpage><lpage>254</lpage>
<author><surname>Sanz</surname> <given-names>Y</given-names> </author><author><surname>De Palma</surname> <given-names>G</given-names> </author><title>Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function</title><source>Int Rev Immunol</source><year>2009</year><volume>28</volume><fpage>397</fpage><lpage>413</lpage>
<author><surname>Manicassamy</surname> <given-names>S</given-names> </author><author><surname>Reizis</surname> <given-names>B</given-names> </author><author><surname>Ravindran</surname> <given-names>R</given-names> </author><author><surname>Nakaya</surname> <given-names>H</given-names> </author><author><surname>Salazar-Gonzalez</surname> <given-names>RM</given-names> </author><author><surname>Wang</surname> <given-names>YC</given-names> </author><author><surname>Pulendran</surname> <given-names>B</given-names> </author><title>Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine</title><source>Science</source><year>2010</year><volume>329</volume><fpage>849</fpage><lpage>853</lpage>
<author><surname>Kawai</surname> <given-names>T</given-names> </author><author><surname>Akira</surname> <given-names>S</given-names> </author><title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</title><source>Nat Immunol</source><year>2010</year><volume>11</volume><fpage>373</fpage><lpage>384</lpage>
<author><surname>Hemmi</surname> <given-names>H</given-names> </author><author><surname>Takeuchi</surname> <given-names>O</given-names> </author><author><surname>Kawai</surname> <given-names>T</given-names> </author><author><surname>Kaisho</surname> <given-names>T</given-names> </author><author><surname>Sato</surname> <given-names>S</given-names> </author><author><surname>Sanjo</surname> <given-names>H</given-names> </author><author><surname>Matsumoto</surname> <given-names>M</given-names> </author><author><surname>Hoshino</surname> <given-names>K</given-names> </author><author><surname>Wagner</surname> <given-names>H</given-names> </author><author><surname>Takeda</surname> <given-names>K</given-names> </author><author><surname>Akira</surname> <given-names>S</given-names> </author><title>A Toll-like receptor recognizes bacterial DNA</title><source>Nature</source><year>2000</year><volume>408</volume><fpage>740</fpage><lpage>745</lpage>
<author><surname>Kang</surname> <given-names>JY</given-names> </author><author><surname>Nan</surname> <given-names>X</given-names> </author><author><surname>Jin</surname> <given-names>MS</given-names> </author><author><surname>Youn</surname> <given-names>SJ</given-names> </author><author><surname>Ryu</surname> <given-names>YH</given-names> </author><author><surname>Mah</surname> <given-names>S</given-names> </author><author><surname>Han</surname> <given-names>SH</given-names> </author><author><surname>Lee</surname> <given-names>H</given-names> </author><author><surname>Paik</surname> <given-names>SG</given-names> </author><author><surname>Lee</surname> <given-names>JO</given-names> </author><title>Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer</title><source>Immunity</source><year>2009</year><volume>31</volume><fpage>873</fpage><lpage>884</lpage>
<author><surname>Hugot</surname> <given-names>JP</given-names> </author><author><surname>Chamaillard</surname> <given-names>M</given-names> </author><author><surname>Zouali</surname> <given-names>H</given-names> </author><author><surname>Lesage</surname> <given-names>S</given-names> </author><author><surname>Cezard</surname> <given-names>JP</given-names> </author><author><surname>Belaiche</surname> <given-names>J</given-names> </author><author><surname>Almer</surname> <given-names>S</given-names> </author><author><surname>Tysk</surname> <given-names>C</given-names> </author><author><surname>O'Morain</surname> <given-names>CA</given-names> </author><author><surname>Gassull</surname> <given-names>M</given-names> </author><author><surname>Binder</surname> <given-names>V</given-names> </author><author><surname>Finkel</surname> <given-names>Y</given-names> </author><author><surname>Cortot</surname> <given-names>A</given-names> </author><author><surname>Modigliani</surname> <given-names>R</given-names> </author><author><surname>Laurent-Puig</surname> <given-names>P</given-names> </author><author><surname>Gower-Rousseau</surname> <given-names>C</given-names> </author><author><surname>Macry</surname> <given-names>J</given-names> </author><author><surname>Colombel</surname> <given-names>JF</given-names> </author><author><surname>Sahbatou</surname> <given-names>M</given-names> </author><author><surname>Thomas</surname> <given-names>G</given-names> </author><title>Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease</title><source>Nature</source><year>2001</year><volume>411</volume><fpage>599</fpage><lpage>603</lpage>
<author><surname>Keshet</surname> <given-names>Y</given-names> </author><author><surname>Seger</surname> <given-names>R</given-names> </author><title>The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions</title><source>Methods Mol Biol</source><year>2010</year><volume>661</volume><fpage>3</fpage><lpage>38</lpage>
<author><surname>Malladi</surname> <given-names>V</given-names> </author><author><surname>Puthenedam</surname> <given-names>M</given-names> </author><author><surname>Williams</surname> <given-names>PH</given-names> </author><author><surname>Balakrishnan</surname> <given-names>A</given-names> </author><title>Enteropathogenic Escherichia coli outer membrane proteins induce iNOS by activation of NF-kappaB and MAP kinases</title><source>Inflammation</source><year>2004</year><volume>28</volume><fpage>345</fpage><lpage>353</lpage>
<author><surname>Shames</surname> <given-names>SR</given-names> </author><author><surname>Auweter</surname> <given-names>SD</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><title>Co-evolution and exploitation of host cell signaling pathways by bacterial pathogens</title><source>Int J Biochem Cell Biol</source><year>2009</year><volume>41</volume><fpage>380</fpage><lpage>389</lpage>
<author><surname>Sasakawa</surname> <given-names>C</given-names> </author><title>A new paradigm of bacteria-gut interplay brought through the study of Shigella</title><source>Proc Jpn Acad Ser B Phys Biol Sci</source><year>2010</year><volume>86</volume><fpage>229</fpage><lpage>243</lpage>
<author><surname>Kim</surname> <given-names>M</given-names> </author><author><surname>Ashida</surname> <given-names>H</given-names> </author><author><surname>Ogawa</surname> <given-names>M</given-names> </author><author><surname>Yoshikawa</surname> <given-names>Y</given-names> </author><author><surname>Mimuro</surname> <given-names>H</given-names> </author><author><surname>Sasakawa</surname> <given-names>C</given-names> </author><title>Bacterial interactions with the host epithelium</title><source>Cell Host Microbe</source><year>2010</year><volume>8</volume><fpage>20</fpage><lpage>35</lpage>
<author><surname>Macdonald</surname> <given-names>TT</given-names> </author><author><surname>Monteleone</surname> <given-names>G</given-names> </author><title>Immunity, inflammation, and allergy in the gut</title><source>Science</source><year>2005</year><volume>307</volume><fpage>1920</fpage><lpage>1925</lpage>
<author><surname>Iwai</surname> <given-names>H</given-names> </author><author><surname>Kim</surname> <given-names>M</given-names> </author><author><surname>Yoshikawa</surname> <given-names>Y</given-names> </author><author><surname>Ashida</surname> <given-names>H</given-names> </author><author><surname>Ogawa</surname> <given-names>M</given-names> </author><author><surname>Fujita</surname> <given-names>Y</given-names> </author><author><surname>Muller</surname> <given-names>D</given-names> </author><author><surname>Kirikae</surname> <given-names>T</given-names> </author><author><surname>Jackson</surname> <given-names>PK</given-names> </author><author><surname>Kotani</surname> <given-names>S</given-names> </author><author><surname>Sasakawa</surname> <given-names>C</given-names> </author><title>A bacterial effector targets Mad2L2, an APC inhibitor, to modulate host cell cycling</title><source>Cell</source><year>2007</year><volume>130</volume><fpage>611</fpage><lpage>623</lpage>
<author><surname>Kim</surname> <given-names>M</given-names> </author><author><surname>Ogawa</surname> <given-names>M</given-names> </author><author><surname>Fujita</surname> <given-names>Y</given-names> </author><author><surname>Yoshikawa</surname> <given-names>Y</given-names> </author><author><surname>Nagai</surname> <given-names>T</given-names> </author><author><surname>Koyama</surname> <given-names>T</given-names> </author><author><surname>Nagai</surname> <given-names>S</given-names> </author><author><surname>Lange</surname> <given-names>A</given-names> </author><author><surname>Fassler</surname> <given-names>R</given-names> </author><author><surname>Sasakawa</surname> <given-names>C</given-names> </author><title>Bacteria hijack integrin-linked kinase to stabilize focal adhesions and block cell detachment</title><source>Nature</source><year>2009</year><volume>459</volume><fpage>578</fpage><lpage>582</lpage>
<author><surname>Tobe</surname> <given-names>T</given-names> </author><author><surname>Beatson</surname> <given-names>SA</given-names> </author><author><surname>Taniguchi</surname> <given-names>H</given-names> </author><author><surname>Abe</surname> <given-names>H</given-names> </author><author><surname>Bailey</surname> <given-names>CM</given-names> </author><author><surname>Fivian</surname> <given-names>A</given-names> </author><author><surname>Younis</surname> <given-names>R</given-names> </author><author><surname>Matthews</surname> <given-names>S</given-names> </author><author><surname>Marches</surname> <given-names>O</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>Hayashi</surname> <given-names>T</given-names> </author><author><surname>Pallen</surname> <given-names>MJ</given-names> </author><title>An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination</title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>14941</fpage><lpage>14946</lpage>
<author><surname>Muenzner</surname> <given-names>P</given-names> </author><author><surname>Bachmann</surname> <given-names>V</given-names> </author><author><surname>Zimmermann</surname> <given-names>W</given-names> </author><author><surname>Hentschel</surname> <given-names>J</given-names> </author><author><surname>Hauck</surname> <given-names>CR</given-names> </author><title>Human-restricted bacterial pathogens block shedding of epithelial cells by stimulating integrin activation</title><source>Science</source><year>2010</year><volume>329</volume><fpage>1197</fpage><lpage>1201</lpage>
<author><surname>Marches</surname> <given-names>O</given-names> </author><author><surname>Ledger</surname> <given-names>TN</given-names> </author><author><surname>Boury</surname> <given-names>M</given-names> </author><author><surname>Ohara</surname> <given-names>M</given-names> </author><author><surname>Tu</surname> <given-names>X</given-names> </author><author><surname>Goffaux</surname> <given-names>F</given-names> </author><author><surname>Mainil</surname> <given-names>J</given-names> </author><author><surname>Rosenshine</surname> <given-names>I</given-names> </author><author><surname>Sugai</surname> <given-names>M</given-names> </author><author><surname>De Rycke</surname> <given-names>J</given-names> </author><author><surname>Oswald</surname> <given-names>E</given-names> </author><title>Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition</title><source>Mol Microbiol</source><year>2003</year><volume>50</volume><fpage>1553</fpage><lpage>1567</lpage>
<author><surname>Jubelin</surname> <given-names>G</given-names> </author><author><surname>Taieb</surname> <given-names>F</given-names> </author><author><surname>Duda</surname> <given-names>DM</given-names> </author><author><surname>Hsu</surname> <given-names>Y</given-names> </author><author><surname>Samba-Louaka</surname> <given-names>A</given-names> </author><author><surname>Nobe</surname> <given-names>R</given-names> </author><author><surname>Penary</surname> <given-names>M</given-names> </author><author><surname>Watrin</surname> <given-names>C</given-names> </author><author><surname>Nougayrede</surname> <given-names>JP</given-names> </author><author><surname>Schulman</surname> <given-names>BA</given-names> </author><author><surname>Stebbins</surname> <given-names>CE</given-names> </author><author><surname>Oswald</surname> <given-names>E</given-names> </author><title>Pathogenic bacteria target NEDD8-conjugated cullins to hijack host-cell signaling pathways</title><source>PLoS Pathog</source><year>2010</year><volume>6</volume>
<author><surname>Samba-Louaka</surname> <given-names>A</given-names> </author><author><surname>Nougayrede</surname> <given-names>JP</given-names> </author><author><surname>Watrin</surname> <given-names>C</given-names> </author><author><surname>Jubelin</surname> <given-names>G</given-names> </author><author><surname>Oswald</surname> <given-names>E</given-names> </author><author><surname>Taieb</surname> <given-names>F</given-names> </author><title>Bacterial cyclomodulin Cif blocks the host cell cycle by stabilizing the cyclin-dependent kinase inhibitors p21 and p27</title><source>Cell Microbiol</source><year>2008</year><volume>10</volume><fpage>2496</fpage><lpage>2508</lpage>
<author><surname>Shames</surname> <given-names>SR</given-names> </author><author><surname>Deng</surname> <given-names>W</given-names> </author><author><surname>Guttman</surname> <given-names>JA</given-names> </author><author><surname>de Hoog</surname> <given-names>CL</given-names> </author><author><surname>Li</surname> <given-names>Y</given-names> </author><author><surname>Hardwidge</surname> <given-names>PR</given-names> </author><author><surname>Sham</surname> <given-names>HP</given-names> </author><author><surname>Vallance</surname> <given-names>BA</given-names> </author><author><surname>Foster</surname> <given-names>LJ</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><title>The pathogenic E. coli type III effector EspZ interacts with host CD98 and facilitates host cell prosurvival signalling</title><source>Cell Microbiol</source><year>2010</year><volume>12</volume><fpage>1322</fpage><lpage>1339</lpage>
<author><surname>Hemrajani</surname> <given-names>C</given-names> </author><author><surname>Berger</surname> <given-names>CN</given-names> </author><author><surname>Robinson</surname> <given-names>KS</given-names> </author><author><surname>Marches</surname> <given-names>O</given-names> </author><author><surname>Mousnier</surname> <given-names>A</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><title>NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection</title><source>Proc Natl Acad Sci USA</source><year>2010</year><volume>107</volume><fpage>3129</fpage><lpage>3134</lpage>
<author><surname>Baruch</surname> <given-names>K</given-names> </author><author><surname>Gur-Arie</surname> <given-names>L</given-names> </author><author><surname>Nadler</surname> <given-names>C</given-names> </author><author><surname>Koby</surname> <given-names>S</given-names> </author><author><surname>Yerushalmi</surname> <given-names>G</given-names> </author><author><surname>Ben-Neriah</surname> <given-names>Y</given-names> </author><author><surname>Yogev</surname> <given-names>O</given-names> </author><author><surname>Shaulian</surname> <given-names>E</given-names> </author><author><surname>Guttman</surname> <given-names>C</given-names> </author><author><surname>Zarivach</surname> <given-names>R</given-names> </author><author><surname>Rosenshine</surname> <given-names>I</given-names> </author><title>Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB</title><source>Embo J</source><year>2010</year><volume>30</volume><fpage>221</fpage><lpage>231</lpage>
<author><surname>Deng</surname> <given-names>W</given-names> </author><author><surname>Puente</surname> <given-names>JL</given-names> </author><author><surname>Gruenheid</surname> <given-names>S</given-names> </author><author><surname>Li</surname> <given-names>Y</given-names> </author><author><surname>Vallance</surname> <given-names>BA</given-names> </author><author><surname>Vazquez</surname> <given-names>A</given-names> </author><author><surname>Barba</surname> <given-names>J</given-names> </author><author><surname>Ibarra</surname> <given-names>JA</given-names> </author><author><surname>O'Donnell</surname> <given-names>P</given-names> </author><author><surname>Metalnikov</surname> <given-names>P</given-names> </author><author><surname>Ashman</surname> <given-names>K</given-names> </author><author><surname>Lee</surname> <given-names>S</given-names> </author><author><surname>Goode</surname> <given-names>D</given-names> </author><author><surname>Pawson</surname> <given-names>T</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><title>Dissecting virulence: systematic and functional analyses of a pathogenicity island</title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>3597</fpage><lpage>3602</lpage>
<author><surname>Kelly</surname> <given-names>M</given-names> </author><author><surname>Hart</surname> <given-names>E</given-names> </author><author><surname>Mundy</surname> <given-names>R</given-names> </author><author><surname>Marches</surname> <given-names>O</given-names> </author><author><surname>Wiles</surname> <given-names>S</given-names> </author><author><surname>Badea</surname> <given-names>L</given-names> </author><author><surname>Luck</surname> <given-names>S</given-names> </author><author><surname>Tauschek</surname> <given-names>M</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>Robins-Browne</surname> <given-names>RM</given-names> </author><author><surname>Hartland</surname> <given-names>EL</given-names> </author><title>Essential role of the type III secretion system effector NleB in colonization of mice by Citrobacter rodentium</title><source>Infect Immun</source><year>2006</year><volume>74</volume><fpage>2328</fpage><lpage>2337</lpage>
<author><surname>Marches</surname> <given-names>O</given-names> </author><author><surname>Wiles</surname> <given-names>S</given-names> </author><author><surname>Dziva</surname> <given-names>F</given-names> </author><author><surname>La Ragione</surname> <given-names>RM</given-names> </author><author><surname>Schuller</surname> <given-names>S</given-names> </author><author><surname>Best</surname> <given-names>A</given-names> </author><author><surname>Phillips</surname> <given-names>AD</given-names> </author><author><surname>Hartland</surname> <given-names>EL</given-names> </author><author><surname>Woodward</surname> <given-names>MJ</given-names> </author><author><surname>Stevens</surname> <given-names>MP</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><title>Characterization of two non-locus of enterocyte effacement-encoded type III-translocated effectors, NleC and NleD, in attaching and effacing pathogens</title><source>Infect Immun</source><year>2005</year><volume>73</volume><fpage>8411</fpage><lpage>8417</lpage>
<author><surname>Bhavsar</surname> <given-names>AP</given-names> </author><author><surname>Guttman</surname> <given-names>JA</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><title>Manipulation of host-cell pathways by bacterial pathogens</title><source>Nature</source><year>2007</year><volume>449</volume><fpage>827</fpage><lpage>834</lpage>
<author><surname>Petty</surname> <given-names>NK</given-names> </author><author><surname>Bulgin</surname> <given-names>R</given-names> </author><author><surname>Crepin</surname> <given-names>VF</given-names> </author><author><surname>Cerdeno-Tarraga</surname> <given-names>AM</given-names> </author><author><surname>Schroeder</surname> <given-names>GN</given-names> </author><author><surname>Quail</surname> <given-names>MA</given-names> </author><author><surname>Lennard</surname> <given-names>N</given-names> </author><author><surname>Corton</surname> <given-names>C</given-names> </author><author><surname>Barron</surname> <given-names>A</given-names> </author><author><surname>Clark</surname> <given-names>L</given-names> </author><author><surname>Toribio</surname> <given-names>AL</given-names> </author><author><surname>Parkhill</surname> <given-names>J</given-names> </author><author><surname>Dougan</surname> <given-names>G</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>Thomson</surname> <given-names>NR</given-names> </author><title>The Citrobacter rodentium genome sequence reveals convergent evolution with human pathogenic Escherichia coli</title><source>J Bacteriol</source><year>2010</year><volume>192</volume><fpage>525</fpage><lpage>538</lpage>
<author><surname>Garmendia</surname> <given-names>J</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>Crepin</surname> <given-names>VF</given-names> </author><title>Enteropathogenic and enterohemorrhagic Escherichia coli infections: translocation, translocation, translocation</title><source>Infect Immun</source><year>2005</year><volume>73</volume><fpage>2573</fpage><lpage>2585</lpage>
<author><surname>Czerucka</surname> <given-names>D</given-names> </author><author><surname>Dahan</surname> <given-names>S</given-names> </author><author><surname>Mograbi</surname> <given-names>B</given-names> </author><author><surname>Rossi</surname> <given-names>B</given-names> </author><author><surname>Rampal</surname> <given-names>P</given-names> </author><title>Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection</title><source>Infect Immun</source><year>2001</year><volume>69</volume><fpage>1298</fpage><lpage>1305</lpage>
<author><surname>Ramirez</surname> <given-names>K</given-names> </author><author><surname>Huerta</surname> <given-names>R</given-names> </author><author><surname>Oswald</surname> <given-names>E</given-names> </author><author><surname>Garcia-Tovar</surname> <given-names>C</given-names> </author><author><surname>Hernandez</surname> <given-names>JM</given-names> </author><author><surname>Navarro-Garcia</surname> <given-names>F</given-names> </author><title>Role of EspA and intimin in expression of proinflammatory cytokines from enterocytes and lymphocytes by rabbit enteropathogenic Escherichia coli-infected rabbits</title><source>Infect Immun</source><year>2005</year><volume>73</volume><fpage>103</fpage><lpage>113</lpage>
<author><surname>Ruchaud-Sparagano</surname> <given-names>MH</given-names> </author><author><surname>Maresca</surname> <given-names>M</given-names> </author><author><surname>Kenny</surname> <given-names>B</given-names> </author><title>Enteropathogenic Escherichia coli (EPEC) inactivate innate immune responses prior to compromising epithelial barrier function</title><source>Cell Microbiol</source><year>2007</year><volume>9</volume><fpage>1909</fpage><lpage>1921</lpage>
<author><surname>Sharma</surname> <given-names>R</given-names> </author><author><surname>Tesfay</surname> <given-names>S</given-names> </author><author><surname>Tomson</surname> <given-names>FL</given-names> </author><author><surname>Kanteti</surname> <given-names>RP</given-names> </author><author><surname>Viswanathan</surname> <given-names>VK</given-names> </author><author><surname>Hecht</surname> <given-names>G</given-names> </author><title>Balance of bacterial pro- and anti-inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells</title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2006</year><volume>290</volume><fpage>G685</fpage><lpage>694</lpage>
<author><surname>Mumy</surname> <given-names>KL</given-names> </author><author><surname>McCormick</surname> <given-names>BA</given-names> </author><title>The role of neutrophils in the event of intestinal inflammation</title><source>Curr Opin Pharmacol</source><year>2009</year><volume>9</volume><fpage>697</fpage><lpage>701</lpage>
<author><surname>Gao</surname> <given-names>X</given-names> </author><author><surname>Wan</surname> <given-names>F</given-names> </author><author><surname>Mateo</surname> <given-names>K</given-names> </author><author><surname>Callegari</surname> <given-names>E</given-names> </author><author><surname>Wang</surname> <given-names>D</given-names> </author><author><surname>Deng</surname> <given-names>W</given-names> </author><author><surname>Puente</surname> <given-names>J</given-names> </author><author><surname>Li</surname> <given-names>F</given-names> </author><author><surname>Chaussee</surname> <given-names>MS</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><author><surname>Lenardo</surname> <given-names>MJ</given-names> </author><author><surname>Hardwidge</surname> <given-names>PR</given-names> </author><title>Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function</title><source>PLoS Pathog</source><year>2009</year><volume>5</volume><fpage>e1000708</fpage>
<author><surname>Wan</surname> <given-names>F</given-names> </author><author><surname>Anderson</surname> <given-names>DE</given-names> </author><author><surname>Barnitz</surname> <given-names>RA</given-names> </author><author><surname>Snow</surname> <given-names>A</given-names> </author><author><surname>Bidere</surname> <given-names>N</given-names> </author><author><surname>Zheng</surname> <given-names>L</given-names> </author><author><surname>Hegde</surname> <given-names>V</given-names> </author><author><surname>Lam</surname> <given-names>LT</given-names> </author><author><surname>Staudt</surname> <given-names>LM</given-names> </author><author><surname>Levens</surname> <given-names>D</given-names> </author><author><surname>Deutsch</surname> <given-names>WA</given-names> </author><author><surname>Lenardo</surname> <given-names>MJ</given-names> </author><title>Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation</title><source>Cell</source><year>2007</year><volume>131</volume><fpage>927</fpage><lpage>939</lpage>
<author><surname>Kim</surname> <given-names>DW</given-names> </author><author><surname>Lenzen</surname> <given-names>G</given-names> </author><author><surname>Page</surname> <given-names>AL</given-names> </author><author><surname>Legrain</surname> <given-names>P</given-names> </author><author><surname>Sansonetti</surname> <given-names>PJ</given-names> </author><author><surname>Parsot</surname> <given-names>C</given-names> </author><title>The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes</title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>14046</fpage><lpage>14051</lpage>
<author><surname>Royan</surname> <given-names>SV</given-names> </author><author><surname>Jones</surname> <given-names>RM</given-names> </author><author><surname>Koutsouris</surname> <given-names>A</given-names> </author><author><surname>Roxas</surname> <given-names>JL</given-names> </author><author><surname>Falzari</surname> <given-names>K</given-names> </author><author><surname>Weflen</surname> <given-names>AW</given-names> </author><author><surname>Kim</surname> <given-names>A</given-names> </author><author><surname>Bellmeyer</surname> <given-names>A</given-names> </author><author><surname>Turner</surname> <given-names>JR</given-names> </author><author><surname>Neish</surname> <given-names>AS</given-names> </author><author><surname>Rhee</surname> <given-names>KJ</given-names> </author><author><surname>Viswanathan</surname> <given-names>VK</given-names> </author><author><surname>Hecht</surname> <given-names>GA</given-names> </author><title>Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-kappaB activation</title><source>Mol Microbiol</source><year>2010</year><volume>78</volume><fpage>1232</fpage><lpage>1245</lpage>
<author><surname>Iguchi</surname> <given-names>A</given-names> </author><author><surname>Thomson</surname> <given-names>NR</given-names> </author><author><surname>Ogura</surname> <given-names>Y</given-names> </author><author><surname>Saunders</surname> <given-names>D</given-names> </author><author><surname>Ooka</surname> <given-names>T</given-names> </author><author><surname>Henderson</surname> <given-names>IR</given-names> </author><author><surname>Harris</surname> <given-names>D</given-names> </author><author><surname>Asadulghani</surname> <given-names>M</given-names> </author><author><surname>Kurokawa</surname> <given-names>K</given-names> </author><author><surname>Dean</surname> <given-names>P</given-names> </author><author><surname>Kenny</surname> <given-names>B</given-names> </author><author><surname>Quail</surname> <given-names>MA</given-names> </author><author><surname>Thurston</surname> <given-names>S</given-names> </author><author><surname>Dougan</surname> <given-names>G</given-names> </author><author><surname>Hayashi</surname> <given-names>T</given-names> </author><author><surname>Parkhill</surname> <given-names>J</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><title>Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69</title><source>J Bacteriol</source><year>2009</year><volume>191</volume><fpage>347</fpage><lpage>354</lpage>
<author><surname>Wickham</surname> <given-names>ME</given-names> </author><author><surname>Lupp</surname> <given-names>C</given-names> </author><author><surname>Mascarenhas</surname> <given-names>M</given-names> </author><author><surname>Vazquez</surname> <given-names>A</given-names> </author><author><surname>Coombes</surname> <given-names>BK</given-names> </author><author><surname>Brown</surname> <given-names>NF</given-names> </author><author><surname>Coburn</surname> <given-names>BA</given-names> </author><author><surname>Deng</surname> <given-names>W</given-names> </author><author><surname>Puente</surname> <given-names>JL</given-names> </author><author><surname>Karmali</surname> <given-names>MA</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><title>Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection</title><source>J Infect Dis</source><year>2006</year><volume>194</volume><fpage>819</fpage><lpage>827</lpage>
<author><surname>Newton</surname> <given-names>HJ</given-names> </author><author><surname>Pearson</surname> <given-names>JS</given-names> </author><author><surname>Badea</surname> <given-names>L</given-names> </author><author><surname>Kelly</surname> <given-names>M</given-names> </author><author><surname>Lucas</surname> <given-names>M</given-names> </author><author><surname>Holloway</surname> <given-names>G</given-names> </author><author><surname>Wagstaff</surname> <given-names>KM</given-names> </author><author><surname>Dunstone</surname> <given-names>MA</given-names> </author><author><surname>Sloan</surname> <given-names>J</given-names> </author><author><surname>Whisstock</surname> <given-names>JC</given-names> </author><author><surname>Kaper</surname> <given-names>JB</given-names> </author><author><surname>Robins-Browne</surname> <given-names>RM</given-names> </author><author><surname>Jans</surname> <given-names>DA</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>Phillips</surname> <given-names>AD</given-names> </author><author><surname>Coulson</surname> <given-names>BS</given-names> </author><author><surname>Hartland</surname> <given-names>EL</given-names> </author><title>The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65</title><source>PLoS Pathog</source><year>2010</year><volume>6</volume><fpage>e1000898</fpage>
<author><surname>Muhlen</surname> <given-names>S</given-names> </author><author><surname>Ruchaud-Sparagano</surname> <given-names>MH</given-names> </author><author><surname>Kenny</surname> <given-names>B</given-names> </author><title>Proteasome-independent Degradation of Canonical NF{kappa}B Complex Components by the NleC Protein of Pathogenic Escherichia coli</title><source>J Biol Chem</source><year>2010</year><volume>286</volume><fpage>5100</fpage><lpage>5107</lpage>
<author><surname>Pearson</surname> <given-names>JS</given-names> </author><author><surname>Riedmaier</surname> <given-names>P</given-names> </author><author><surname>Marches</surname> <given-names>O</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>Hartland</surname> <given-names>EL</given-names> </author><title>A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation</title><source>Mol Microbiol</source><year>2010</year>
<author><surname>Yen</surname> <given-names>H</given-names> </author><author><surname>Ooka</surname> <given-names>T</given-names> </author><author><surname>Iguchi</surname> <given-names>A</given-names> </author><author><surname>Hayashi</surname> <given-names>T</given-names> </author><author><surname>Sugimoto</surname> <given-names>N</given-names> </author><author><surname>Tobe</surname> <given-names>T</given-names> </author><title>NleC, a type III secretion protease, compromises NF-kappaB activation by targeting p65/RelA</title><source>PLoS Pathog</source><year>2010</year><volume>6</volume><fpage>e1001231</fpage>
<author><surname>Zurawski</surname> <given-names>DV</given-names> </author><author><surname>Mumy</surname> <given-names>KL</given-names> </author><author><surname>Badea</surname> <given-names>L</given-names> </author><author><surname>Prentice</surname> <given-names>JA</given-names> </author><author><surname>Hartland</surname> <given-names>EL</given-names> </author><author><surname>McCormick</surname> <given-names>BA</given-names> </author><author><surname>Maurelli</surname> <given-names>AT</given-names> </author><title>The NleE/OspZ family of effector proteins is required for polymorphonuclear transepithelial migration, a characteristic shared by enteropathogenic Escherichia coli and Shigella flexneri infections</title><source>Infect Immun</source><year>2008</year><volume>76</volume><fpage>369</fpage><lpage>379</lpage>
<author><surname>Wickham</surname> <given-names>ME</given-names> </author><author><surname>Lupp</surname> <given-names>C</given-names> </author><author><surname>Vazquez</surname> <given-names>A</given-names> </author><author><surname>Mascarenhas</surname> <given-names>M</given-names> </author><author><surname>Coburn</surname> <given-names>B</given-names> </author><author><surname>Coombes</surname> <given-names>BK</given-names> </author><author><surname>Karmali</surname> <given-names>MA</given-names> </author><author><surname>Puente</surname> <given-names>JL</given-names> </author><author><surname>Deng</surname> <given-names>W</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><title>Citrobacter rodentium virulence in mice associates with bacterial load and the type III effector NleE</title><source>Microbes Infect</source><year>2007</year><volume>9</volume><fpage>400</fpage><lpage>407</lpage>
<author><surname>Deng</surname> <given-names>W</given-names> </author><author><surname>de Hoog</surname> <given-names>CL</given-names> </author><author><surname>Yu</surname> <given-names>HB</given-names> </author><author><surname>Li</surname> <given-names>Y</given-names> </author><author><surname>Croxen</surname> <given-names>MA</given-names> </author><author><surname>Thomas</surname> <given-names>NA</given-names> </author><author><surname>Puente</surname> <given-names>JL</given-names> </author><author><surname>Foster</surname> <given-names>LJ</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><title>A comprehensive proteomic analysis of the type III secretome of Citrobacter rodentium</title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>6790</fpage><lpage>6800</lpage>
<author><surname>Nadler</surname> <given-names>C</given-names> </author><author><surname>Baruch</surname> <given-names>K</given-names> </author><author><surname>Kobi</surname> <given-names>S</given-names> </author><author><surname>Mills</surname> <given-names>E</given-names> </author><author><surname>Haviv</surname> <given-names>G</given-names> </author><author><surname>Farago</surname> <given-names>M</given-names> </author><author><surname>Alkalay</surname> <given-names>I</given-names> </author><author><surname>Bartfeld</surname> <given-names>S</given-names> </author><author><surname>Meyer</surname> <given-names>TF</given-names> </author><author><surname>Ben-Neriah</surname> <given-names>Y</given-names> </author><author><surname>Rosenshine</surname> <given-names>I</given-names> </author><title>The type III secretion effector NleE inhibits NF-kappaB activation</title><source>PLoS Pathog</source><year>2010</year><volume>6</volume><fpage>e1000743</fpage>
<author><surname>Vossenkamper</surname> <given-names>A</given-names> </author><author><surname>Marches</surname> <given-names>O</given-names> </author><author><surname>Fairclough</surname> <given-names>PD</given-names> </author><author><surname>Warnes</surname> <given-names>G</given-names> </author><author><surname>Stagg</surname> <given-names>AJ</given-names> </author><author><surname>Lindsay</surname> <given-names>JO</given-names> </author><author><surname>Evans</surname> <given-names>PC</given-names> </author><author><surname>Luong le</surname> <given-names>A</given-names> </author><author><surname>Croft</surname> <given-names>NM</given-names> </author><author><surname>Naik</surname> <given-names>S</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>MacDonald</surname> <given-names>TT</given-names> </author><title>Inhibition of NF-kappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE</title><source>J Immunol</source><year>2010</year><volume>185</volume><fpage>4118</fpage><lpage>4127</lpage>
<author><surname>Fitzhenry</surname> <given-names>RJ</given-names> </author><author><surname>Reece</surname> <given-names>S</given-names> </author><author><surname>Trabulsi</surname> <given-names>LR</given-names> </author><author><surname>Heuschkel</surname> <given-names>R</given-names> </author><author><surname>Murch</surname> <given-names>S</given-names> </author><author><surname>Thomson</surname> <given-names>M</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>Phillips</surname> <given-names>AD</given-names> </author><title>Tissue tropism of enteropathogenic Escherichia coli strains belonging to the O55 serogroup</title><source>Infect Immun</source><year>2002</year><volume>70</volume><fpage>4362</fpage><lpage>4368</lpage>
<author><surname>Caron</surname> <given-names>E</given-names> </author><author><surname>Hall</surname> <given-names>A</given-names> </author><title>Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases</title><source>Science</source><year>1998</year><volume>282</volume><fpage>1717</fpage><lpage>1721</lpage>
<author><surname>Celli</surname> <given-names>J</given-names> </author><author><surname>Olivier</surname> <given-names>M</given-names> </author><author><surname>Finlay</surname> <given-names>BB</given-names> </author><title>Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways</title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>1245</fpage><lpage>1258</lpage>
<author><surname>Dong</surname> <given-names>N</given-names> </author><author><surname>Liu</surname> <given-names>L</given-names> </author><author><surname>Shao</surname> <given-names>F</given-names> </author><title>A bacterial effector targets host DH-PH domain RhoGEFs and antagonizes macrophage phagocytosis</title><source>EMBO J</source><year>2010</year><volume>29</volume><fpage>1363</fpage><lpage>1376</lpage>
<author><surname>Iizumi</surname> <given-names>Y</given-names> </author><author><surname>Sagara</surname> <given-names>H</given-names> </author><author><surname>Kabe</surname> <given-names>Y</given-names> </author><author><surname>Azuma</surname> <given-names>M</given-names> </author><author><surname>Kume</surname> <given-names>K</given-names> </author><author><surname>Ogawa</surname> <given-names>M</given-names> </author><author><surname>Nagai</surname> <given-names>T</given-names> </author><author><surname>Gillespie</surname> <given-names>PG</given-names> </author><author><surname>Sasakawa</surname> <given-names>C</given-names> </author><author><surname>Handa</surname> <given-names>H</given-names> </author><title>The enteropathogenic E. coli effector EspB facilitates microvillus effacing and antiphagocytosis by inhibiting myosin function</title><source>Cell Host Microbe</source><year>2007</year><volume>2</volume><fpage>383</fpage><lpage>392</lpage>
<author><surname>Marches</surname> <given-names>O</given-names> </author><author><surname>Covarelli</surname> <given-names>V</given-names> </author><author><surname>Dahan</surname> <given-names>S</given-names> </author><author><surname>Cougoule</surname> <given-names>C</given-names> </author><author><surname>Bhatta</surname> <given-names>P</given-names> </author><author><surname>Frankel</surname> <given-names>G</given-names> </author><author><surname>Caron</surname> <given-names>E</given-names> </author><title>EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis</title><source>Cell Microbiol</source><year>2008</year><volume>10</volume><fpage>1104</fpage><lpage>1115</lpage>
<author><surname>Martinez-Argudo</surname> <given-names>I</given-names> </author><author><surname>Sands</surname> <given-names>C</given-names> </author><author><surname>Jepson</surname> <given-names>MA</given-names> </author><title>Translocation of enteropathogenic Escherichia coli across an in vitro M cell model is regulated by its type III secretion system</title><source>Cell Microbiol</source><year>2007</year><volume>9</volume><fpage>1538</fpage><lpage>1546</lpage>
<author><surname>Quitard</surname> <given-names>S</given-names> </author><author><surname>Dean</surname> <given-names>P</given-names> </author><author><surname>Maresca</surname> <given-names>M</given-names> </author><author><surname>Kenny</surname> <given-names>B</given-names> </author><title>The enteropathogenic Escherichia coli EspF effector molecule inhibits PI-3 kinase-mediated uptake independently of mitochondrial targeting</title><source>Cell Microbiol</source><year>2006</year><volume>8</volume><fpage>972</fpage><lpage>981</lpage>
<author><surname>Holmes</surname> <given-names>A</given-names> </author><author><surname>Muhlen</surname> <given-names>S</given-names> </author><author><surname>Roe</surname> <given-names>AJ</given-names> </author><author><surname>Dean</surname> <given-names>P</given-names> </author><title>The EspF effector, a bacterial pathogen's Swiss army knife</title><source>Infect Immun</source><year>2010</year><volume>78</volume><fpage>4445</fpage><lpage>4453</lpage>
<author><surname>Weflen</surname> <given-names>AW</given-names> </author><author><surname>Alto</surname> <given-names>NM</given-names> </author><author><surname>Viswanathan</surname> <given-names>VK</given-names> </author><author><surname>Hecht</surname> <given-names>G</given-names> </author><title>E. coli secreted protein F promotes EPEC invasion of intestinal epithelial cells via an SNX9-dependent mechanism</title><source>Cell Microbiol</source><year>2010</year><volume>12</volume><fpage>919</fpage><lpage>929</lpage>
<author><surname>Selyunin</surname> <given-names>AS</given-names> </author><author><surname>Sutton</surname> <given-names>SE</given-names> </author><author><surname>Weigele</surname> <given-names>BA</given-names> </author><author><surname>Reddick</surname> <given-names>LE</given-names> </author><author><surname>Orchard</surname> <given-names>RC</given-names> </author><author><surname>Bresson</surname> <given-names>SM</given-names> </author><author><surname>Tomchick</surname> <given-names>DR</given-names> </author><author><surname>Alto</surname> <given-names>NM</given-names> </author><title>The assembly of a GTPase-kinase signalling complex by a bacterial catalytic scaffold</title><source>Nature</source><year>2011</year><volume>469</volume><fpage>107</fpage><lpage>111</lpage>
<author><surname>Niedergang</surname> <given-names>F</given-names> </author><author><surname>Colucci-Guyon</surname> <given-names>E</given-names> </author><author><surname>Dubois</surname> <given-names>T</given-names> </author><author><surname>Raposo</surname> <given-names>G</given-names> </author><author><surname>Chavrier</surname> <given-names>P</given-names> </author><title>ADP ribosylation factor 6 is activated and controls membrane delivery during phagocytosis in macrophages</title><source>J Cell Biol</source><year>2003</year><volume>161</volume><fpage>1143</fpage><lpage>1150</lpage>
<author><surname>Maddocks</surname> <given-names>OD</given-names> </author><author><surname>Short</surname> <given-names>AJ</given-names> </author><author><surname>Donnenberg</surname> <given-names>MS</given-names> </author><author><surname>Bader</surname> <given-names>S</given-names> </author><author><surname>Harrison</surname> <given-names>DJ</given-names> </author><title>Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans</title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e5517</fpage>
<author><surname>Spehlmann</surname> <given-names>ME</given-names> </author><author><surname>Dann</surname> <given-names>SM</given-names> </author><author><surname>Hruz</surname> <given-names>P</given-names> </author><author><surname>Hanson</surname> <given-names>E</given-names> </author><author><surname>McCole</surname> <given-names>DF</given-names> </author><author><surname>Eckmann</surname> <given-names>L</given-names> </author><title>CXCR2-dependent mucosal neutrophil influx protects against colitis-associated diarrhea caused by an attaching/effacing lesion-forming bacterial pathogen</title><source>J Immunol</source><year>2009</year><volume>183</volume><fpage>3332</fpage><lpage>3343</lpage>
<title>IAAF.org Home of World Athletics</title><url>http://www.iaaf.org/mm/document/imported/38451.pdf</url>
<author><surname>Rodriguez</surname> <given-names>NR</given-names> </author><author><surname>Di Marco</surname> <given-names>NM</given-names> </author><author><surname>Langley</surname> <given-names>S</given-names> </author><title>American College of Sports Medicine position stand. Nutrition and athletic performance</title><source>Med Sci Sports Exerc</source><year>2009</year><volume>41</volume><fpage>709</fpage><lpage>731</lpage>
<author><surname>Friedman</surname> <given-names>JE</given-names> </author><author><surname>Lemon</surname> <given-names>PW</given-names> </author><title>Effect of chronic endurance exercise on retention of dietary protein</title><source>Int J Sports Med</source><year>1989</year><volume>10</volume><fpage>118</fpage><lpage>123</lpage>
<author><surname>Gaine</surname> <given-names>PC</given-names> </author><author><surname>Pikosky</surname> <given-names>MA</given-names> </author><author><surname>Martin</surname> <given-names>WF</given-names> </author><author><surname>Bolster</surname> <given-names>DR</given-names> </author><author><surname>Maresh</surname> <given-names>CM</given-names> </author><author><surname>Rodriguez</surname> <given-names>NR</given-names> </author><title>Level of dietary protein impacts whole body protein turnover in trained males at rest</title><source>Metabolism</source><year>2006</year><volume>55</volume><fpage>501</fpage><lpage>507</lpage>
<author><surname>Meredith</surname> <given-names>CN</given-names> </author><author><surname>Zackin</surname> <given-names>MJ</given-names> </author><author><surname>Frontera</surname> <given-names>WR</given-names> </author><author><surname>Evans</surname> <given-names>WJ</given-names> </author><title>Dietary protein requirements and body protein metabolism in endurance-trained men</title><source>J Appl Physiol</source><year>1989</year><volume>66</volume><fpage>2850</fpage><lpage>2856</lpage>
Genton<title>Clinical Nutrition University: Calorie and macronutrient requirements for physical fitness</title><source>e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism</source> in press
<author><surname>Sawka</surname> <given-names>MN</given-names> </author><author><surname>Burke</surname> <given-names>LM</given-names> </author><author><surname>Eichner</surname> <given-names>ER</given-names> </author><author><surname>Maughan</surname> <given-names>RJ</given-names> </author><author><surname>Montain</surname> <given-names>SJ</given-names> </author><author><surname>Stachenfeld</surname> <given-names>NS</given-names> </author><title>American College of Sports Medicine position stand. Exercise and fluid replacement</title><source>Med Sci Sports Exerc</source><year>2007</year><volume>39</volume><fpage>377</fpage><lpage>390</lpage>
<author><surname>Fudge</surname> <given-names>BW</given-names> </author><author><surname>Easton</surname> <given-names>C</given-names> </author><author><surname>Kingsmore</surname> <given-names>D</given-names> </author><author><surname>Kiplamai</surname> <given-names>FK</given-names> </author><author><surname>Onywera</surname> <given-names>VO</given-names> </author><author><surname>Westerterp</surname> <given-names>KR</given-names> </author><author><surname>Kayser</surname> <given-names>B</given-names> </author><author><surname>Noakes</surname> <given-names>TD</given-names> </author><author><surname>Pitsiladis</surname> <given-names>YP</given-names> </author><title>Elite Kenyan endurance runners are hydrated day-to-day with ad libitum fluid intake</title><source>Med Sci Sports Exerc</source><year>2008</year><volume>40</volume><fpage>1171</fpage><lpage>1179</lpage>
<author><surname>Onywera</surname> <given-names>VO</given-names> </author><author><surname>Kiplamai</surname> <given-names>FK</given-names> </author><author><surname>Boit</surname> <given-names>MK</given-names> </author><author><surname>Pitsiladis</surname> <given-names>YP</given-names> </author><title>Food and macronutrient intake of elite kenyan distance runners</title><source>Int J Sport Nutr Exerc Metab</source><year>2004</year><volume>14</volume><fpage>709</fpage><lpage>719</lpage>
<author><surname>Scott</surname> <given-names>RA</given-names> </author><author><surname>Fuku</surname> <given-names>N</given-names> </author><author><surname>Onywera</surname> <given-names>VO</given-names> </author><author><surname>Boit</surname> <given-names>M</given-names> </author><author><surname>Wilson</surname> <given-names>RH</given-names> </author><author><surname>Tanaka</surname> <given-names>M</given-names> </author><author><surname>W</surname> <given-names>HG</given-names> </author><author><surname>Pitsiladis</surname> <given-names>YP</given-names> </author><title>Mitochondrial haplogroups associated with elite Kenyan athlete status</title><source>Med Sci Sports Exerc</source><year>2009</year><volume>41</volume><fpage>123</fpage><lpage>128</lpage>
<author><surname>Scott</surname> <given-names>RA</given-names> </author><author><surname>Pitsiladis</surname> <given-names>YP</given-names> </author><title>Genotypes and distance running: clues from Africa</title><source>Sports Med</source><year>2007</year><volume>37</volume><fpage>424</fpage><lpage>427</lpage>
<title>IAAF.org Home of World Athletics</title><url>http://www.iaaf.org</url>
<author><surname>Hamilton</surname> <given-names>B</given-names> </author><title>East African running dominance: what is behind it?</title><source>Br J Sports Med</source><year>2000</year><volume>34</volume><fpage>391</fpage><lpage>394</lpage>
<author><surname>Scott</surname> <given-names>RA</given-names> </author><author><surname>Georgiades</surname> <given-names>E</given-names> </author><author><surname>Wilson</surname> <given-names>RH</given-names> </author><author><surname>Goodwin</surname> <given-names>WH</given-names> </author><author><surname>Wolde</surname> <given-names>B</given-names> </author><author><surname>Pitsiladis</surname> <given-names>YP</given-names> </author><title>Demographic characteristics of elite Ethiopian endurance runners</title><source>Med Sci Sports Exerc</source><year>2003</year><volume>35</volume><fpage>1727</fpage><lpage>1732</lpage>
<author><surname>Onywera</surname> <given-names>VO</given-names> </author><author><surname>Scott</surname> <given-names>RA</given-names> </author><author><surname>Boit</surname> <given-names>MK</given-names> </author><author><surname>Pitsiladis</surname> <given-names>YP</given-names> </author><title>Demographic characteristics of elite Kenyan endurance runners</title><source>J Sports Sci</source><year>2006</year><volume>24</volume><fpage>415</fpage><lpage>422</lpage>
<author><surname>Christensen</surname> <given-names>DL</given-names> </author><author><surname>Van Hall</surname> <given-names>G</given-names> </author><author><surname>Hambraeus</surname> <given-names>L</given-names> </author><title>Food and macronutrient intake of male adolescent Kalenjin runners in Kenya</title><source>Br J Nutr</source><year>2002</year><volume>88</volume><fpage>711</fpage><lpage>717</lpage>
<author><surname>Mukeshi</surname> <given-names>M</given-names> </author><author><surname>Thairu</surname> <given-names>K</given-names> </author><title>Nutrition and body build: a Kenyan review</title><source>World Rev Nutr Diet</source><year>1993</year><volume>72</volume><fpage>218</fpage><lpage>226</lpage>
<author><surname>Fudge</surname> <given-names>BW</given-names> </author><author><surname>Westerterp</surname> <given-names>KR</given-names> </author><author><surname>Kiplamai</surname> <given-names>FK</given-names> </author><author><surname>Onywera</surname> <given-names>VO</given-names> </author><author><surname>Boit</surname> <given-names>MK</given-names> </author><author><surname>Kayser</surname> <given-names>B</given-names> </author><author><surname>Pitsiladis</surname> <given-names>YP</given-names> </author><title>Evidence of negative energy balance using doubly labelled water in elite Kenyan endurance runners prior to competition</title><source>Br J Nutr</source><year>2006</year><volume>95</volume><fpage>59</fpage><lpage>66</lpage>
<author><surname>Marfell-Jones</surname> <given-names>M</given-names> </author><author><surname>Olds</surname> <given-names>T</given-names> </author><author><surname>Stewart</surname> <given-names>A</given-names> </author><author><surname>Carter</surname> <given-names>L</given-names> </author><title>International Standards for Anthropometric Assessment</title><source>International Society for the Advancement of Kinanthropometry ISAK</source><year>2006</year><issue>2</issue><publisher>Potchefstroom</publisher>
<author><surname>Lissner</surname> <given-names>L</given-names> </author><author><surname>Heitmann</surname> <given-names>BL</given-names> </author><author><surname>Lindroos</surname> <given-names>AK</given-names> </author><title>Measuring intake in free-living human subjects: a question of bias</title><source>Proc Nutr Soc</source><year>1998</year><volume>57</volume><fpage>333</fpage><lpage>339</lpage>
<author><surname>Ainsworth</surname> <given-names>BE</given-names> </author><author><surname>Haskell</surname> <given-names>WL</given-names> </author><author><surname>Whitt</surname> <given-names>MC</given-names> </author><author><surname>Irwin</surname> <given-names>ML</given-names> </author><author><surname>Swartz</surname> <given-names>AM</given-names> </author><author><surname>Strath</surname> <given-names>SJ</given-names> </author><author><surname>O'Brien</surname> <given-names>WL</given-names> </author><author><surname>Bassett</surname> <given-names>DR</given-names> <suffix>Jr</suffix> </author><author><surname>Schmitz</surname> <given-names>KH</given-names> </author><author><surname>Emplaincourt</surname> <given-names>PO</given-names> </author><etal /><title>Compendium of physical activities: an update of activity codes and MET intensities</title><source>Med Sci Sports Exerc</source><year>2000</year><volume>32</volume><fpage>S498</fpage><lpage>504</lpage>
<author><surname>Schofield</surname> <given-names>WN</given-names> </author><title>Predicting basal metabolic rate, new standards and review of previous work</title><source>Hum Nutr Clin Nutr</source><year>1985</year><volume>39</volume><issue>Suppl 1</issue><fpage>5</fpage><lpage>41</lpage>
<author><surname>Fjeld</surname> <given-names>CR</given-names> </author><author><surname>Brown</surname> <given-names>KH</given-names> </author><author><surname>Schoeller</surname> <given-names>DA</given-names> </author><title>Validation of the deuterium oxide method for measuring average daily milk intake in infants</title><source>Am J Clin Nutr</source><year>1988</year><volume>48</volume><fpage>671</fpage><lpage>679</lpage>
<author><surname>Holland</surname> <given-names>B</given-names> </author><author><surname>Welch</surname> <given-names>AA</given-names> </author><author><surname>Unwin</surname> <given-names>ID</given-names> </author><author><surname>Buss</surname> <given-names>DH</given-names> </author><author><surname>Paul</surname> <given-names>AA</given-names> </author><author><surname>Southgate</surname> <given-names>DAT</given-names> </author><source>The composition of foods. Fifth revised and extended edition of McCance RA, Widdowson ED</source><year>1991</year><publisher>Cambridge, UK</publisher>
Ethiopian Health and Nutrition Research Institute<title>Food Composition Table For Use In Ethiopia Part IV</title><year>1998</year>
<author><surname>Westerterp-Plantenga</surname> <given-names>MS</given-names> </author><author><surname>Rolland</surname> <given-names>V</given-names> </author><author><surname>Wilson</surname> <given-names>SA</given-names> </author><author><surname>Westerterp</surname> <given-names>KR</given-names> </author><title>Satiety related to 24 h diet-induced thermogenesis during high protein/carbohydrate vs high fat diets measured in a respiration chamber</title><source>Eur J Clin Nutr</source><year>1999</year><volume>53</volume><fpage>495</fpage><lpage>502</lpage>
<author><surname>Ward</surname> <given-names>MP</given-names> </author><author><surname>Milledge</surname> <given-names>JS</given-names> </author><author><surname>West</surname> <given-names>JB</given-names> </author><source>High Altitude Medicine and Physiology</source><year>1995</year><publisher>Chapman &amp; Hall Medical, London</publisher>
<author><surname>Coyle</surname> <given-names>EF</given-names> </author><author><surname>Jeukendrup</surname> <given-names>AE</given-names> </author><author><surname>Oseto</surname> <given-names>MC</given-names> </author><author><surname>Hodgkinson</surname> <given-names>BJ</given-names> </author><author><surname>Zderic</surname> <given-names>TW</given-names> </author><title>Low-fat diet alters intramuscular substrates and reduces lipolysis and fat oxidation during exercise</title><source>Am J Physiol Endocrinol Metab</source><year>2001</year><volume>280</volume><fpage>E391</fpage><lpage>398</lpage>
<author><surname>Cerqueira</surname> <given-names>MT</given-names> </author><author><surname>Fry</surname> <given-names>MM</given-names> </author><author><surname>Connor</surname> <given-names>WE</given-names> </author><title>The food and nutrient intakes of the Tarahumara Indians of Mexico</title><source>Am J Clin Nutr</source><year>1979</year><volume>32</volume><fpage>905</fpage><lpage>915</lpage>
<author><surname>Burke</surname> <given-names>LM</given-names> </author><author><surname>Gollan</surname> <given-names>RA</given-names> </author><author><surname>Read</surname> <given-names>RS</given-names> </author><title>Dietary intakes and food use of groups of elite Australian male athletes</title><source>Int J Sport Nutr</source><year>1991</year><volume>1</volume><fpage>378</fpage><lpage>394</lpage>
<author><surname>Grandjean</surname> <given-names>AC</given-names> </author><title>Macronutrient intake of US athletes compared with the general population and recommendations made for athletes</title><source>Am J Clin Nutr</source><year>1989</year><volume>49</volume><fpage>1070</fpage><lpage>1076</lpage>
<author><surname>van Erp-Baart</surname> <given-names>AM</given-names> </author><author><surname>Saris</surname> <given-names>WH</given-names> </author><author><surname>Binkhorst</surname> <given-names>RA</given-names> </author><author><surname>Vos</surname> <given-names>JA</given-names> </author><author><surname>Elvers</surname> <given-names>JW</given-names> </author><title>Nationwide survey on nutritional habits in elite athletes. Part I. Energy, carbohydrate, protein, and fat intake</title><source>Int J Sports Med</source><year>1989</year><volume>10</volume><issue>Suppl 1</issue><fpage>S3</fpage><lpage>10</lpage>
National Research Council<source>Recommended Dietary Allowances</source><year>1989</year><publisher>DC Press: National Academy, Washington</publisher><fpage>249</fpage>
<author><surname>Armstrong</surname> <given-names>LE</given-names> </author><author><surname>Costill</surname> <given-names>DL</given-names> </author><author><surname>Fink</surname> <given-names>WJ</given-names> </author><title>Influence of diuretic-induced dehydration on competitive running performance</title><source>Med Sci Sports Exerc</source><year>1985</year><volume>17</volume><fpage>456</fpage><lpage>461</lpage>
<author><surname>Coyle</surname> <given-names>EF</given-names> </author><title>Fluid and fuel intake during exercise</title><source>J Sports Sci</source><year>2004</year><volume>22</volume><fpage>39</fpage><lpage>55</lpage>
<author><surname>Ballantyne</surname> <given-names>GH</given-names> </author><title>The historical evolution of anatomic concepts of rectal prolapse</title><source>Semin Colon Rectal Surg</source><year>1991</year><volume>2</volume><fpage>170</fpage><lpage>179</lpage>
<author><surname>Moschowitz</surname> <given-names>AV</given-names> </author><title>The pathogenesis, anatomy and cure of prolapse of the rectum</title><source>Surg Gynecol Obstet</source><year>1912</year><volume>15</volume><fpage>7</fpage><lpage>21</lpage>
<author><surname>Broden</surname> <given-names>B</given-names> </author><author><surname>Snellman</surname> <given-names>B</given-names> </author><title>Procidentia of the rectum studied with cineradiography: a contribution to the discussion of causative mechanism</title><source>Dis Colon Rectum</source><year>1968</year><volume>11</volume><fpage>330</fpage><lpage>347</lpage>
<author><surname>Theuerkauf</surname> <given-names>FJ</given-names> <suffix>Jr</suffix> </author><author><surname>Beahrs</surname> <given-names>OH</given-names> </author><author><surname>Hill</surname> <given-names>JR</given-names> </author><title>Rectal prolapsed: causation and surgical treatment</title><source>Ann Surg</source><year>1970</year><volume>171</volume><fpage>819</fpage><lpage>835</lpage>
<author><surname>Shorvon</surname> <given-names>PJ</given-names> </author><author><surname>McHugh</surname> <given-names>S</given-names> </author><author><surname>Diamant</surname> <given-names>NE</given-names> </author><author><surname>Somers</surname> <given-names>S</given-names> </author><author><surname>Stevenson</surname> <given-names>GW</given-names> </author><title>Defecography in normal volunteers: results and implications</title><source>Gut</source><year>1989</year><volume>30</volume><fpage>1737</fpage><lpage>1749</lpage>
<author><surname>Mellgren</surname> <given-names>A</given-names> </author><author><surname>Schultz</surname> <given-names>I</given-names> </author><author><surname>Johansson</surname> <given-names>C</given-names> </author><author><surname>Dolk</surname> <given-names>A</given-names> </author><title>Internal rectal intussusception seldom develops into total rectal prolapse</title><source>Dis Colon Rectum</source><year>1997</year><volume>40</volume><fpage>817</fpage><lpage>820</lpage>
<author><surname>Parks</surname> <given-names>AG</given-names> </author><author><surname>Swash</surname> <given-names>M</given-names> </author><author><surname>Urich</surname> <given-names>H</given-names> </author><title>Sphincter denervation in anorectal incontinence and rectal prolapse</title><source>Gut</source><year>1977</year><volume>18</volume><fpage>656</fpage><lpage>665</lpage>
<author><surname>Kuijpers</surname> <given-names>HC</given-names> </author><title>Treatment of complete rectal prolapse: to narrow, to wrap, to suspend, to fix, to encircle, to plicate or to resect?</title><source>World J Surg</source><year>1992</year><volume>16</volume><fpage>826</fpage><lpage>830</lpage>
<author><surname>Altman</surname> <given-names>D</given-names> </author><author><surname>Zetterstrom</surname> <given-names>J</given-names> </author><author><surname>Schultz</surname> <given-names>I</given-names> </author><author><surname>Nordenstam</surname> <given-names>J</given-names> </author><author><surname>Hjern</surname> <given-names>F</given-names> </author><author><surname>Lopez</surname> <given-names>A</given-names> </author><title>Pelvic organ prolapse and urinary incontinence in women with surgically managed rectal prolapse: a population-based case-control study</title><source>Dis Colon Rectum</source><year>2006</year><volume>49</volume><fpage>28</fpage><lpage>35</lpage>
<author><surname>Hamalainen</surname> <given-names>KJ</given-names> </author><author><surname>Raivio</surname> <given-names>P</given-names> </author><author><surname>Antila</surname> <given-names>S</given-names> </author><author><surname>Palmu</surname> <given-names>A</given-names> </author><author><surname>Mecklin</surname> <given-names>JP</given-names> </author><title>Biofeedback therapy in rectal prolapse patients</title><source>Dis Colon Rectum</source><year>1996</year><volume>39</volume><fpage>262</fpage><lpage>265</lpage>
<author><surname>Corman</surname> <given-names>ML</given-names> </author><source>Colon and rectal surgery</source><year>2005</year><other>Philadelphia</other><publisher>Lippincott Williams &amp; Wilkins</publisher>
<author><surname>Thiersch</surname> <given-names>C</given-names> </author><title>Carl Thiersch 1822-1895. Concerning prolapse of the rectum with special emphasis on the operation by Thiersch</title><source>Dis Colon Rectum</source><year>1988</year><volume>31</volume><fpage>154</fpage><lpage>155</lpage>
<author><surname>Labow</surname> <given-names>S</given-names> </author><author><surname>Rubin</surname> <given-names>RJ</given-names> </author><author><surname>Hoexter</surname> <given-names>B</given-names> </author><author><surname>Salvati</surname> <given-names>EP</given-names> </author><title>Perineal repair of rectal procidentia with an elastic fabric sling</title><source>Dis Colon Rectum</source><year>1980</year><volume>23</volume><fpage>467</fpage><lpage>469</lpage>
<author><surname>Poole</surname> <given-names>GV</given-names> <suffix>Jr</suffix> </author><author><surname>Pennell</surname> <given-names>TC</given-names> </author><author><surname>Myers</surname> <given-names>RT</given-names> </author><author><surname>Hightower</surname> <given-names>F</given-names> </author><title>Modified Thiersch operation for rectal prolapse. Technique and results</title><source>Am Surg</source><year>1985</year><volume>51</volume><fpage>226</fpage><lpage>229</lpage>
<author><surname>Earnshaw</surname> <given-names>JJ</given-names> </author><author><surname>Hopkinson</surname> <given-names>BR</given-names> </author><title>Late results of silicone rubber perianal suture for rectal prolapse</title><source>Dis Colon Rectum</source><year>1987</year><volume>30</volume><fpage>86</fpage><lpage>88</lpage>
<author><surname>Hunt</surname> <given-names>TM</given-names> </author><author><surname>Fraser</surname> <given-names>IA</given-names> </author><author><surname>Maybury</surname> <given-names>NK</given-names> </author><title>Treatment of rectal prolapse by sphincteric support using silastic rods</title><source>Br J Surg</source><year>1985</year><volume>72</volume><fpage>491</fpage><lpage>492</lpage>
<title>Classic articles in colonic and rectal surgery. Edmond Delorme 1847-1929. On the treatment of total prolapse of the rectum by excision of the rectal mucous membranes or recto-colic</title><source>Dis Colon Rectum</source><year>1985</year><volume>28</volume><fpage>544</fpage><lpage>553</lpage>
<author><surname>Senapati</surname> <given-names>A</given-names> </author><author><surname>Nicholls</surname> <given-names>RJ</given-names> </author><author><surname>Thomson</surname> <given-names>JP</given-names> </author><author><surname>Phillips</surname> <given-names>RK</given-names> </author><title>Results of Delorme's procedure for rectal prolapse</title><source>Dis Colon Rectum</source><year>1994</year><volume>37</volume><fpage>456</fpage><lpage>460</lpage>
<author><surname>Watts</surname> <given-names>AM</given-names> </author><author><surname>Thompson</surname> <given-names>MR</given-names> </author><title>Evaluation of Delorme's procedure as a treatment for full-thickness rectal prolapse</title><source>Br J Surg</source><year>2000</year><volume>87</volume><fpage>218</fpage><lpage>222</lpage>
<author><surname>Lechaux</surname> <given-names>JP</given-names> </author><author><surname>Lechaux</surname> <given-names>D</given-names> </author><author><surname>Perez</surname> <given-names>M</given-names> </author><title>Results of Delorme's procedure for rectal prolapsed: advantages of a modified technique</title><source>Dis Colon Rectum</source><year>1995</year><volume>38</volume><fpage>301</fpage><lpage>307</lpage>
<author><surname>Oliver</surname> <given-names>GC</given-names> </author><author><surname>Vachon</surname> <given-names>D</given-names> </author><author><surname>Eisenstat</surname> <given-names>TE</given-names> </author><author><surname>Rubin</surname> <given-names>RJ</given-names> </author><author><surname>Salvati</surname> <given-names>EP</given-names> </author><title>Delorme's procedure for complete rectal prolapse in severely debilitated patients: an analysis of 41 cases</title><source>Dis Colon Rectum</source><year>1994</year><volume>37</volume><fpage>461</fpage><lpage>467</lpage>
<author><surname>Byun</surname> <given-names>SW</given-names> </author><author><surname>Kim</surname> <given-names>HS</given-names> </author><title>Results of Delorme's procedure for rectal prolapse</title><source>J Korean Soc Coloproctol</source><year>2000</year><volume>16</volume><fpage>407</fpage><lpage>414</lpage>
<author><surname>Tobin</surname> <given-names>SA</given-names> </author><author><surname>Scott</surname> <given-names>IH</given-names> </author><title>Delorme operation for rectal prolapse</title><source>Br J Surg</source><year>1994</year><volume>81</volume><fpage>1681</fpage><lpage>1684</lpage>
<author><surname>Altemeier</surname> <given-names>WA</given-names> </author><author><surname>Culbertson</surname> <given-names>WR</given-names> </author><author><surname>Schowengerdt</surname> <given-names>C</given-names> </author><author><surname>Hunt</surname> <given-names>J</given-names> </author><title>Nineteen years' experience with the one-stage perineal repair of rectal prolapse</title><source>Ann Surg</source><year>1971</year><volume>173</volume><fpage>993</fpage><lpage>1006</lpage>
<author><surname>Agachan</surname> <given-names>F</given-names> </author><author><surname>Pfeifer</surname> <given-names>J</given-names> </author><author><surname>Joo</surname> <given-names>JS</given-names> </author><author><surname>Nogueras</surname> <given-names>JJ</given-names> </author><author><surname>Weiss</surname> <given-names>EG</given-names> </author><author><surname>Wexner</surname> <given-names>SD</given-names> </author><title>Results of perineal procedures for the treatment of rectal prolapse</title><source>Am Surg</source><year>1997</year><volume>63</volume><fpage>9</fpage><lpage>12</lpage>
<author><surname>Watts</surname> <given-names>JD</given-names> </author><author><surname>Rothenberger</surname> <given-names>DA</given-names> </author><author><surname>Buls</surname> <given-names>JG</given-names> </author><author><surname>Goldberg</surname> <given-names>SM</given-names> </author><author><surname>Nivatvongs</surname> <given-names>S</given-names> </author><title>The management of procidentia. 30 years' experience</title><source>Dis Colon Rectum</source><year>1985</year><volume>28</volume><fpage>96</fpage><lpage>102</lpage>
<author><surname>Williams</surname> <given-names>JG</given-names> </author><author><surname>Rothenberger</surname> <given-names>DA</given-names> </author><author><surname>Madoff</surname> <given-names>RD</given-names> </author><author><surname>Goldberg</surname> <given-names>SM</given-names> </author><title>Treatment of rectal prolapse in the elderly by perineal rectosigmoidectomy</title><source>Dis Colon Rectum</source><year>1992</year><volume>35</volume><fpage>830</fpage><lpage>834</lpage>
<author><surname>Prasad</surname> <given-names>ML</given-names> </author><author><surname>Pearl</surname> <given-names>RK</given-names> </author><author><surname>Abcarian</surname> <given-names>H</given-names> </author><author><surname>Orsay</surname> <given-names>CP</given-names> </author><author><surname>Nelson</surname> <given-names>RL</given-names> </author><title>Perineal proctectomy, posterior rectopexy, and postanal levator repair for the treatment of rectal prolapse</title><source>Dis Colon Rectum</source><year>1986</year><volume>29</volume><fpage>547</fpage><lpage>552</lpage>
<author><surname>Rhyu</surname> <given-names>PG</given-names> </author><author><surname>Baek</surname> <given-names>MJ</given-names> </author><author><surname>Lee</surname> <given-names>MS</given-names> </author><author><surname>Kim</surname> <given-names>CH</given-names> </author><author><surname>Song</surname> <given-names>OP</given-names> </author><author><surname>Cho</surname> <given-names>MS</given-names> </author><title>Treatment of rectal prolapse by a perineal rectosigmoidectomy</title><source>J Korean Surg Soc</source><year>1998</year><volume>55</volume><fpage>868</fpage><lpage>873</lpage>
<author><surname>Pikarsky</surname> <given-names>AJ</given-names> </author><author><surname>Joo</surname> <given-names>JS</given-names> </author><author><surname>Wexner</surname> <given-names>SD</given-names> </author><author><surname>Weiss</surname> <given-names>EG</given-names> </author><author><surname>Nogueras</surname> <given-names>JJ</given-names> </author><author><surname>Agachan</surname> <given-names>F</given-names> </author><title>Recurrent rectal prolapse: what is the next good option?</title><source>Dis Colon Rectum</source><year>2000</year><volume>43</volume><fpage>1273</fpage><lpage>1276</lpage>
<author><surname>Fengler</surname> <given-names>SA</given-names> </author><author><surname>Pearl</surname> <given-names>RK</given-names> </author><author><surname>Prasad</surname> <given-names>ML</given-names> </author><author><surname>Orsay</surname> <given-names>CP</given-names> </author><author><surname>Cintron</surname> <given-names>JR</given-names> </author><author><surname>Hambrick</surname> <given-names>E</given-names> </author><title>Management of recurrent rectal prolapse</title><source>Dis Colon Rectum</source><year>1997</year><volume>40</volume><fpage>832</fpage><lpage>834</lpage>
<author><surname>Yamana</surname> <given-names>T</given-names> </author><author><surname>Iwadare</surname> <given-names>J</given-names> </author><title>Mucosal plication (Gant-Miwa procedure) with anal encircling for rectal prolapsed: a review of the Japanese experience</title><source>Dis Colon Rectum</source><year>2003</year><volume>46</volume><fpage>S94</fpage><lpage>S99</lpage>
<author><surname>Lim</surname> <given-names>SW</given-names> </author><author><surname>Lee</surname> <given-names>CH</given-names> </author><author><surname>Lee</surname> <given-names>KR</given-names> </author><author><surname>Yoo</surname> <given-names>CJ</given-names> </author><author><surname>Park</surname> <given-names>SY</given-names> </author><author><surname>Kim</surname> <given-names>HS</given-names> </author><title>Clinical analysis of Gant-Miwa operation with Thiersch wiring based on 50 cases of rectal prolapse</title><source>J Korean Soc Coloproctol</source><year>1996</year><volume>12</volume><fpage>503</fpage><lpage>510</lpage>
<author><surname>Kim</surname> <given-names>JD</given-names> </author><author><surname>Ye</surname> <given-names>BK</given-names> </author><author><surname>Jo</surname> <given-names>HJ</given-names> </author><author><surname>Oh</surname> <given-names>NG</given-names> </author><title>Transanal posterior anorectoplasty of rectal prolapse</title><source>J Korean Soc Coloproctol</source><year>2002</year><volume>18</volume><fpage>269</fpage><lpage>273</lpage>
<author><surname>Muir</surname> <given-names>EG</given-names> </author><title>The surgical treatment of severe rectal prolapse</title><source>Proc R Soc Med</source><year>1959</year><volume>52</volume><issue>Suppl</issue><fpage>104</fpage><lpage>105</lpage>
<author><surname>Novell</surname> <given-names>JR</given-names> </author><author><surname>Osborne</surname> <given-names>MJ</given-names> </author><author><surname>Winslet</surname> <given-names>MC</given-names> </author><author><surname>Lewis</surname> <given-names>AA</given-names> </author><title>Prospective randomized trial of Ivalon sponge versus sutured rectopexy for full-thickness rectal prolapse</title><source>Br J Surg</source><year>1994</year><volume>81</volume><fpage>904</fpage><lpage>906</lpage>
<author><surname>Kim</surname> <given-names>KY</given-names> </author><author><surname>Shin</surname> <given-names>JH</given-names> </author><author><surname>Kim</surname> <given-names>YS</given-names> </author><title>A clinical analysis of rectal prolapse treated by presacral rectopexy</title><source>J Korean Soc Coloproctol</source><year>1991</year><volume>7</volume><fpage>45</fpage><lpage>49</lpage>
<author><surname>Briel</surname> <given-names>JW</given-names> </author><author><surname>Schouten</surname> <given-names>WR</given-names> </author><author><surname>Boerma</surname> <given-names>MO</given-names> </author><title>Long-term results of suture rectopexy in patients with fecal incontinence associated with incomplete rectal prolapse</title><source>Dis Colon Rectum</source><year>1997</year><volume>40</volume><fpage>1228</fpage><lpage>1232</lpage>
<author><surname>Holmstrom</surname> <given-names>B</given-names> </author><author><surname>Broden</surname> <given-names>G</given-names> </author><author><surname>Dolk</surname> <given-names>A</given-names> </author><title>Results of the Ripstein operation in the treatment of rectal prolapse and internal rectal procidentia</title><source>Dis Colon Rectum</source><year>1986</year><volume>29</volume><fpage>845</fpage><lpage>848</lpage>
<author><surname>Tjandra</surname> <given-names>JJ</given-names> </author><author><surname>Fazio</surname> <given-names>VW</given-names> </author><author><surname>Church</surname> <given-names>JM</given-names> </author><author><surname>Milsom</surname> <given-names>JW</given-names> </author><author><surname>Oakley</surname> <given-names>JR</given-names> </author><author><surname>Lavery</surname> <given-names>IC</given-names> </author><title>Ripstein procedure is an effective treatment for rectal prolapse without constipation</title><source>Dis Colon Rectum</source><year>1993</year><volume>36</volume><fpage>501</fpage><lpage>507</lpage>
<author><surname>Roberts</surname> <given-names>PL</given-names> </author><author><surname>Schoetz</surname> <given-names>DJ</given-names> <suffix>Jr</suffix> </author><author><surname>Coller</surname> <given-names>JA</given-names> </author><author><surname>Veidenheimer</surname> <given-names>MC</given-names> </author><title>Ripstein procedure. Lahey Clinic experience: 1963-1985</title><source>Arch Surg</source><year>1988</year><volume>123</volume><fpage>554</fpage><lpage>557</lpage>
<author><surname>Launer</surname> <given-names>DP</given-names> </author><author><surname>Fazio</surname> <given-names>VW</given-names> </author><author><surname>Weakley</surname> <given-names>FL</given-names> </author><author><surname>Turnhull</surname> <given-names>RB</given-names> <suffix>Jr</suffix> </author><author><surname>Jagelman</surname> <given-names>DG</given-names> </author><author><surname>Lavery</surname> <given-names>IC</given-names> </author><title>The Ripstein procedure: a 16-year experience</title><source>Dis Colon Rectum</source><year>1982</year><volume>25</volume><fpage>41</fpage><lpage>45</lpage>
<author><surname>Schultz</surname> <given-names>I</given-names> </author><author><surname>Mellgren</surname> <given-names>A</given-names> </author><author><surname>Dolk</surname> <given-names>A</given-names> </author><author><surname>Johansson</surname> <given-names>C</given-names> </author><author><surname>Holmstr&#246;m</surname> <given-names>B</given-names> </author><title>Long-term results and functional outcome after Ripstein rectopexy</title><source>Dis Colon Rectum</source><year>2000</year><volume>43</volume><fpage>35</fpage><lpage>43</lpage>
<author><surname>Winde</surname> <given-names>G</given-names> </author><author><surname>Reers</surname> <given-names>B</given-names> </author><author><surname>Nottberg</surname> <given-names>H</given-names> </author><author><surname>Berns</surname> <given-names>T</given-names> </author><author><surname>Meyer</surname> <given-names>J</given-names> </author><author><surname>B&#252;nte</surname> <given-names>H</given-names> </author><title>Clinical and functional results of abdominal rectopexy with absorbable mesh-graft for treatment of complete rectal prolapse</title><source>Eur J Surg</source><year>1993</year><volume>159</volume><fpage>301</fpage><lpage>305</lpage>
<author><surname>McMahan</surname> <given-names>JD</given-names> </author><author><surname>Ripstein</surname> <given-names>CB</given-names> </author><title>Rectal prolapsed: an update on the rectal sling procedure</title><source>Am Surg</source><year>1987</year><volume>53</volume><fpage>37</fpage><lpage>40</lpage>
<author><surname>Wells</surname> <given-names>C</given-names> </author><title>New operation for rectal prolapse</title><source>Proc R Soc Med</source><year>1959</year><volume>52</volume><fpage>602</fpage><lpage>603</lpage>
<author><surname>Penfold</surname> <given-names>JC</given-names> </author><author><surname>Hawley</surname> <given-names>PR</given-names> </author><title>Experiences of Ivalon-sponge implant for complete rectal prolapse at St. Mark's Hospital, 1960-70</title><source>Br J Surg</source><year>1972</year><volume>59</volume><fpage>846</fpage><lpage>848</lpage>
<author><surname>Morgan</surname> <given-names>CN</given-names> </author><author><surname>Porter</surname> <given-names>NH</given-names> </author><author><surname>Klugman</surname> <given-names>DJ</given-names> </author><title>Ivalon (polyvinyl alcohol) sponge in the repair of complete rectal prolapse</title><source>Br J Surg</source><year>1972</year><volume>59</volume><fpage>841</fpage><lpage>846</lpage>
<author><surname>Keighley</surname> <given-names>MR</given-names> </author><author><surname>Fielding</surname> <given-names>JW</given-names> </author><author><surname>Alexander-Williams</surname> <given-names>J</given-names> </author><title>Results of Marlex mesh abdominal rectopexy for rectal prolapse in 100 consecutive patients</title><source>Br J Surg</source><year>1983</year><volume>70</volume><fpage>229</fpage><lpage>232</lpage>
<author><surname>Yakut</surname> <given-names>M</given-names> </author><author><surname>Kaymakcioglu</surname> <given-names>N</given-names> </author><author><surname>Simsek</surname> <given-names>A</given-names> </author><author><surname>Tan</surname> <given-names>A</given-names> </author><author><surname>Sen</surname> <given-names>D</given-names> </author><title>Surgical treatment of rectal prolapsed: a retrospective analysis of 94 cases</title><source>Int Surg</source><year>1998</year><volume>83</volume><fpage>53</fpage><lpage>55</lpage>
<author><surname>Aitola</surname> <given-names>PT</given-names> </author><author><surname>Hiltunen</surname> <given-names>KM</given-names> </author><author><surname>Matikainen</surname> <given-names>MJ</given-names> </author><title>Functional results of operative treatment of rectal prolapse over an 11-year period: emphasis on transabdominal approach</title><source>Dis Colon Rectum</source><year>1999</year><volume>42</volume><fpage>655</fpage><lpage>660</lpage>
<author><surname>Ross</surname> <given-names>AH</given-names> </author><author><surname>Thomson</surname> <given-names>JP</given-names> </author><title>Management of infection after prosthetic abdominal rectopexy (Wells' procedure)</title><source>Br J Surg</source><year>1989</year><volume>76</volume><fpage>610</fpage><lpage>612</lpage>
<author><surname>Kim</surname> <given-names>DS</given-names> </author><author><surname>Tsang</surname> <given-names>CB</given-names> </author><author><surname>Wong</surname> <given-names>WD</given-names> </author><author><surname>Lowry</surname> <given-names>AC</given-names> </author><author><surname>Goldberg</surname> <given-names>SM</given-names> </author><author><surname>Madoff</surname> <given-names>RD</given-names> </author><title>Complete rectal prolapse: evolution of management and results</title><source>Dis Colon Rectum</source><year>1999</year><volume>42</volume><fpage>460</fpage><lpage>466</lpage>
<author><surname>Cirocco</surname> <given-names>WC</given-names> </author><author><surname>Brown</surname> <given-names>AC</given-names> </author><title>Anterior resection for the treatment of rectal prolapse: a 20-year experience</title><source>Am Surg</source><year>1993</year><volume>59</volume><fpage>265</fpage><lpage>269</lpage>
<author><surname>Luukkonen</surname> <given-names>P</given-names> </author><author><surname>Mikkonen</surname> <given-names>U</given-names> </author><author><surname>Jarvinen</surname> <given-names>H</given-names> </author><title>Abdominal rectopexy with sigmoidectomy vs. rectopexy alone for rectal prolapse: a prospective, randomized study</title><source>Int J Colorectal Dis</source><year>1992</year><volume>7</volume><fpage>219</fpage><lpage>222</lpage>
<author><surname>Frykman</surname> <given-names>HM</given-names> </author><author><surname>Goldberg</surname> <given-names>SM</given-names> </author><title>The surgical treatment of rectal procidentia</title><source>Surg Gynecol Obstet</source><year>1969</year><volume>129</volume><fpage>1225</fpage><lpage>1230</lpage>
<author><surname>Mollen</surname> <given-names>RM</given-names> </author><author><surname>Kuijpers</surname> <given-names>JH</given-names> </author><author><surname>van Hoek</surname> <given-names>F</given-names> </author><title>Effects of rectal mobilization and lateral ligaments division on colonic and anorectal function</title><source>Dis Colon Rectum</source><year>2000</year><volume>43</volume><fpage>1283</fpage><lpage>1287</lpage>
<author><surname>Speakman</surname> <given-names>CT</given-names> </author><author><surname>Madden</surname> <given-names>MV</given-names> </author><author><surname>Nicholls</surname> <given-names>RJ</given-names> </author><author><surname>Kamm</surname> <given-names>MA</given-names> </author><title>Lateral ligament division during rectopexy causes constipation but prevents recurrence: results of a prospective randomized study</title><source>Br J Surg</source><year>1991</year><volume>78</volume><fpage>1431</fpage><lpage>1433</lpage>
<author><surname>Bachoo</surname> <given-names>P</given-names> </author><author><surname>Brazzelli</surname> <given-names>M</given-names> </author><author><surname>Grant</surname> <given-names>A</given-names> </author><title>Surgery for complete rectal prolapse in adults</title><source>Cochrane Database Syst Rev</source><year>2000</year><issue>2</issue><fpage>CD001758</fpage>
<author><surname>Kellokumpu</surname> <given-names>IH</given-names> </author><author><surname>Vironen</surname> <given-names>J</given-names> </author><author><surname>Scheinin</surname> <given-names>T</given-names> </author><title>Laparoscopic repair of rectal prolapse: a prospective study evaluating surgical outcome and changes in symptoms and bowel function</title><source>Surg Endosc</source><year>2000</year><volume>14</volume><fpage>634</fpage><lpage>640</lpage>
<author><surname>Kessler</surname> <given-names>H</given-names> </author><author><surname>Jerby</surname> <given-names>BL</given-names> </author><author><surname>Milsom</surname> <given-names>JW</given-names> </author><title>Successful treatment of rectal prolapse by laparoscopic suture rectopexy</title><source>Surg Endosc</source><year>1999</year><volume>13</volume><fpage>858</fpage><lpage>861</lpage>
<author><surname>Bruch</surname> <given-names>HP</given-names> </author><author><surname>Herold</surname> <given-names>A</given-names> </author><author><surname>Schiedeck</surname> <given-names>T</given-names> </author><author><surname>Schwandner</surname> <given-names>O</given-names> </author><title>Laparoscopic surgery for rectal prolapse and outlet obstruction</title><source>Dis Colon Rectum</source><year>1999</year><volume>42</volume><fpage>1189</fpage><lpage>1194</lpage>
<author><surname>Benoist</surname> <given-names>S</given-names> </author><author><surname>Taffinder</surname> <given-names>N</given-names> </author><author><surname>Gould</surname> <given-names>S</given-names> </author><author><surname>Chang</surname> <given-names>A</given-names> </author><author><surname>Darzi</surname> <given-names>A</given-names> </author><title>Functional results two years after laparoscopic rectopexy</title><source>Am J Surg</source><year>2001</year><volume>182</volume><fpage>168</fpage><lpage>173</lpage>
<author><surname>Scaglia</surname> <given-names>M</given-names> </author><author><surname>Fasth</surname> <given-names>S</given-names> </author><author><surname>Hallgren</surname> <given-names>T</given-names> </author><author><surname>Nordgren</surname> <given-names>S</given-names> </author><author><surname>Oresland</surname> <given-names>T</given-names> </author><author><surname>Hulten</surname> <given-names>L</given-names> </author><title>Abdominal rectopexy for rectal prolapse. Influence of surgical technique on functional outcome</title><source>Dis Colon Rectum</source><year>1994</year><volume>37</volume><fpage>805</fpage><lpage>813</lpage>
<author><surname>Himpens</surname> <given-names>J</given-names> </author><author><surname>Cadiere</surname> <given-names>GB</given-names> </author><author><surname>Bruyns</surname> <given-names>J</given-names> </author><author><surname>Vertruyen</surname> <given-names>M</given-names> </author><title>Laparoscopic rectopexy according to Wells</title><source>Surg Endosc</source><year>1999</year><volume>13</volume><fpage>139</fpage><lpage>141</lpage>
<author><surname>Boccasanta</surname> <given-names>P</given-names> </author><author><surname>Venturi</surname> <given-names>M</given-names> </author><author><surname>Reitano</surname> <given-names>MC</given-names> </author><author><surname>Salamina</surname> <given-names>G</given-names> </author><author><surname>Rosati</surname> <given-names>R</given-names> </author><author><surname>Montorsi</surname> <given-names>M</given-names> </author><title>Laparotomic vs. laparoscopic rectopexy in complete rectal prolapse</title><source>Dig Surg</source><year>1999</year><volume>16</volume><fpage>415</fpage><lpage>419</lpage>
<author><surname>Zittel</surname> <given-names>TT</given-names> </author><author><surname>Manncke</surname> <given-names>K</given-names> </author><author><surname>Haug</surname> <given-names>S</given-names> </author><author><surname>Schafer</surname> <given-names>JF</given-names> </author><author><surname>Kreis</surname> <given-names>ME</given-names> </author><author><surname>Becker</surname> <given-names>HD</given-names> </author><title>Functional results after laparoscopic rectopexy for rectal prolapse</title><source>J Gastrointest Surg</source><year>2000</year><volume>4</volume><fpage>632</fpage><lpage>641</lpage>
<author><surname>Dulucq</surname> <given-names>JL</given-names> </author><author><surname>Wintringer</surname> <given-names>P</given-names> </author><author><surname>Mahajna</surname> <given-names>A</given-names> </author><title>Clinical and functional outcome of laparoscopic posterior rectopexy (Wells) for full-thickness rectal prolapsed: a prospective study</title><source>Surg Endosc</source><year>2007</year><volume>21</volume><fpage>2226</fpage><lpage>2230</lpage>
<author><surname>Purkayastha</surname> <given-names>S</given-names> </author><author><surname>Tekkis</surname> <given-names>P</given-names> </author><author><surname>Athanasiou</surname> <given-names>T</given-names> </author><author><surname>Aziz</surname> <given-names>O</given-names> </author><author><surname>Paraskevas</surname> <given-names>P</given-names> </author><author><surname>Ziprin</surname> <given-names>P</given-names> </author><title>A comparison of open vs. laparoscopic abdominal rectopexy for full-thickness rectal prolapse: a meta-analysis</title><source>Dis Colon Rectum</source><year>2005</year><volume>48</volume><fpage>1930</fpage><lpage>1940</lpage>
<author><surname>Solomon</surname> <given-names>MJ</given-names> </author><author><surname>Young</surname> <given-names>CJ</given-names> </author><author><surname>Eyers</surname> <given-names>AA</given-names> </author><author><surname>Roberts</surname> <given-names>RA</given-names> </author><title>Randomized clinical trial of laparoscopic versus open abdominal rectopexy for rectal prolapse</title><source>Br J Surg</source><year>2002</year><volume>89</volume><fpage>35</fpage><lpage>39</lpage>
<author><surname>Ashari</surname> <given-names>LH</given-names> </author><author><surname>Lumley</surname> <given-names>JW</given-names> </author><author><surname>Stevenson</surname> <given-names>AR</given-names> </author><author><surname>Stitz</surname> <given-names>RW</given-names> </author><title>Laparoscopically-assisted resection rectopexy for rectal prolapse: ten years' experience</title><source>Dis Colon Rectum</source><year>2005</year><volume>48</volume><fpage>982</fpage><lpage>987</lpage>
<author><surname>Xynos</surname> <given-names>E</given-names> </author><author><surname>Chrysos</surname> <given-names>E</given-names> </author><author><surname>Tsiaoussis</surname> <given-names>J</given-names> </author><author><surname>Epanomeritakis</surname> <given-names>E</given-names> </author><author><surname>Vassilakis</surname> <given-names>JS</given-names> </author><title>Resection rectopexy for rectal prolapse. The laparoscopic approach</title><source>Surg Endosc</source><year>1999</year><volume>13</volume><fpage>862</fpage><lpage>864</lpage>
<author><surname>Yoon</surname> <given-names>SG</given-names> </author><author><surname>Kim</surname> <given-names>KU</given-names> </author><author><surname>Noh</surname> <given-names>KY</given-names> </author><author><surname>Lee</surname> <given-names>JK</given-names> </author><author><surname>Kim</surname> <given-names>KY</given-names> </author><title>Laparoscopic suture rectopexy for rectal prolapse</title><source>J Korean Soc Coloproctol</source><year>2002</year><volume>18</volume><fpage>89</fpage><lpage>94</lpage>
<author><surname>Jacobs</surname> <given-names>LK</given-names> </author><author><surname>Lin</surname> <given-names>YJ</given-names> </author><author><surname>Orkin</surname> <given-names>BA</given-names> </author><title>The best operation for rectal prolapse</title><source>Surg Clin North Am</source><year>1997</year><volume>77</volume><fpage>49</fpage><lpage>70</lpage>
<author><surname>Madiba</surname> <given-names>TE</given-names> </author><author><surname>Baig</surname> <given-names>MK</given-names> </author><author><surname>Wexner</surname> <given-names>SD</given-names> </author><title>Surgical management of rectal prolapse</title><source>Arch Surg</source><year>2005</year><volume>140</volume><fpage>63</fpage><lpage>73</lpage>
<author><surname>Schiedeck</surname> <given-names>TH</given-names> </author><author><surname>Schwandner</surname> <given-names>O</given-names> </author><author><surname>Scheele</surname> <given-names>J</given-names> </author><author><surname>Farke</surname> <given-names>S</given-names> </author><author><surname>Bruch</surname> <given-names>HP</given-names> </author><title>Rectal prolapse: which surgical option is appropriate?</title><source>Langenbecks Arch Surg</source><year>2005</year><volume>390</volume><fpage>8</fpage><lpage>14</lpage>
<author><surname>Gourgiotis</surname> <given-names>S</given-names> </author><author><surname>Baratsis</surname> <given-names>S</given-names> </author><title>Rectal prolapse</title><source>Int J Colorectal Dis</source><year>2007</year><volume>22</volume><fpage>231</fpage><lpage>243</lpage>
<author><surname>Adachi</surname> <given-names>J</given-names> </author><author><surname>Hasegawa</surname> <given-names>M</given-names> </author><title>Model of amino acid substitution in proteins encoded by mitochondrial DNA</title><source>J Mol Evol</source><year>1996</year><volume>42</volume><fpage>459</fpage><lpage>468</lpage>
<author><surname>Clackson</surname> <given-names>T</given-names> </author><author><surname>Wells</surname> <given-names>JA</given-names> </author><title>A hot spot of binding energy in a hormone-receptor interface</title><source>Science</source><year>1995</year><volume>267</volume><fpage>383</fpage><lpage>386</lpage>
<author><surname>Frank</surname> <given-names>SA</given-names> </author><source>Immunology and evolution of infectious disease</source><year>2002</year><other>Princeton, NJ</other><publisher>Princeton University Press</publisher>
<author><surname>Goldman</surname> <given-names>N</given-names> </author><author><surname>Whelan</surname> <given-names>S</given-names> </author><title>A novel use of equilibrium frequencies in models of sequence evolution</title><source>Mol Biol Evol</source><year>2002</year><volume>19</volume><fpage>1821</fpage><lpage>1831</lpage>
<author><surname>Gupta</surname> <given-names>V</given-names> </author><author><surname>Earl</surname> <given-names>DJ</given-names> </author><author><surname>Deem</surname> <given-names>MW</given-names> </author><title>Quantifying influenza vaccine efficacy and antigenic distance</title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>3881</fpage><lpage>3888</lpage>
<author><surname>Henikoff</surname> <given-names>S</given-names> </author><author><surname>Henikoff</surname> <given-names>JG</given-names> </author><title>Amino-acid substitution matrices from protein blocks</title><source>Proc Natl Acad Sci USA</source><year>1992</year><volume>89</volume><fpage>10915</fpage><lpage>10919</lpage>
<author><surname>Kaverin</surname> <given-names>NV</given-names> </author><author><surname>Matrosovich</surname> <given-names>MN</given-names> </author><author><surname>Gambaryan</surname> <given-names>AS</given-names> </author><author><surname>Rudneva</surname> <given-names>IA</given-names> </author><author><surname>Shilov</surname> <given-names>AA</given-names> </author><author><surname>Varich</surname> <given-names>NL</given-names> </author><author><surname>Makarova</surname> <given-names>NV</given-names> </author><author><surname>Kropotkina</surname> <given-names>EA</given-names> </author><author><surname>Sinitsin</surname> <given-names>BV</given-names> </author><title>Intergenic HA&#8211;NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes</title><source>Virus Res</source><year>2000</year><volume>66</volume><fpage>123</fpage><lpage>129</lpage>
<author><surname>Kosiol</surname> <given-names>C</given-names> </author><author><surname>Goldman</surname> <given-names>N</given-names> </author><title>Different versions of the Dayhoff rate matrix</title><source>Mol Biol Evol</source><year>2005</year><volume>22</volume><fpage>193</fpage><lpage>199</lpage>
<author><surname>Leunissen</surname> <given-names>JA</given-names> </author><author><surname>Hooven</surname> <given-names>HW</given-names> </author><author><surname>Jong</surname> <given-names>WW</given-names> </author><title>Extreme differences in charge changes during protein evolution</title><source>J Mol Evol</source><year>1990</year><volume>31</volume><fpage>33</fpage><lpage>39</lpage>
<author><surname>Lowen</surname> <given-names>AC</given-names> </author><author><surname>Mubareka</surname> <given-names>S</given-names> </author><author><surname>Tumpey</surname> <given-names>TM</given-names> </author><author><surname>Garc&#237;a-Sastre</surname> <given-names>A</given-names> </author><author><surname>Palese</surname> <given-names>P</given-names> </author><title>The Guinea pig as a transmission model for human influenza viruses</title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>9988</fpage><lpage>9992</lpage>
<url>http://www.flu.lanl.gov/</url>
<author><surname>McDonald</surname> <given-names>JH</given-names> </author><title>Apparent trends of amino acid gain and loss in protein evolution due to nearly neutral variation</title><source>Mol Biol Evol</source><year>2006</year><volume>23</volume><fpage>240</fpage><lpage>244</lpage>
<author><surname>Minin</surname> <given-names>VN</given-names> </author><author><surname>Suchard</surname> <given-names>MA</given-names> </author><title>Counting labeled transitions in continuous-time markov models of evolution</title><source>J Math Biol</source><year>2008</year><volume>56</volume><fpage>391</fpage><lpage>412</lpage>
<author><surname>Mu&#241;oz</surname> <given-names>ET</given-names> </author><author><surname>Deem</surname> <given-names>MW</given-names> </author><title>Epitope analysis for influenza vaccine design</title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1144</fpage><lpage>1148</lpage>
<author><surname>M&#252;ller</surname> <given-names>T</given-names> </author><author><surname>Vingron</surname> <given-names>M</given-names> </author><title>Modeling amino acid replacement</title><source>J Comput Biol</source><year>2000</year><volume>7</volume><fpage>761</fpage><lpage>776</lpage>
<author><surname>M&#252;ller</surname> <given-names>T</given-names> </author><author><surname>Spang</surname> <given-names>R</given-names> </author><author><surname>Vingron</surname> <given-names>M</given-names> </author><title>Estimating amino acid substitution models: a comparison of Dayhoff&#8217;s estimator, the resolvent approach and a maximum likelihood method</title><source>Mol Biol Evol</source><year>2002</year><volume>19</volume><fpage>8</fpage><lpage>13</lpage>
<author><surname>Nakajima</surname> <given-names>S</given-names> </author><author><surname>Nakajima</surname> <given-names>K</given-names> </author><author><surname>Nobusawa</surname> <given-names>E</given-names> </author><author><surname>Zhao</surname> <given-names>J</given-names> </author><author><surname>Tanaka</surname> <given-names>S</given-names> </author><author><surname>Fukuzawa</surname> <given-names>K</given-names> </author><title>Comparison of epitope structures of H3HAs through protein modeling of influenza a virus hemagglutinin: mechanism for selection of antigenic variants in the presence of a monoclonal antibody</title><source>Microbiol Immunol</source><year>2007</year><volume>51</volume><fpage>1179</fpage><lpage>1187</lpage>
<author><surname>Pan</surname> <given-names>K</given-names> </author><author><surname>Deem</surname> <given-names>MW</given-names> </author><title>Comment on Ndifon et&#160;al., &#8220;On the use of hemagglutination-inhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness&#8221;</title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>5033</fpage><lpage>5034</lpage>
<author><surname>Sinha</surname> <given-names>N</given-names> </author><author><surname>Mohan</surname> <given-names>S</given-names> </author><author><surname>Lipschultz</surname> <given-names>CA</given-names> </author><author><surname>Smith-Gill</surname> <given-names>SJ</given-names> </author><title>Differences in electrostatic properties at antibody-antigen binding sites: Implications for specificity and cross-reactivity</title><source>Biophys J</source><year>2002</year><volume>83</volume><fpage>2946</fpage><lpage>2968</lpage>
<author><surname>Smith</surname> <given-names>DJ</given-names> </author><author><surname>Forrest</surname> <given-names>S</given-names> </author><author><surname>Ackley</surname> <given-names>DH</given-names> </author><author><surname>Perelson</surname> <given-names>AS</given-names> </author><title>Variable efficacy of repeated annual influenza vaccination</title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>14001</fpage><lpage>14006</lpage>
<author><surname>Smith</surname> <given-names>DJ</given-names> </author><author><surname>Lapedes</surname> <given-names>AS</given-names> </author><author><surname>Jong</surname> <given-names>JC</given-names> </author><author><surname>Bestebroer</surname> <given-names>TM</given-names> </author><author><surname>Rimmelzwaan</surname> <given-names>GF</given-names> </author><author><surname>Osterhaus</surname> <given-names>ADME</given-names> </author><author><surname>Fouchier</surname> <given-names>RAM</given-names> </author><title>Mapping the antigenic and genetic evolution of influenza virus</title><source>Science</source><year>2004</year><volume>305</volume><fpage>371</fpage><lpage>376</lpage>
<author><surname>Sun</surname> <given-names>J</given-names> </author><author><surname>Deem</surname> <given-names>MW</given-names> </author><editor>Zaman MH</editor><title>Statistical mechanics of the immune response to vaccines</title><source>Statistical mechanics of cellular systems and processes</source><year>2009</year><other>Cambridge</other><publisher>Cambridge University Press</publisher><fpage>177</fpage><lpage>213</lpage>
<author><surname>Sun</surname> <given-names>J</given-names> </author><author><surname>Earl</surname> <given-names>DJ</given-names> </author><author><surname>Deem</surname> <given-names>MW</given-names> </author><title>Localization and glassy dynamics in the immune system</title><source>Mod Phys Lett B</source><year>2006</year><volume>20</volume><fpage>63</fpage><lpage>95</lpage>
<author><surname>Thorne</surname> <given-names>JL</given-names> </author><title>Models of protein sequence evolution and their applications</title><source>Curr Opin Genet Dev</source><year>2000</year><volume>10</volume><fpage>602</fpage><lpage>605</lpage>
<author><surname>Tseng</surname> <given-names>YY</given-names> </author><author><surname>Liang</surname> <given-names>J</given-names> </author><title>Estimation of amino acid residue substitution rates at local spatial regions and application in protein function inference: a Bayesian Monte Carlo approach</title><source>Mol Biol Evol</source><year>2006</year><volume>23</volume><fpage>421</fpage><lpage>436</lpage>
<author><surname>Bechstedt</surname> <given-names>S</given-names> </author><author><surname>Albert</surname> <given-names>JT</given-names> </author><author><surname>Kreil</surname> <given-names>DP</given-names> </author><author><surname>M&#252;ller-Reichert</surname> <given-names>T</given-names> </author><author><surname>G&#246;pfert</surname> <given-names>MC</given-names> </author><author><surname>Howard</surname> <given-names>J</given-names> </author><title>A doublecortin-domain-containing microtubule-associated protein (DCX-EMAP) required for mechanoreception in Drosophila sensory cilia</title><source>Nat Commun</source><year>2010</year><volume>1</volume><fpage>1</fpage><lpage>11</lpage>
<author><surname>Bounoutas</surname> <given-names>A</given-names> </author><author><surname>O'Hagan</surname> <given-names>R</given-names> </author><author><surname>Chalfie</surname> <given-names>M</given-names> </author><title>The multipurpose 15-protofilament microtubules in C. elegans have specific roles in mechanosensation</title><source>Curr Biol</source><year>2009</year><volume>19</volume><fpage>1362</fpage><lpage>1367</lpage>
<author><surname>Chalfie</surname> <given-names>M</given-names> </author><title>Neurosensory mechanotransduction</title><source>Nat Rev Mol Cell Biol</source><year>2009</year><volume>10</volume><fpage>44</fpage><lpage>52</lpage>
<author><surname>Chalfie</surname> <given-names>M</given-names> </author><author><surname>Au</surname> <given-names>M</given-names> </author><title>Genetic control of differentiation of the Caenorhabditis elegans touch receptor neurons</title><source>Science</source><year>1989</year><volume>243</volume><fpage>1027</fpage><lpage>1033</lpage>
<author><surname>Chelur</surname> <given-names>DS</given-names> </author><author><surname>Ernstrom</surname> <given-names>GG</given-names> </author><author><surname>Goodman</surname> <given-names>MB</given-names> </author><author><surname>Yao</surname> <given-names>CA</given-names> </author><author><surname>Chen</surname> <given-names>L</given-names> </author><author><surname>O'Hagan</surname> <given-names>R</given-names> </author><author><surname>Chalfie</surname> <given-names>M</given-names> </author><title>The mechanosensory protein MEC-6 is a subunit of the C. elegans touch-cell degenerin channel</title><source>Nature</source><year>2002</year><volume>420</volume><fpage>669</fpage><lpage>673</lpage>
<author><surname>Cheng</surname> <given-names>LE</given-names> </author><author><surname>Song</surname> <given-names>W</given-names> </author><author><surname>Looger</surname> <given-names>LL</given-names> </author><author><surname>Jan</surname> <given-names>LY</given-names> </author><author><surname>Jan</surname> <given-names>YN</given-names> </author><title>The role of the TRP channel NompC in Drosophila larval and adult locomotion</title><source>Neuron</source><year>2010</year><volume>67</volume><fpage>373</fpage><lpage>380</lpage>
<author><surname>Cueva</surname> <given-names>JG</given-names> </author><author><surname>Mulholland</surname> <given-names>A</given-names> </author><author><surname>Goodman</surname> <given-names>MB</given-names> </author><title>Nanoscale organization of the MEC-4 DEG/ENaC sensory mechanotransduction channel in Caenorhabditis elegans touch receptor neurons</title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>14089</fpage><lpage>14098</lpage>
<author><surname>Eberl</surname> <given-names>DF</given-names> </author><author><surname>Hardy</surname> <given-names>RW</given-names> </author><author><surname>Kernan</surname> <given-names>MJ</given-names> </author><title>Genetically similar transduction mechanisms for touch and hearing in Drosophila</title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>5981</fpage><lpage>5988</lpage>
<author><surname>Emtage</surname> <given-names>L</given-names> </author><author><surname>Gu</surname> <given-names>G</given-names> </author><author><surname>Hartwieg</surname> <given-names>E</given-names> </author><author><surname>Chalfie</surname> <given-names>M</given-names> </author><title>Extracellular proteins organize the mechanosensory channel complex in C. elegans touch receptor neurons</title><source>Neuron</source><year>2004</year><volume>44</volume><fpage>795</fpage><lpage>807</lpage>
<author><surname>Gillespie</surname> <given-names>PG</given-names> </author><author><surname>Walker</surname> <given-names>RG</given-names> </author><title>Molecular basis of mechanosensory transduction</title><source>Nature</source><year>2001</year><volume>413</volume><fpage>194</fpage><lpage>202</lpage>
<author><surname>Gong</surname> <given-names>Z</given-names> </author><author><surname>Son</surname> <given-names>W</given-names> </author><author><surname>Chung</surname> <given-names>YD</given-names> </author><author><surname>Kim</surname> <given-names>J</given-names> </author><author><surname>Shin</surname> <given-names>DW</given-names> </author><author><surname>McClung</surname> <given-names>CA</given-names> </author><author><surname>Lee</surname> <given-names>Y</given-names> </author><author><surname>Lee</surname> <given-names>HW</given-names> </author><author><surname>Chang</surname> <given-names>DJ</given-names> </author><author><surname>Kaang</surname> <given-names>BK</given-names> </author><author><surname>Cho</surname> <given-names>H</given-names> </author><author><surname>Oh</surname> <given-names>U</given-names> </author><author><surname>Hirsh</surname> <given-names>J</given-names> </author><author><surname>Kernan</surname> <given-names>MJ</given-names> </author><author><surname>Kim</surname> <given-names>C</given-names> </author><title>Two interdependent channel subunits, inactive and Nanchung, mediate hearing in Drosophila</title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>9059</fpage><lpage>9066</lpage>
<author><surname>Goodman</surname> <given-names>MB</given-names> </author><author><surname>Ernstrom</surname> <given-names>GG</given-names> </author><author><surname>Chelur</surname> <given-names>DS</given-names> </author><author><surname>O'Hagan</surname> <given-names>R</given-names> </author><author><surname>Yao</surname> <given-names>CA</given-names> </author><author><surname>Chalfie</surname> <given-names>M</given-names> </author><title>MEC-2 regulates C. elegans DEG/ENaC channels needed for mechanosensation</title><source>Nature</source><year>2002</year><volume>415</volume><fpage>1039</fpage><lpage>1042</lpage>
<author><surname>Gopfert</surname> <given-names>MC</given-names> </author><author><surname>Albert</surname> <given-names>JT</given-names> </author><author><surname>Nadrowski</surname> <given-names>B</given-names> </author><author><surname>Kamikouchi</surname> <given-names>A</given-names> </author><title>Specification of auditory sensitivity by Drosophila TRP channels</title><source>Nat Neurosci</source><year>2006</year><volume>9</volume><fpage>999</fpage><lpage>1000</lpage>
<author><surname>Howard</surname> <given-names>J</given-names> </author><author><surname>Bechstedt</surname> <given-names>S</given-names> </author><title>Hypothesis: a helix of ankyrin repeats of the NOMPC-TRP ion channel is the gating spring of mechanoreceptors</title><source>Curr Biol</source><year>2004</year><volume>14</volume><fpage>R224</fpage><lpage>R226</lpage>
<author><surname>Hudspeth</surname> <given-names>AJ</given-names> </author><title>How the ear's works work</title><source>Nature</source><year>1989</year><volume>341</volume><fpage>397</fpage><lpage>404</lpage>
<author><surname>Kamikouchi</surname> <given-names>A</given-names> </author><author><surname>Inagaki</surname> <given-names>HK</given-names> </author><author><surname>Effertz</surname> <given-names>T</given-names> </author><author><surname>Hendrich</surname> <given-names>O</given-names> </author><author><surname>Fiala</surname> <given-names>A</given-names> </author><author><surname>Gopfert</surname> <given-names>MC</given-names> </author><author><surname>Ito</surname> <given-names>K</given-names> </author><title>The neural basis of Drosophila gravity-sensing and hearing</title><source>Nature</source><year>2009</year><volume>458</volume><fpage>165</fpage><lpage>171</lpage>
<author><surname>Kang</surname> <given-names>L</given-names> </author><author><surname>Gao</surname> <given-names>J</given-names> </author><author><surname>Schafer</surname> <given-names>WR</given-names> </author><author><surname>Xie</surname> <given-names>Z</given-names> </author><author><surname>Xu</surname> <given-names>XZ</given-names> </author><title>C. elegans TRP family protein TRP-4 is a pore-forming subunit of a native mechanotransduction channel</title><source>Neuron</source><year>2010</year><volume>67</volume><fpage>381</fpage><lpage>391</lpage>
<author><surname>Kazmierczak</surname> <given-names>P</given-names> </author><author><surname>Sakaguchi</surname> <given-names>H</given-names> </author><author><surname>Tokita</surname> <given-names>J</given-names> </author><author><surname>Wilson-Kubalek</surname> <given-names>EM</given-names> </author><author><surname>Milligan</surname> <given-names>RA</given-names> </author><author><surname>Muller</surname> <given-names>U</given-names> </author><author><surname>Kachar</surname> <given-names>B</given-names> </author><title>Cadherin 23 and protocadherin 15 interact to form tip-link filaments in sensory hair cells</title><source>Nature</source><year>2007</year><volume>449</volume><fpage>87</fpage><lpage>91</lpage>
<author><surname>Keil</surname> <given-names>TA</given-names> </author><title>Functional morphology of insect mechanoreceptors</title><source>Microsc Res Tech</source><year>1997</year><volume>39</volume><fpage>506</fpage><lpage>531</lpage>
<author><surname>Kernan</surname> <given-names>MJ</given-names> </author><title>Mechanotransduction and auditory transduction in Drosophila</title><source>Pflugers Arch</source><year>2007</year><volume>454</volume><fpage>703</fpage><lpage>720</lpage>
<author><surname>Kernan</surname> <given-names>M</given-names> </author><author><surname>Cowan</surname> <given-names>D</given-names> </author><author><surname>Zuker</surname> <given-names>C</given-names> </author><title>Genetic dissection of mechanosensory transduction: mechanoreception-defective mutations of Drosophila</title><source>Neuron</source><year>1994</year><volume>12</volume><fpage>1195</fpage><lpage>1206</lpage>
<author><surname>Kim</surname> <given-names>J</given-names> </author><author><surname>Chung</surname> <given-names>YD</given-names> </author><author><surname>Park</surname> <given-names>DY</given-names> </author><author><surname>Choi</surname> <given-names>S</given-names> </author><author><surname>Shin</surname> <given-names>DW</given-names> </author><author><surname>Soh</surname> <given-names>H</given-names> </author><author><surname>Lee</surname> <given-names>HW</given-names> </author><author><surname>Son</surname> <given-names>W</given-names> </author><author><surname>Yim</surname> <given-names>J</given-names> </author><author><surname>Park</surname> <given-names>CS</given-names> </author><author><surname>Kernan</surname> <given-names>MJ</given-names> </author><author><surname>Kim</surname> <given-names>C</given-names> </author><title>A TRPV family ion channel required for hearing in Drosophila</title><source>Nature</source><year>2003</year><volume>424</volume><fpage>81</fpage><lpage>84</lpage>
<author><surname>Lee</surname> <given-names>J</given-names> </author><author><surname>Moon</surname> <given-names>S</given-names> </author><author><surname>Cha</surname> <given-names>Y</given-names> </author><author><surname>Chung</surname> <given-names>YD</given-names> </author><title>Drosophila TRPN(=NOMPC) channel localizes to the distal end of mechanosensory cilia</title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e11012</fpage>
<author><surname>Li</surname> <given-names>W</given-names> </author><author><surname>Feng</surname> <given-names>Z</given-names> </author><author><surname>Sternberg</surname> <given-names>PW</given-names> </author><author><surname>Xu</surname> <given-names>XZ</given-names> </author><title>A C. elegans stretch receptor neuron revealed by a mechanosensitive TRP channel homologue</title><source>Nature</source><year>2006</year><volume>440</volume><fpage>684</fpage><lpage>687</lpage>
<author><surname>O'Hagan</surname> <given-names>R</given-names> </author><author><surname>Chalfie</surname> <given-names>M</given-names> </author><author><surname>Goodman</surname> <given-names>MB</given-names> </author><title>The MEC-4 DEG/ENaC channel of Caenorhabditis elegans touch receptor neurons transduces mechanical signals</title><source>Nat Neurosci</source><year>2005</year><volume>8</volume><fpage>43</fpage><lpage>50</lpage>
<author><surname>Pickles</surname> <given-names>JO</given-names> </author><author><surname>Comis</surname> <given-names>SD</given-names> </author><author><surname>Osborne</surname> <given-names>MP</given-names> </author><title>Cross-links between stereocilia in the guinea pig organ of Corti, and their possible relation to sensory transduction</title><source>Hear Res</source><year>1984</year><volume>15</volume><fpage>103</fpage><lpage>112</lpage>
<author><surname>Richard</surname> <given-names>M</given-names> </author><author><surname>Grawe</surname> <given-names>F</given-names> </author><author><surname>Knust</surname> <given-names>E</given-names> </author><title>DPATJ plays a role in retinal morphogenesis and protects against light-dependent degeneration of photoreceptor cells in the Drosophila eye</title><source>Dev Dyn</source><year>2006</year><volume>235</volume><fpage>895</fpage><lpage>907</lpage>
<author><surname>Shin</surname> <given-names>JB</given-names> </author><author><surname>Adams</surname> <given-names>D</given-names> </author><author><surname>Paukert</surname> <given-names>M</given-names> </author><author><surname>Siba</surname> <given-names>M</given-names> </author><author><surname>Sidi</surname> <given-names>S</given-names> </author><author><surname>Levin</surname> <given-names>M</given-names> </author><author><surname>Gillespie</surname> <given-names>PG</given-names> </author><author><surname>Grunder</surname> <given-names>S</given-names> </author><title>Xenopus TRPN1 (NOMPC) localizes to microtubule-based cilia in epithelial cells, including inner-ear hair cells</title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>12572</fpage><lpage>12577</lpage>
<author><surname>Sidi</surname> <given-names>S</given-names> </author><author><surname>Friedrich</surname> <given-names>RW</given-names> </author><author><surname>Nicolson</surname> <given-names>T</given-names> </author><title>NompC TRP channel required for vertebrate sensory hair cell mechanotransduction</title><source>Science</source><year>2003</year><volume>301</volume><fpage>96</fpage><lpage>99</lpage>
<author><surname>Walker</surname> <given-names>RG</given-names> </author><author><surname>Willingham</surname> <given-names>AT</given-names> </author><author><surname>Zuker</surname> <given-names>CS</given-names> </author><title>A Drosophila mechanosensory transduction channel</title><source>Science</source><year>2000</year><volume>287</volume><fpage>2229</fpage><lpage>2234</lpage>
<author><surname>Yorozu</surname> <given-names>S</given-names> </author><author><surname>Wong</surname> <given-names>A</given-names> </author><author><surname>Fischer</surname> <given-names>BJ</given-names> </author><author><surname>Dankert</surname> <given-names>H</given-names> </author><author><surname>Kernan</surname> <given-names>MJ</given-names> </author><author><surname>Kamikouchi</surname> <given-names>A</given-names> </author><author><surname>Ito</surname> <given-names>K</given-names> </author><author><surname>Anderson</surname> <given-names>DJ</given-names> </author><title>Distinct sensory representations of wind and near-field sound in the Drosophila brain</title><source>Nature</source><year>2009</year><volume>458</volume><fpage>201</fpage><lpage>205</lpage>
<author><surname>Abzhanov</surname> <given-names>A</given-names> </author><author><surname>Kaufman</surname> <given-names>TC</given-names> </author><title>Homeotic genes and the arthropod head: expression patterns of the labial, proboscipedia, and Deformed genes in crustaceans and insects</title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>10224</fpage><lpage>10229</lpage>
<author><surname>Bejerano</surname> <given-names>G</given-names> </author><author><surname>Siepel</surname> <given-names>AC</given-names> </author><author><surname>Kent</surname> <given-names>WJ</given-names> </author><author><surname>Haussler</surname> <given-names>D</given-names> </author><title>Computational screening of conserved genomic DNA in search of functional noncoding elements</title><source>Nat Meth</source><year>2005</year><volume>2</volume><fpage>535</fpage><lpage>545</lpage>
<author><surname>Bischof</surname> <given-names>J</given-names> </author><author><surname>Maeda</surname> <given-names>RK</given-names> </author><author><surname>Hediger</surname> <given-names>M</given-names> </author><author><surname>Karch</surname> <given-names>F</given-names> </author><author><surname>Basler</surname> <given-names>K</given-names> </author><title>An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases</title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><fpage>3312</fpage><lpage>3317</lpage>
<author><surname>Bucher</surname> <given-names>G</given-names> </author><author><surname>Wimmer</surname> <given-names>EA</given-names> </author><title>Beetle a-head. B.I.F</title><source>Futura</source><year>2005</year><volume>20</volume><fpage>164</fpage><lpage>169</lpage>
<author><surname>Butler</surname> <given-names>JE</given-names> </author><author><surname>Kadonaga</surname> <given-names>JT</given-names> </author><title>Enhancer&#8211;promoter specificity mediated by DPE or TATA core promoter motifs</title><source>Genes Dev</source><year>2001</year><volume>15</volume><fpage>2515</fpage><lpage>2519</lpage>
<author><surname>Campos-Ortega</surname> <given-names>JA</given-names> </author><author><surname>Hartenstein</surname> <given-names>V</given-names> </author><source>The embryonic development of Drosophila melenogaster</source><year>1997</year><issue>2</issue><other>Berlin</other><publisher>Springer</publisher>
<author><surname>Cartharius</surname> <given-names>K</given-names> </author><author><surname>Frech</surname> <given-names>K</given-names> </author><author><surname>Grote</surname> <given-names>K</given-names> </author><author><surname>Klocke</surname> <given-names>B</given-names> </author><author><surname>Haltmeier</surname> <given-names>M</given-names> </author><author><surname>Klingenhoff</surname> <given-names>A</given-names> </author><author><surname>Frisch</surname> <given-names>M</given-names> </author><author><surname>Bayerlein</surname> <given-names>M</given-names> </author><author><surname>Werner</surname> <given-names>T</given-names> </author><title>MatInspector and beyond: promoter analysis based on transcription factor binding sites</title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>2933</fpage><lpage>2942</lpage>
<author><surname>Cerny</surname> <given-names>AC</given-names> </author><author><surname>Grossmann</surname> <given-names>D</given-names> </author><author><surname>Bucher</surname> <given-names>G</given-names> </author><author><surname>Klingler</surname> <given-names>M</given-names> </author><title>The Tribolium ortholog of knirps and knirps-related is crucial for head segmentation but plays a minor role during abdominal patterning</title><source>Dev Biol</source><year>2008</year><volume>321</volume><fpage>284</fpage><lpage>294</lpage>
<author><surname>Chang</surname> <given-names>T</given-names> </author><author><surname>Mazotta</surname> <given-names>J</given-names> </author><author><surname>Dumstrei</surname> <given-names>K</given-names> </author><author><surname>Dumitrescu</surname> <given-names>A</given-names> </author><author><surname>Hartenstein</surname> <given-names>V</given-names> </author><title>Dpp and Hh signaling in the Drosophila embryonic eye field</title><source>Development</source><year>2001</year><volume>128</volume><fpage>4691</fpage><lpage>4704</lpage>
<author><surname>Chipman</surname> <given-names>AD</given-names> </author><author><surname>Akam</surname> <given-names>M</given-names> </author><title>The segmentation cascade in the centipede Strigamia maritima: involvement of the Notch pathway and pair-rule gene homologues</title><source>Dev Biol</source><year>2008</year><volume>319</volume><fpage>160</fpage><lpage>169</lpage>
<author><surname>Choe</surname> <given-names>CP</given-names> </author><author><surname>Brown</surname> <given-names>SJ</given-names> </author><title>Evolutionary flexibility of pair-rule patterning revealed by functional analysis of secondary pair-rule genes, paired and sloppy-paired in the short-germ insect, Tribolium castaneum</title><source>Dev Biol</source><year>2007</year><volume>302</volume><fpage>281</fpage><lpage>294</lpage>
<author><surname>Choe</surname> <given-names>CP</given-names> </author><author><surname>Brown</surname> <given-names>SJ</given-names> </author><title>Genetic regulation of engrailed and wingless in Tribolium segmentation and the evolution of pair-rule segmentation</title><source>Dev Biol</source><year>2009</year><volume>325</volume><fpage>482</fpage><lpage>491</lpage>
<author><surname>Choe</surname> <given-names>CP</given-names> </author><author><surname>Miller</surname> <given-names>SC</given-names> </author><author><surname>Brown</surname> <given-names>SJ</given-names> </author><title>A pair-rule gene circuit defines segments sequentially in the short-germ insect Tribolium castaneum</title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>6560</fpage><lpage>6564</lpage>
<author><surname>Churchill</surname> <given-names>ME</given-names> </author><author><surname>Jones</surname> <given-names>DN</given-names> </author><author><surname>Glaser</surname> <given-names>T</given-names> </author><author><surname>Hefner</surname> <given-names>H</given-names> </author><author><surname>Searles</surname> <given-names>MA</given-names> </author><author><surname>Travers</surname> <given-names>AA</given-names> </author><title>HMG-D is an architecture-specific protein that preferentially binds to DNA containing the dinucleotide TG</title><source>EMBO J</source><year>1995</year><volume>14</volume><fpage>1264</fpage><lpage>1275</lpage>
<author><surname>Cohen</surname> <given-names>SM</given-names> </author><author><surname>J&#252;rgens</surname> <given-names>G</given-names> </author><title>Mediation of Drosophila head development by gap-like segmentation genes</title><source>Nature</source><year>1990</year><volume>346</volume><fpage>482</fpage><lpage>485</lpage>
<author><surname>Cohen</surname> <given-names>S</given-names> </author><author><surname>J&#252;rgens</surname> <given-names>G</given-names> </author><title>Drosophila headlines</title><source>Trends Genet</source><year>1991</year><volume>7</volume><fpage>267</fpage><lpage>272</lpage>
<author><surname>Cr&#233;mazy</surname> <given-names>F</given-names> </author><author><surname>Berta</surname> <given-names>P</given-names> </author><author><surname>Girard</surname> <given-names>F</given-names> </author><title>Genome-wide analysis of Sox genes in Drosophila melanogaster</title><source>Mech Dev</source><year>2001</year><volume>109</volume><fpage>371</fpage><lpage>375</lpage>
<author><surname>Crozatier</surname> <given-names>M</given-names> </author><author><surname>Valle</surname> <given-names>D</given-names> </author><author><surname>Dubois</surname> <given-names>L</given-names> </author><author><surname>Ibnsouda</surname> <given-names>S</given-names> </author><author><surname>Vincent</surname> <given-names>A</given-names> </author><title>Collier, a novel regulator of Drosophila head development, is expressed in a single mitotic domain</title><source>Curr Biol</source><year>1996</year><volume>6</volume><fpage>707</fpage><lpage>718</lpage>
<author><surname>Crozatier</surname> <given-names>M</given-names> </author><author><surname>Valle</surname> <given-names>D</given-names> </author><author><surname>Dubois</surname> <given-names>L</given-names> </author><author><surname>Ibnsouda</surname> <given-names>S</given-names> </author><author><surname>Vincent</surname> <given-names>A</given-names> </author><title>Head versus trunk patterning in the Drosophila embryo; collier requirement for formation of the intercalary segment</title><source>Development</source><year>1999</year><volume>126</volume><fpage>4385</fpage><lpage>4394</lpage>
<author><surname>Dailey</surname> <given-names>L</given-names> </author><author><surname>Basilico</surname> <given-names>C</given-names> </author><title>Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes</title><source>J Cell Physiol</source><year>2001</year><volume>186</volume><fpage>315</fpage><lpage>328</lpage>
<author><surname>Damen</surname> <given-names>WG</given-names> </author><title>Parasegmental organization of the spider embryo implies that the parasegment is an evolutionary conserved entity in arthropod embryogenesis</title><source>Development</source><year>2002</year><volume>129</volume><fpage>1239</fpage><lpage>1250</lpage>
<author><surname>Velasco</surname> <given-names>B</given-names> </author><author><surname>Mandal</surname> <given-names>L</given-names> </author><author><surname>Mkrtchyan</surname> <given-names>M</given-names> </author><author><surname>Hartenstein</surname> <given-names>V</given-names> </author><title>Subdivision and developmental fate of the head mesoderm in Drosophila melanogaster</title><source>Dev Genes Evol</source><year>2006</year><volume>216</volume><fpage>39</fpage><lpage>51</lpage>
<author><surname>Dragan</surname> <given-names>AI</given-names> </author><author><surname>Read</surname> <given-names>CM</given-names> </author><author><surname>Makeyeva</surname> <given-names>EN</given-names> </author><author><surname>Milgotina</surname> <given-names>EI</given-names> </author><author><surname>Churchill</surname> <given-names>ME</given-names> </author><author><surname>Crane-Robinson</surname> <given-names>C</given-names> </author><author><surname>Privalov</surname> <given-names>PL</given-names> </author><title>DNA binding and bending by HMG boxes: energetic determinants of specificity</title><source>J Mol Biol</source><year>2004</year><volume>343</volume><fpage>371</fpage><lpage>393</lpage>
<author><surname>Dray</surname> <given-names>N</given-names> </author><author><surname>Tessmar-Raible</surname> <given-names>K</given-names> </author><author><surname>Gouar</surname> <given-names>M</given-names> </author><author><surname>Vibert</surname> <given-names>L</given-names> </author><author><surname>Christodoulou</surname> <given-names>F</given-names> </author><author><surname>Schipany</surname> <given-names>K</given-names> </author><author><surname>Guillou</surname> <given-names>A</given-names> </author><author><surname>Zantke</surname> <given-names>J</given-names> </author><author><surname>Snyman</surname> <given-names>H</given-names> </author><author><surname>B&#233;hague</surname> <given-names>J</given-names> </author><author><surname>Vervoort</surname> <given-names>M</given-names> </author><author><surname>Arendt</surname> <given-names>D</given-names> </author><author><surname>Balavoine</surname> <given-names>G</given-names> </author><title>Hedgehog signaling regulates segment formation in the annelid Platynereis</title><source>Science</source><year>2010</year><volume>329</volume><fpage>339</fpage><lpage>342</lpage>
<author><surname>Gallitano-Mendel</surname> <given-names>A</given-names> </author><author><surname>Finkelstein</surname> <given-names>R</given-names> </author><title>Novel segment polarity gene interactions during embryonic head development in Drosophila</title><source>Dev Biol</source><year>1997</year><volume>192</volume><fpage>599</fpage><lpage>613</lpage>
<author><surname>Giese</surname> <given-names>K</given-names> </author><author><surname>Pagel</surname> <given-names>J</given-names> </author><author><surname>Grosschedl</surname> <given-names>R</given-names> </author><title>Functional analysis of DNA bending and unwinding by the high mobility group domain of LEF-1</title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>12845</fpage><lpage>12850</lpage>
<author><surname>Grossniklaus</surname> <given-names>U</given-names> </author><author><surname>Cadigan</surname> <given-names>KM</given-names> </author><author><surname>Gehring</surname> <given-names>WJ</given-names> </author><title>Three maternal coordinate systems cooperate in the patterning of the Drosophila head</title><source>Development</source><year>1994</year><volume>120</volume><fpage>3155</fpage><lpage>3171</lpage>
<author><surname>Horn</surname> <given-names>C</given-names> </author><author><surname>Wimmer</surname> <given-names>EA</given-names> </author><title>A versatile vector set for animal transgenesis</title><source>Dev Genes Evol</source><year>2000</year><volume>210</volume><fpage>630</fpage><lpage>637</lpage>
<author><surname>Horn</surname> <given-names>C</given-names> </author><author><surname>Jaunich</surname> <given-names>B</given-names> </author><author><surname>Wimmer</surname> <given-names>EA</given-names> </author><title>Highly sensitive, fluorescent transformation marker for Drosophila transgenesis</title><source>Dev Genes Evol</source><year>2000</year><volume>210</volume><fpage>623</fpage><lpage>629</lpage>
<author><surname>Hsu</surname> <given-names>JY</given-names> </author><author><surname>Juven-Gershon</surname> <given-names>T</given-names> </author><author><surname>Marr</surname> <given-names>MT</given-names> <suffix>2nd</suffix> </author><author><surname>Wright</surname> <given-names>KJ</given-names> </author><author><surname>Tjian</surname> <given-names>R</given-names> </author><author><surname>Kadonaga</surname> <given-names>JT</given-names> </author><title>TBP, Mot1, and NC2 establish a regulatory circuit that controls DPE-dependent versus TATA-dependent transcription</title><source>Genes Dev</source><year>2008</year><volume>22</volume><fpage>2353</fpage><lpage>2358</lpage>
<author><surname>Juven-Gershon</surname> <given-names>T</given-names> </author><author><surname>Kadonaga</surname> <given-names>JT</given-names> </author><title>Regulation of gene expression via the core promoter and the basal transcriptional machinery</title><source>Dev Biol</source><year>2010</year><volume>339</volume><fpage>225</fpage><lpage>229</lpage>
<author><surname>Juven-Gershon</surname> <given-names>T</given-names> </author><author><surname>Hsu</surname> <given-names>JY</given-names> </author><author><surname>Kadonaga</surname> <given-names>JT</given-names> </author><title>Caudal, a key developmental regulator, is a DPE-specific transcriptional factor</title><source>Genes Dev</source><year>2008</year><volume>22</volume><fpage>2823</fpage><lpage>2830</lpage>
<author><surname>Kamachi</surname> <given-names>Y</given-names> </author><author><surname>Uchikawa</surname> <given-names>M</given-names> </author><author><surname>Collignon</surname> <given-names>J</given-names> </author><author><surname>Lovell-Badge</surname> <given-names>R</given-names> </author><author><surname>Kondoh</surname> <given-names>H</given-names> </author><title>Involvement of Sox1, 2 and 3 in the early and subsequent molecular events of lens induction</title><source>Development</source><year>1998</year><volume>125</volume><fpage>2521</fpage><lpage>2532</lpage>
<author><surname>Kamachi</surname> <given-names>Y</given-names> </author><author><surname>Uchikawa</surname> <given-names>M</given-names> </author><author><surname>Tanouchi</surname> <given-names>A</given-names> </author><author><surname>Sekido</surname> <given-names>R</given-names> </author><author><surname>Kondoh</surname> <given-names>H</given-names> </author><title>Pax6 and SOX2 form a co-DNA-binding partner complex that regulates initiation of lens development</title><source>Genes Dev</source><year>2001</year><volume>15</volume><fpage>1272</fpage><lpage>1286</lpage>
<author><surname>Kondoh</surname> <given-names>H</given-names> </author><author><surname>Kamachi</surname> <given-names>Y</given-names> </author><title>SOX-partner code for cell specification: regulatory target selection and underlying molecular mechanisms</title><source>Int J Biochem Cell Biol</source><year>2010</year><volume>42</volume><fpage>391</fpage><lpage>399</lpage>
<author><surname>Kutach</surname> <given-names>AK</given-names> </author><author><surname>Kadonaga</surname> <given-names>JT</given-names> </author><title>The downstream promoter element DPE appears to be as widely used as the TATA box in Drosophila core promoters</title><source>Mol Cell Biol</source><year>2000</year><volume>20</volume><fpage>4754</fpage><lpage>4764</lpage>
<author><surname>Lee</surname> <given-names>HH</given-names> </author><author><surname>Frasch</surname> <given-names>M</given-names> </author><title>Wingless effects mesoderm patterning and ectoderm segmentation events via induction of its downstream target sloppy paired</title><source>Development</source><year>2000</year><volume>127</volume><fpage>5497</fpage><lpage>5508</lpage>
<author><surname>Lee</surname> <given-names>JJ</given-names> </author><author><surname>Kessler</surname> <given-names>DP</given-names> </author><author><surname>Parks</surname> <given-names>S</given-names> </author><author><surname>Beachy</surname> <given-names>PA</given-names> </author><title>Secretion and localized transcription suggest a role in positional signaling for products of the segmentation gene hedgehog</title><source>Cell</source><year>1992</year><volume>71</volume><fpage>33</fpage><lpage>50</lpage>
<author><surname>Lefebvre</surname> <given-names>V</given-names> </author><author><surname>Dumitriu</surname> <given-names>B</given-names> </author><author><surname>Penzo-M&#233;ndez</surname> <given-names>A</given-names> </author><author><surname>Han</surname> <given-names>Y</given-names> </author><author><surname>Pallavi</surname> <given-names>B</given-names> </author><title>Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors</title><source>Int J Biochem Cell Biol</source><year>2007</year><volume>39</volume><fpage>2195</fpage><lpage>2214</lpage>
<author><surname>Lessing</surname> <given-names>D</given-names> </author><author><surname>Nusse</surname> <given-names>R</given-names> </author><title>Expression of wingless in the Drosophila embryo: a conserved cis-acting element lacking conserved Ci-binding sites is required for patched-mediated repression</title><source>Development</source><year>1998</year><volume>125</volume><fpage>1469</fpage><lpage>1476</lpage>
<author><surname>Lim</surname> <given-names>CY</given-names> </author><author><surname>Santoso</surname> <given-names>B</given-names> </author><author><surname>Boulay</surname> <given-names>T</given-names> </author><author><surname>Dong</surname> <given-names>E</given-names> </author><author><surname>Ohler</surname> <given-names>U</given-names> </author><author><surname>Kadonaga</surname> <given-names>JT</given-names> </author><title>The MTE, a new core promoter element for transcription by RNA polymerase II</title><source>Genes Dev</source><year>2004</year><volume>18</volume><fpage>1606</fpage><lpage>1617</lpage>
<author><surname>Liu</surname> <given-names>Z</given-names> </author><author><surname>Yang</surname> <given-names>X</given-names> </author><author><surname>Dong</surname> <given-names>Y</given-names> </author><author><surname>Friedrich</surname> <given-names>M</given-names> </author><title>Tracking down the &#8220;head blob&#8221;: comparative analysis of wingless expression in the developing insect procephalon reveals progressive reduction of embryonic visual system patterning in higher insects</title><source>Arthropod Struct Dev</source><year>2006</year><volume>35</volume><fpage>341</fpage><lpage>356</lpage>
<author><surname>Love</surname> <given-names>JJ</given-names> </author><author><surname>Li</surname> <given-names>X</given-names> </author><author><surname>Case</surname> <given-names>DA</given-names> </author><author><surname>Giese</surname> <given-names>K</given-names> </author><author><surname>Grosschedl</surname> <given-names>R</given-names> </author><author><surname>Wright</surname> <given-names>PE</given-names> </author><title>Structural basis for DNA bending by the architectural transcription factor LEF-1</title><source>Nature</source><year>1995</year><volume>376</volume><fpage>791</fpage><lpage>795</lpage>
<author><surname>Maderspacher</surname> <given-names>F</given-names> </author><author><surname>Bucher</surname> <given-names>G</given-names> </author><author><surname>Klingler</surname> <given-names>M</given-names> </author><title>Pair-rule and gap gene mutants in the flour beetle Tribolium castaneum</title><source>Dev Genes Evol</source><year>1998</year><volume>208</volume><fpage>558</fpage><lpage>568</lpage>
<author><surname>McGinnis</surname> <given-names>W</given-names> </author><author><surname>Krumlauf</surname> <given-names>R</given-names> </author><title>Homeobox genes and axial patterning</title><source>Cell</source><year>1992</year><volume>68</volume><fpage>283</fpage><lpage>302</lpage>
<author><surname>McKimmie</surname> <given-names>C</given-names> </author><author><surname>Woerfel</surname> <given-names>G</given-names> </author><author><surname>Russell</surname> <given-names>S</given-names> </author><title>Conserved genomic organisation of group B Sox genes in insects</title><source>BMC Genet</source><year>2005</year><volume>6</volume><fpage>26</fpage>
<author><surname>Minelli</surname> <given-names>A</given-names> </author><title>A three-phase model of arthropod segmentation</title><source>Dev Genes Evol</source><year>2001</year><volume>211</volume><fpage>509</fpage><lpage>521</lpage>
<author><surname>Mohler</surname> <given-names>J</given-names> </author><title>Spatial regulation of segment polarity gene expression in the anterior terminal region of the Drosophila blastoderm embryo</title><source>Mech Dev</source><year>1995</year><volume>50</volume><fpage>151</fpage><lpage>161</lpage>
<author><surname>Mohler</surname> <given-names>J</given-names> </author><author><surname>Mahaffey</surname> <given-names>JW</given-names> </author><author><surname>Deutsch</surname> <given-names>E</given-names> </author><author><surname>Vani</surname> <given-names>K</given-names> </author><title>Control of Drosophila head segment identity by the bZIP homeotic gene cnc</title><source>Development</source><year>1995</year><volume>121</volume><fpage>237</fpage><lpage>247</lpage>
<author><surname>Nambu</surname> <given-names>PA</given-names> </author><author><surname>Nambu</surname> <given-names>JR</given-names> </author><title>The Drosophila fish-hook gene encodes a HMG domain protein essential for segmentation and CNS development</title><source>Development</source><year>1996</year><volume>122</volume><fpage>3467</fpage><lpage>3475</lpage>
<author><surname>Onichtchouk</surname> <given-names>D</given-names> </author><author><surname>Geier</surname> <given-names>F</given-names> </author><author><surname>Polok</surname> <given-names>B</given-names> </author><author><surname>Messerschmidt</surname> <given-names>DM</given-names> </author><author><surname>M&#246;ssner</surname> <given-names>R</given-names> </author><author><surname>Wendik</surname> <given-names>B</given-names> </author><author><surname>Song</surname> <given-names>S</given-names> </author><author><surname>Taylor</surname> <given-names>V</given-names> </author><author><surname>Timmer</surname> <given-names>J</given-names> </author><author><surname>Driever</surname> <given-names>W</given-names> </author><title>Zebrafish Pou5f1-dependent transcriptional networks in temporal control of early development</title><source>Mol Syst Biol</source><year>2010</year><volume>6</volume><fpage>354</fpage>
<author><surname>Patel</surname> <given-names>NH</given-names> </author><title>Developmental evolution: insights from studies of insect segmentation</title><source>Science</source><year>1994</year><volume>266</volume><fpage>581</fpage><lpage>590</lpage>
<author><surname>Pechmann</surname> <given-names>M</given-names> </author><author><surname>McGregor</surname> <given-names>AP</given-names> </author><author><surname>Schwager</surname> <given-names>EE</given-names> </author><author><surname>Feitosa</surname> <given-names>NM</given-names> </author><author><surname>Damen</surname> <given-names>WG</given-names> </author><title>Dynamic gene expression is required for anterior regionalization in a spider</title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>1468</fpage><lpage>1472</lpage>
<author><surname>Posnien</surname> <given-names>N</given-names> </author><author><surname>Bucher</surname> <given-names>G</given-names> </author><title>Formation of the insect head involves lateral contribution of the intercalary segment, which depends on Tc-labial function</title><source>Dev Biol</source><year>2010</year><volume>338</volume><fpage>107</fpage><lpage>116</lpage>
<author><surname>Rehm</surname> <given-names>EJ</given-names> </author><author><surname>Hannibal</surname> <given-names>RL</given-names> </author><author><surname>Chaw</surname> <given-names>RC</given-names> </author><author><surname>Vargas-Vila</surname> <given-names>MA</given-names> </author><author><surname>Patel</surname> <given-names>NH</given-names> </author><title>In situ hybridization of labeled RNA probes to fixed Parhyale hawaiensis embryos</title><source>Cold Spring Harb Protoc</source><year>2009</year>
<author><surname>Reichert</surname> <given-names>H</given-names> </author><author><surname>Simeone</surname> <given-names>A</given-names> </author><title>Conserved usage of gap and homeotic genes in patterning the CNS</title><source>Curr Opin Neurobiol</source><year>1999</year><volume>9</volume><fpage>589</fpage><lpage>595</lpage>
<author><surname>Remane</surname> <given-names>A</given-names> </author><title>Enstehung der Metamerie der Wirbellosen</title><source>Zool Anz Suppl</source><year>1950</year><volume>14</volume><fpage>16</fpage><lpage>23</lpage>
<author><surname>Rogers</surname> <given-names>BT</given-names> </author><author><surname>Kaufman</surname> <given-names>TC</given-names> </author><title>Structure of the insect head in ontogeny and phylogeny: a view from Drosophila</title><source>Int Rev Cytol</source><year>1997</year><volume>174</volume><fpage>1</fpage><lpage>84</lpage>
<author><surname>Russell</surname> <given-names>SR</given-names> </author><author><surname>Sanchez-Soriano</surname> <given-names>N</given-names> </author><author><surname>Wright</surname> <given-names>CR</given-names> </author><author><surname>Ashburner</surname> <given-names>M</given-names> </author><title>The Dichaete gene of Drosophila melanogaster encodes a SOX-domain protein required for embryonic segmentation</title><source>Development</source><year>1996</year><volume>122</volume><fpage>3669</fpage><lpage>3676</lpage>
<author><surname>S&#225;nchez-Soriano</surname> <given-names>N</given-names> </author><author><surname>Russell</surname> <given-names>S</given-names> </author><title>Regulatory mutations of the Drosophila Sox gene Dichaete reveal new functions in embryonic brain and hindgut development</title><source>Dev Biol</source><year>2000</year><volume>220</volume><fpage>307</fpage><lpage>321</lpage>
<author><surname>Sander</surname> <given-names>K</given-names> </author><editor>Goodwin BC , Holder N , Wylie CC</editor><title>The evolution of patterning mechanisms: gleanings from insect embryogenesis and spermatogenesis</title><source>Development and evolution</source><year>1983</year><other>Cambridge</other><publisher>Cambridge University Press</publisher><fpage>137</fpage><lpage>160</lpage>
<author><surname>Schaeper</surname> <given-names>ND</given-names> </author><author><surname>Pechmann</surname> <given-names>M</given-names> </author><author><surname>Damen</surname> <given-names>WG</given-names> </author><author><surname>Prpic</surname> <given-names>NM</given-names> </author><author><surname>Wimmer</surname> <given-names>EA</given-names> </author><title>Evolutionary plasticity of collier function in head development of diverse arthropods</title><source>Dev Biol</source><year>2010</year><volume>344</volume><fpage>363</fpage><lpage>376</lpage>
<author><surname>Schinko</surname> <given-names>JB</given-names> </author><author><surname>Kreuzer</surname> <given-names>N</given-names> </author><author><surname>Offen</surname> <given-names>N</given-names> </author><author><surname>Posnien</surname> <given-names>N</given-names> </author><author><surname>Wimmer</surname> <given-names>EA</given-names> </author><author><surname>Bucher</surname> <given-names>G</given-names> </author><title>Divergent functions of orthodenticle, empty spiracles and buttonhead in early head patterning of the beetle Tribolium castaneum (Coleoptera)</title><source>Dev Biol</source><year>2008</year><volume>317</volume><fpage>600</fpage><lpage>613</lpage>
<author><surname>Schmidt-Ott</surname> <given-names>U</given-names> </author><author><surname>Technau</surname> <given-names>GM</given-names> </author><title>Expression of en and wg in the embryonic head and brain of Drosophila indicates a refolded band of seven segment remnants</title><source>Development</source><year>1992</year><volume>116</volume><fpage>111</fpage><lpage>125</lpage>
<author><surname>Schmidt-Ott</surname> <given-names>U</given-names> </author><author><surname>Gonz&#225;lez-Gait&#225;n</surname> <given-names>M</given-names> </author><author><surname>J&#228;ckle</surname> <given-names>H</given-names> </author><author><surname>Technau</surname> <given-names>GM</given-names> </author><title>Number, identity, and sequence of the Drosophila head segments as revealed by neural elements and their deletion patterns in mutants</title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>8363</fpage><lpage>8367</lpage>
<author><surname>Scholtz</surname> <given-names>G</given-names> </author><title>Evolution of the nauplius stage in malacostracan crustaceans</title><source>J Zoolog Syst Evol Res</source><year>2000</year><volume>38</volume><fpage>175</fpage><lpage>187</lpage>
<author><surname>Scholtz</surname> <given-names>G</given-names> </author><author><surname>Edgecombe</surname> <given-names>GD</given-names> </author><title>The evolution of arthropod heads: reconciling morphological, developmental and palaeontological evidence</title><source>Dev Genes Evol</source><year>2006</year><volume>216</volume><fpage>395</fpage><lpage>415</lpage>
<author><surname>St Johnston</surname> <given-names>D</given-names> </author><author><surname>N&#252;sslein-Volhard</surname> <given-names>C</given-names> </author><title>The origin of pattern and polarity in the Drosophila embryo</title><source>Cell</source><year>1992</year><volume>68</volume><fpage>201</fpage><lpage>219</lpage>
<author><surname>Stolt</surname> <given-names>CC</given-names> </author><author><surname>Lommes</surname> <given-names>P</given-names> </author><author><surname>Sock</surname> <given-names>E</given-names> </author><author><surname>Chaboissier</surname> <given-names>MC</given-names> </author><author><surname>Schedl</surname> <given-names>A</given-names> </author><author><surname>Wegner</surname> <given-names>M</given-names> </author><title>The Sox9 transcription factor determines glial fate choice in the developing spinal cord</title><source>Genes Dev</source><year>2003</year><volume>17</volume><fpage>1677</fpage><lpage>1689</lpage>
<author><surname>Tautz</surname> <given-names>D</given-names> </author><title>Segmentation</title><source>Dev Cell</source><year>2004</year><volume>7</volume><fpage>301</fpage><lpage>312</lpage>
<author><surname>Thummel</surname> <given-names>CS</given-names> </author><author><surname>Pirotta</surname> <given-names>V</given-names> </author><title>New pCaSpeR P-element vectors</title><source>Drosoph Inf Serv</source><year>1992</year><volume>71</volume><fpage>150</fpage>
<author><surname>Urbach</surname> <given-names>R</given-names> </author><author><surname>Technau</surname> <given-names>GM</given-names> </author><title>Early steps in building the insect brain: neuroblast formation and segmental patterning in the developing brain of different insect species</title><source>Arthropod Struct Dev</source><year>2003</year><volume>32</volume><fpage>103</fpage><lpage>123</lpage>
<author><surname>Wetering</surname> <given-names>M</given-names> </author><author><surname>Oosterwegel</surname> <given-names>M</given-names> </author><author><surname>Dooijes</surname> <given-names>D</given-names> </author><author><surname>Clevers</surname> <given-names>H</given-names> </author><title>Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box</title><source>EMBO J</source><year>1991</year><volume>10</volume><fpage>123</fpage><lpage>132</lpage>
<author><surname>Wetering</surname> <given-names>M</given-names> </author><author><surname>Oosterwegel</surname> <given-names>M</given-names> </author><author><surname>Norren</surname> <given-names>K</given-names> </author><author><surname>Clevers</surname> <given-names>H</given-names> </author><title>Sox-4, an Sry-like HMG box protein, is a transcriptional activator in lymphocytes</title><source>EMBO J</source><year>1993</year><volume>12</volume><fpage>3847</fpage><lpage>3854</lpage>
<author><surname>Wetering</surname> <given-names>M</given-names> </author><author><surname>Cavallo</surname> <given-names>R</given-names> </author><author><surname>Dooijes</surname> <given-names>D</given-names> </author><author><surname>Beest</surname> <given-names>M</given-names> </author><author><surname>Es</surname> <given-names>J</given-names> </author><author><surname>Loureiro</surname> <given-names>J</given-names> </author><author><surname>Ypma</surname> <given-names>A</given-names> </author><author><surname>Hursh</surname> <given-names>D</given-names> </author><author><surname>Jones</surname> <given-names>T</given-names> </author><author><surname>Bejsovec</surname> <given-names>A</given-names> </author><author><surname>Peifer</surname> <given-names>M</given-names> </author><author><surname>Mortin</surname> <given-names>M</given-names> </author><author><surname>Clevers</surname> <given-names>H</given-names> </author><title>Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF</title><source>Cell</source><year>1997</year><volume>88</volume><fpage>789</fpage><lpage>799</lpage>
<author><surname>Veraksa</surname> <given-names>A</given-names> </author><author><surname>McGinnis</surname> <given-names>N</given-names> </author><author><surname>Li</surname> <given-names>X</given-names> </author><author><surname>Mohler</surname> <given-names>J</given-names> </author><author><surname>McGinnis</surname> <given-names>W</given-names> </author><title>Cap &#8216;n&#8217; collar B cooperates with a small Maf subunit to specify pharyngeal development and suppress deformed homeotic function in the Drosophila head</title><source>Development</source><year>2000</year><volume>127</volume><fpage>4023</fpage><lpage>4037</lpage>
<author><surname>Vincent</surname> <given-names>A</given-names> </author><author><surname>Blankenship</surname> <given-names>JT</given-names> </author><author><surname>Wieschaus</surname> <given-names>E</given-names> </author><title>Integration of the head and trunk segmentation systems controls cephalic furrow formation in Drosophila</title><source>Development</source><year>1997</year><volume>124</volume><fpage>3747</fpage><lpage>3754</lpage>
<author><surname>Werner</surname> <given-names>MH</given-names> </author><author><surname>Huth</surname> <given-names>JR</given-names> </author><author><surname>Gronenborn</surname> <given-names>AM</given-names> </author><author><surname>Clore</surname> <given-names>GM</given-names> </author><title>Molecular basis of human 46X, Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex</title><source>Cell</source><year>1995</year><volume>81</volume><fpage>705</fpage><lpage>714</lpage>
<author><surname>Wilson</surname> <given-names>M</given-names> </author><author><surname>Koopman</surname> <given-names>P</given-names> </author><title>Matching SOX partner proteins and co-factors of the SOX family of transcriptional regulators</title><source>Curr Opin Genet Dev</source><year>2002</year><volume>12</volume><fpage>441</fpage><lpage>446</lpage>
<author><surname>Wimmer</surname> <given-names>EA</given-names> </author><author><surname>Cohen</surname> <given-names>SM</given-names> </author><author><surname>J&#228;ckle</surname> <given-names>H</given-names> </author><author><surname>Desplan</surname> <given-names>C</given-names> </author><title>buttonhead does not contribute to a combinatorial code proposed for Drosophila head development</title><source>Development</source><year>1997</year><volume>124</volume><fpage>1509</fpage><lpage>1517</lpage>
IDF<source>Diabetes Atlas</source><year>2009</year><issue>4th edn</issue><other>Brussels</other><publisher>International Diabetes Federation</publisher>
IDF Clinical Guidelines Task Force<source>Global Guideline for Type 2 Diabetes</source><year>2005</year><other>Brussels</other><publisher>International Diabetes Federation</publisher>
NICE<source>Type 2 Diabetes. The Management of Type 2 Diabetes</source><year>2008</year><other>London</other><publisher>National Institute for Health and Clinical Excellence</publisher>NICE clinical guideline 66
American Diabetes Association<title>Standards of medical care in diabetes&#8212;2010</title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>S11</fpage><lpage>S61</lpage>
<author><surname>Gray</surname> <given-names>A</given-names> </author><author><surname>Raikou</surname> <given-names>M</given-names> </author><author><surname>McGuire</surname> <given-names>A</given-names> </author><author><surname>Fenn</surname> <given-names>P</given-names> </author><author><surname>Stevens</surname> <given-names>R</given-names> </author><author><surname>Cull</surname> <given-names>C</given-names> </author><title>Cost-effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). UK Prospective Diabetes Study Group</title><source>Br Med J</source><year>2000</year><volume>320</volume><fpage>1373</fpage><lpage>1378</lpage>
<author><surname>Huang</surname> <given-names>ES</given-names> </author><author><surname>Zhang</surname> <given-names>Q</given-names> </author><author><surname>Brown</surname> <given-names>SE</given-names> </author><author><surname>Drum</surname> <given-names>ML</given-names> </author><author><surname>Meltzer</surname> <given-names>DO</given-names> </author><author><surname>Chin</surname> <given-names>MH</given-names> </author><title>The cost-effectiveness of improving diabetes care in US federally qualified community health centers</title><source>Health Serv Res</source><year>2007</year><volume>42</volume><fpage>2174</fpage><lpage>2193</lpage>
<author><surname>Holman</surname> <given-names>RR</given-names> </author><author><surname>Paul</surname> <given-names>SK</given-names> </author><author><surname>Bethel</surname> <given-names>MA</given-names> </author><author><surname>Matthews</surname> <given-names>DR</given-names> </author><author><surname>Neil</surname> <given-names>HA</given-names> </author><title>10-year follow-up of intensive glucose control in type 2 diabetes</title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1577</fpage><lpage>1589</lpage>
<author><surname>Gaede</surname> <given-names>P</given-names> </author><author><surname>Lund-Andersen</surname> <given-names>H</given-names> </author><author><surname>Parving</surname> <given-names>HH</given-names> </author><author><surname>Pedersen</surname> <given-names>O</given-names> </author><title>Effect of a multifactorial intervention on mortality in type 2 diabetes</title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>580</fpage><lpage>591</lpage>
<author><surname>Stratton</surname> <given-names>IM</given-names> </author><author><surname>Adler</surname> <given-names>AI</given-names> </author><author><surname>Neil</surname> <given-names>HA</given-names> </author><author><surname>Matthews</surname> <given-names>DR</given-names> </author><author><surname>Manley</surname> <given-names>SE</given-names> </author><author><surname>Cull</surname> <given-names>CA</given-names> </author><title>Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study</title><source>Br Med J</source><year>2000</year><volume>321</volume><fpage>405</fpage><lpage>412</lpage>
UKPDS Research Group<title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group</title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>837</fpage><lpage>853</lpage>
<author><surname>Zoungas</surname> <given-names>S</given-names> </author><author><surname>de Galan</surname> <given-names>BE</given-names> </author><author><surname>Ninomiya</surname> <given-names>T</given-names> </author><author><surname>Grobbee</surname> <given-names>D</given-names> </author><author><surname>Hamet</surname> <given-names>P</given-names> </author><author><surname>Heller</surname> <given-names>S</given-names> </author><title>Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial</title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>2068</fpage><lpage>2074</lpage>
American Diabetes Association<title>Diagnosis and classification of diabetes mellitus</title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>S62</fpage><lpage>S69</lpage>
<author><surname>Geistanger</surname> <given-names>A</given-names> </author><author><surname>Arends</surname> <given-names>S</given-names> </author><author><surname>Berding</surname> <given-names>C</given-names> </author><author><surname>Hoshino</surname> <given-names>T</given-names> </author><author><surname>Jeppsson</surname> <given-names>JO</given-names> </author><author><surname>Little</surname> <given-names>R</given-names> </author><title>Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan and Sweden</title><source>Clin Chem</source><year>2008</year><volume>54</volume><fpage>1379</fpage><lpage>1385</lpage>
<author><surname>Duke</surname> <given-names>SA</given-names> </author><author><surname>Colagiuri</surname> <given-names>S</given-names> </author><author><surname>Colagiuri</surname> <given-names>R</given-names> </author><title>Individual patient education for people with type 2 diabetes mellitus</title><source>Cochrane Database Syst Rev</source><year>2009</year><volume>1</volume><fpage>CD005268</fpage>
<author><surname>Ellis</surname> <given-names>SE</given-names> </author><author><surname>Speroff</surname> <given-names>T</given-names> </author><author><surname>Dittus</surname> <given-names>RS</given-names> </author><author><surname>Brown</surname> <given-names>A</given-names> </author><author><surname>Pichert</surname> <given-names>JW</given-names> </author><author><surname>Elasy</surname> <given-names>TA</given-names> </author><title>Diabetes patient education: a meta-analysis and meta-regression</title><source>Patient Educ Couns</source><year>2004</year><volume>52</volume><fpage>97</fpage><lpage>105</lpage>
<author><surname>Loveman</surname> <given-names>E</given-names> </author><author><surname>Frampton</surname> <given-names>GK</given-names> </author><author><surname>Clegg</surname> <given-names>AJ</given-names> </author><title>The clinical effectiveness of diabetes education models for Type 2 diabetes: a systematic review</title><source>Health Technol Assess</source><year>2008</year><volume>12</volume><fpage>1</fpage><lpage>136</lpage>
<author><surname>Peyrot</surname> <given-names>M</given-names> </author><author><surname>Rubin</surname> <given-names>RR</given-names> </author><author><surname>Lauritzen</surname> <given-names>T</given-names> </author><author><surname>Snoek</surname> <given-names>FJ</given-names> </author><author><surname>Matthews</surname> <given-names>DR</given-names> </author><author><surname>Skovlund</surname> <given-names>SE</given-names> </author><title>Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study</title><source>Diabet Med</source><year>2005</year><volume>22</volume><fpage>1379</fpage><lpage>1385</lpage>
<author><surname>Simmons</surname> <given-names>D</given-names> </author><author><surname>Lillis</surname> <given-names>S</given-names> </author><author><surname>Swan</surname> <given-names>J</given-names> </author><author><surname>Haar</surname> <given-names>J</given-names> </author><title>Discordance in perceptions of barriers to diabetes care between patients and primary care and secondary care</title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>490</fpage><lpage>495</lpage>
<author><surname>Kraushaar</surname> <given-names>LE</given-names> </author><author><surname>Kr&#228;mer</surname> <given-names>A</given-names> </author><title>Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention</title><source>BMC Public Health</source><year>2009</year><volume>9</volume><fpage>64</fpage>
<author><surname>Davies</surname> <given-names>MJ</given-names> </author><author><surname>Heller</surname> <given-names>S</given-names> </author><author><surname>Skinner</surname> <given-names>TC</given-names> </author><author><surname>Campbell</surname> <given-names>MJ</given-names> </author><author><surname>Carey</surname> <given-names>ME</given-names> </author><author><surname>Cradock</surname> <given-names>S</given-names> </author><title>Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial</title><source>Br Med J</source><year>2008</year><volume>336</volume><fpage>491</fpage><lpage>495</lpage>
<author><surname>Stettler</surname> <given-names>C</given-names> </author><author><surname>Allemann</surname> <given-names>S</given-names> </author><author><surname>J&#252;ni</surname> <given-names>P</given-names> </author><author><surname>Cull</surname> <given-names>CA</given-names> </author><author><surname>Holman</surname> <given-names>RR</given-names> </author><author><surname>Egger</surname> <given-names>M</given-names> </author><title>Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials</title><source>Am Heart J</source><year>2006</year><volume>152</volume><fpage>27</fpage><lpage>38</lpage>
<author><surname>Kirkman</surname> <given-names>MS</given-names> </author><author><surname>Williams</surname> <given-names>SR</given-names> </author><author><surname>Caffrey</surname> <given-names>HH</given-names> </author><author><surname>Marrero</surname> <given-names>DG</given-names> </author><title>Impact of a program to improve adherence to diabetes guidelines by primary care physicians</title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>1946</fpage><lpage>1951</lpage>
<author><surname>Tabrizi</surname> <given-names>JS</given-names> </author><author><surname>O'Rourke</surname> <given-names>PK</given-names> </author><author><surname>Wilson</surname> <given-names>AJ</given-names> </author><author><surname>Coyne</surname> <given-names>ET</given-names> </author><title>Service quality for Type 2 diabetes in Australia: the patient perspective</title><source>Diabet Med</source><year>2008</year><volume>25</volume><fpage>612</fpage><lpage>617</lpage>
<author><surname>Guldberg</surname> <given-names>TL</given-names> </author><author><surname>Lauritzen</surname> <given-names>T</given-names> </author><author><surname>Kristensen</surname> <given-names>JK</given-names> </author><author><surname>Vedsted</surname> <given-names>P</given-names> </author><title>The effect of feedback to general practitioners on quality of care for people with type 2 diabetes. A systematic review of the literature</title><source>BMC Fam Pract</source><year>2009</year><volume>10</volume><fpage>30</fpage>
<author><surname>Duran</surname> <given-names>A</given-names> </author><author><surname>Runkle</surname> <given-names>I</given-names> </author><author><surname>Matia</surname> <given-names>P</given-names> </author><author><surname>de Miguel</surname> <given-names>MP</given-names> </author><author><surname>Garrido</surname> <given-names>S</given-names> </author><author><surname>Cervera</surname> <given-names>E</given-names> </author><title>Family physician and endocrinologist coordination as the basis for diabetes care in clinical practice</title><source>BMC Endocr Disord</source><year>2008</year><volume>8</volume><fpage>9</fpage>
<author><surname>Grant</surname> <given-names>RW</given-names> </author><author><surname>Meigs</surname> <given-names>JB</given-names> </author><title>Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction</title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>479</fpage><lpage>484</lpage>
The Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu)<title>Diabetes Nutrition and Complications Trial: adherence to the ADA nutritional recommendations, targets of metabolic control, and onset of diabetes complications. A 7-year, prospective, population-based, observational multi-center study</title><source>J Diabetes Complications</source><year>2006</year><volume>20</volume><fpage>361</fpage><lpage>366</lpage>
The Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu)<title>Diabetes Nutrition and Complications Trial (DNCT). Diet and risk of microangiopathy progression: the role of polyunsaturated fatty acids and monounsaturated fatty acids consumption</title><source>Obes Metab</source><year>2006</year><volume>2</volume><fpage>6</fpage><lpage>12</lpage>
<author><surname>da Silva</surname> <given-names>R</given-names> </author><author><surname>Bach-Faig</surname> <given-names>A</given-names> </author><author><surname>Raid&#243; Quintana</surname> <given-names>B</given-names> </author><author><surname>Buckland</surname> <given-names>G</given-names> </author><author><surname>Vaz de Almeida</surname> <given-names>MD</given-names> </author><author><surname>Serra-Majem</surname> <given-names>L</given-names> </author><title>Worldwide variation of adherence to the Mediterranean diet, in 1961&#8211;1965 and 2000&#8211;2003</title><source>Public Health Nutr</source><year>2009</year><volume>12</volume><fpage>1676</fpage><lpage>1684</lpage>
<author><surname>Stacy</surname> <given-names>M</given-names> </author><title>Medical treatment of Parkinson disease</title><source>Neurol Clin</source><year>2009</year><volume>27</volume><issue>3</issue><fpage>605</fpage><lpage>631</lpage>
<author><surname>Tanner</surname> <given-names>CM</given-names> </author><author><surname>Ross</surname> <given-names>GW</given-names> </author><author><surname>Jewell</surname> <given-names>SA</given-names> </author><title>Occupation and risk of parkinsonism: a multicenter case-control study</title><source>Arch Neurol</source><year>2009</year><volume>66</volume><issue>9</issue><fpage>1106</fpage><lpage>1113</lpage>
<title>US interim projections by age, sex, race, and hispanic origin: 2000&#8211;2050</title>Available from:
<author><surname>Cotzias</surname> <given-names>GC</given-names> </author><author><surname>Papavasiliou</surname> <given-names>PS</given-names> </author><author><surname>Gellene</surname> <given-names>R</given-names> </author><title>Modif ication of Parkinsonism &#8211; chronic treatment with L-dopa</title><source>N Engl J Med</source><year>1969</year><volume>280</volume><issue>7</issue><fpage>337</fpage><lpage>345</lpage>
<author><surname>Lang</surname> <given-names>AE</given-names> </author><author><surname>Lozano</surname> <given-names>AM</given-names> </author><title>Parkinson&#8217;s disease. First of two parts</title><source>N Engl J Med</source><year>1998</year><volume>339</volume><issue>15</issue><fpage>1044</fpage><lpage>1053</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><title>Motor fluctuations and dyskinesia in Parkinson&#8217;s disease</title><source>Parkinsonism Relat Disord</source><year>2001</year><volume>8</volume><issue>2</issue><fpage>101</fpage><lpage>108</lpage>
<author><surname>Fahn</surname> <given-names>S</given-names> </author><author><surname>Oakes</surname> <given-names>D</given-names> </author><author><surname>Shoulson</surname> <given-names>I</given-names> </author><title>Levodopa and the progression of Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2004</year><volume>351</volume><issue>24</issue><fpage>2498</fpage><lpage>2508</lpage>
<author><surname>Fahn</surname> <given-names>S</given-names> </author><title>The spectrum of levodopa-induced dyskinesias</title><source>Ann Neurol</source><year>2000</year><volume>47</volume><issue>Suppl 1</issue><fpage>2</fpage><lpage>11</lpage>
<author><surname>Golbe</surname> <given-names>LI</given-names> </author><title>Young-onset Parkinson&#8217;s disease: a clinical review</title><source>Neurology</source><year>1991</year><volume>41</volume><issue>2 Pt 1</issue><fpage>168</fpage><lpage>173</lpage>
<author><surname>Forno</surname> <given-names>LS</given-names> </author><title>Neuropathology of Parkinson&#8217;s disease</title><source>J Neuropathol Exp Neurol</source><year>1996</year><volume>55</volume><issue>3</issue><fpage>259</fpage><lpage>272</lpage>
<author><surname>Jellinger</surname> <given-names>KA</given-names> </author><title>Post mortem studies in Parkinson&#8217;s disease &#8211; is it possible to detect brain areas for specific symptoms?</title><source>J Neural Transm Suppl</source><year>1999</year><volume>56</volume><fpage>1</fpage><lpage>29</lpage>
<author><surname>Grace</surname> <given-names>AA</given-names> </author><author><surname>Bunney</surname> <given-names>BS</given-names> </author><title>The control of firing pattern in nigral dopamine neurons: single spike firing</title><source>J Neurosci</source><year>1984</year><volume>4</volume><issue>11</issue><fpage>2866</fpage><lpage>2876</lpage>
<author><surname>Grace</surname> <given-names>AA</given-names> </author><title>Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia</title><source>Neuroscience</source><year>1991</year><volume>41</volume><issue>1</issue><fpage>1</fpage><lpage>24</lpage>
<author><surname>Abercrombie</surname> <given-names>ED</given-names> </author><author><surname>Bonatz</surname> <given-names>AE</given-names> </author><author><surname>Zigmond</surname> <given-names>MJ</given-names> </author><title>Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats</title><source>Brain Res</source><year>1990</year><volume>525</volume><issue>1</issue><fpage>36</fpage><lpage>44</lpage>
<author><surname>Schultz</surname> <given-names>W</given-names> </author><title>Predictive reward signal of dopamine neurons</title><source>J Neurophysiol</source><year>1998</year><volume>80</volume><issue>1</issue><fpage>1</fpage><lpage>27</lpage>
<author><surname>Venton</surname> <given-names>BJ</given-names> </author><author><surname>Zhang</surname> <given-names>H</given-names> </author><author><surname>Garris</surname> <given-names>PA</given-names> </author><author><surname>Phillips</surname> <given-names>PE</given-names> </author><author><surname>Sulzer</surname> <given-names>D</given-names> </author><author><surname>Wightman</surname> <given-names>RM</given-names> </author><title>Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing</title><source>J Neurochem</source><year>2003</year><volume>87</volume><issue>5</issue><fpage>1284</fpage><lpage>1295</lpage>
<author><surname>Olanow</surname> <given-names>CW</given-names> </author><author><surname>Obeso</surname> <given-names>JA</given-names> </author><author><surname>Stocchi</surname> <given-names>F</given-names> </author><title>Continuous dopamine-receptor treatment of Parkinson&#8217;s disease: scientific rationale and clinical implications</title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><issue>8</issue><fpage>677</fpage><lpage>687</lpage>
<author><surname>Lewitt</surname> <given-names>PA</given-names> </author><title>Levodopa for the treatment of Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>23</issue><fpage>2468</fpage><lpage>2476</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><author><surname>Woodward</surname> <given-names>WR</given-names> </author><author><surname>Beckner</surname> <given-names>RM</given-names> </author><title>Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients</title><source>Neurology</source><year>1994</year><volume>44</volume><issue>5</issue><fpage>913</fpage><lpage>919</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><title>Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients</title><source>Neurology</source><year>2000</year><volume>55</volume><issue>11 Suppl 4</issue><fpage>S33</fpage><lpage>S37</lpage>
<author><surname>De la Fuente-Fern&#225;ndez</surname> <given-names>R</given-names> </author><author><surname>Sossi</surname> <given-names>V</given-names> </author><author><surname>Huang</surname> <given-names>Z</given-names> </author><title>Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson&#8217;s disease: implications for dyskinesias</title><source>Brain</source><year>2004</year><volume>127</volume><issue>Pt 12</issue><fpage>2747</fpage><lpage>2754</lpage>
<author><surname>Olanow</surname> <given-names>CW</given-names> </author><author><surname>Obeso</surname> <given-names>JA</given-names> </author><title>Preventing levodopa-induced dyskinesias</title><source>Ann Neurol</source><year>2000</year><volume>47</volume><issue>4 Suppl 1</issue><fpage>S167</fpage><lpage>S176</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><author><surname>Carter</surname> <given-names>JH</given-names> </author><author><surname>Lea</surname> <given-names>ES</given-names> </author><author><surname>Woodward</surname> <given-names>WR</given-names> </author><title>Motor fluctuations during continuous levodopa infusions in patients with Parkinson&#8217;s disease</title><source>Mov Disord</source><year>1997</year><volume>12</volume><issue>3</issue><fpage>285</fpage><lpage>292</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Vacca</surname> <given-names>L</given-names> </author><author><surname>Ruggieri</surname> <given-names>S</given-names> </author><author><surname>Olanow</surname> <given-names>CW</given-names> </author><title>Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study</title><source>Arch Neurol</source><year>2005</year><volume>62</volume><issue>6</issue><fpage>905</fpage><lpage>910</lpage>
<author><surname>Antonini</surname> <given-names>A</given-names> </author><author><surname>Isaias</surname> <given-names>IU</given-names> </author><author><surname>Canesi</surname> <given-names>M</given-names> </author><title>Duodenal levodopa infusion for advanced Parkinson&#8217;s disease: 12-month treatment outcome</title><source>Mov Disord</source><year>2007</year><volume>22</volume><issue>8</issue><fpage>1145</fpage><lpage>1149</lpage>
<author><surname>Pearce</surname> <given-names>RK</given-names> </author><author><surname>Banerji</surname> <given-names>T</given-names> </author><author><surname>Jenner</surname> <given-names>P</given-names> </author><author><surname>Marsden</surname> <given-names>CD</given-names> </author><title>De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset</title><source>Mov Disord</source><year>1998</year><volume>13</volume><issue>2</issue><fpage>234</fpage><lpage>241</lpage>
<author><surname>Rascol</surname> <given-names>O</given-names> </author><author><surname>Brooks</surname> <given-names>DJ</given-names> </author><author><surname>Korczyn</surname> <given-names>AD</given-names> </author><author><surname>de Deyn</surname> <given-names>PP</given-names> </author><author><surname>Clarke</surname> <given-names>CE</given-names> </author><author><surname>Lang</surname> <given-names>AE</given-names> </author><title>A five-year study of the incidence of dyskinesia in patients with early Parkinson&#8217;s disease who were treated with ropinirole or levodopa</title><source>N Engl J Med</source><year>2000</year><volume>342</volume><issue>20</issue><fpage>1484</fpage><lpage>1491</lpage>
<author><surname>Olanow</surname> <given-names>CW</given-names> </author><title>The scientific basis for the current treatment of Parkinson&#8217;s disease</title><source>Annu Rev Med</source><year>2004</year><volume>55</volume><fpage>41</fpage><lpage>60</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Rascol</surname> <given-names>O</given-names> </author><author><surname>Kieburtz</surname> <given-names>K</given-names> </author><title>Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study</title><source>Ann Neurol</source><year>2010</year><volume>68</volume><issue>1</issue><fpage>18</fpage><lpage>27</lpage>
<author><surname>Smith</surname> <given-names>LA</given-names> </author><author><surname>Jackson</surname> <given-names>MJ</given-names> </author><author><surname>Al-Barghouthy</surname> <given-names>G</given-names> </author><title>Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates</title><source>Mov Disord</source><year>2005</year><volume>20</volume><issue>3</issue><fpage>306</fpage><lpage>314</lpage>
<author><surname>Suzuki</surname> <given-names>K</given-names> </author><author><surname>Nakazato</surname> <given-names>H</given-names> </author><author><surname>Matsui</surname> <given-names>H</given-names> </author><title>Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population</title><source>Cancer</source><year>2003</year><volume>98</volume><issue>7</issue><fpage>1411</fpage><lpage>1416</lpage>
<author><surname>Tanaka</surname> <given-names>Y</given-names> </author><author><surname>Sasaki</surname> <given-names>M</given-names> </author><author><surname>Shiina</surname> <given-names>H</given-names> </author><title>Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer</title><source>Cancer Epidemiol Biomarkers Prev</source><year>2006</year><volume>15</volume><issue>2</issue><fpage>238</fpage><lpage>244</lpage>
<author><surname>Shoulson</surname> <given-names>I</given-names> </author><author><surname>Glaubiger</surname> <given-names>GA</given-names> </author><author><surname>Chase</surname> <given-names>TN</given-names> </author><title>On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients</title><source>Neurology</source><year>1975</year><volume>25</volume><issue>12</issue><fpage>1144</fpage><lpage>1148</lpage>
<author><surname>Hardie</surname> <given-names>RJ</given-names> </author><author><surname>Lees</surname> <given-names>AJ</given-names> </author><author><surname>Stern</surname> <given-names>GM</given-names> </author><title>On-off fluctuations in Parkinson&#8217;s disease. A clinical and neuropharmacological study</title><source>Brain</source><year>1984</year><volume>107</volume><issue>Pt 2</issue><fpage>487</fpage><lpage>506</lpage>
<author><surname>Bredberg</surname> <given-names>E</given-names> </author><author><surname>Nilsson</surname> <given-names>D</given-names> </author><author><surname>Johansson</surname> <given-names>K</given-names> </author><title>Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson&#8217;s disease</title><source>Eur J Clin Pharmacol</source><year>1993</year><volume>45</volume><issue>2</issue><fpage>117</fpage><lpage>122</lpage>
<author><surname>Sage</surname> <given-names>JI</given-names> </author><author><surname>Schuh</surname> <given-names>L</given-names> </author><author><surname>Heikkila</surname> <given-names>RE</given-names> </author><author><surname>Duvoisin</surname> <given-names>RC</given-names> </author><title>Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson&#8217;s disease</title><source>Clin Neuropharmacol</source><year>1988</year><volume>11</volume><issue>1</issue><fpage>36</fpage><lpage>44</lpage>
<author><surname>Nyholm</surname> <given-names>D</given-names> </author><author><surname>Nilsson Remahl</surname> <given-names>AI</given-names> </author><author><surname>Dizdar</surname> <given-names>N</given-names> </author><title>Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease</title><source>Neurology</source><year>2005</year><volume>64</volume><issue>2</issue><fpage>216</fpage><lpage>223</lpage>
<author><surname>Nilsson</surname> <given-names>D</given-names> </author><author><surname>Nyholm</surname> <given-names>D</given-names> </author><author><surname>Aquilonius</surname> <given-names>SM</given-names> </author><title>Duodenal levodopa infusion in Parkinson&#8217;s disease &#8211; long-term experience</title><source>Acta Neurol Scand</source><year>2001</year><volume>104</volume><issue>6</issue><fpage>343</fpage><lpage>348</lpage>
<author><surname>Devos</surname> <given-names>D</given-names> </author><title>Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2009</year><volume>24</volume><issue>7</issue><fpage>993</fpage><lpage>1000</lpage>
<author><surname>Nyholm</surname> <given-names>D</given-names> </author><title>Pharmacokinetics of levodopa/carbidopa infusion with and without oral catechol-O-methyl transferase (COMT) inhibitors (DuoCOMT)</title>Available from:
<author><surname>Pekkonen</surname> <given-names>E</given-names> </author><title>Duodenal levodopa infusion, quality of life and autonomic nervous system in Parkinson&#8217;s disease</title>Available from:
<author><surname>Lundqvist</surname> <given-names>C</given-names> </author><author><surname>Beiske</surname> <given-names>A</given-names> </author><title>Continuous delivery of levodopa in patients with advanced idiopathic Parkinsons disease &#8211; cost-benefit</title>Available from:
<author><surname>Nyholm</surname> <given-names>D</given-names> </author><title>Different dyskinesias in Parkinson&#8217;s disease and their relation to levodopa pharmacokinetics (DYSK-PD-2007)</title>Available from:
<author><surname>Kurlan</surname> <given-names>R</given-names> </author><author><surname>Rothfield</surname> <given-names>KP</given-names> </author><author><surname>Woodward</surname> <given-names>WR</given-names> </author><title>Erratic gastric emptying of levodopa may cause &#8220;random&#8221; fluctuations of parkinsonian mobility</title><source>Neurology</source><year>1988</year><volume>38</volume><issue>3</issue><fpage>419</fpage><lpage>421</lpage>
<author><surname>Djaldetti</surname> <given-names>R</given-names> </author><author><surname>Baron</surname> <given-names>J</given-names> </author><author><surname>Ziv</surname> <given-names>I</given-names> </author><author><surname>Melamed</surname> <given-names>E</given-names> </author><title>Gastric emptying in Parkinson&#8217;s disease: patients with and without response fluctuations</title><source>Neurology</source><year>1996</year><volume>46</volume><issue>4</issue><fpage>1051</fpage><lpage>1054</lpage>
<author><surname>Pfeiffer</surname> <given-names>RF</given-names> </author><title>Gastrointestinal dysfunction in Parkinson&#8217;s disease</title><source>Lancet Neurol</source><year>2003</year><volume>2</volume><issue>2</issue><fpage>107</fpage><lpage>116</lpage>
<author><surname>Goetze</surname> <given-names>O</given-names> </author><author><surname>Nikodem</surname> <given-names>AB</given-names> </author><author><surname>Wiezcorek</surname> <given-names>J</given-names> </author><title>Predictors of gastric emptying in Parkinson&#8217;s disease</title><source>Neurogastroenterol Motil</source><year>2006</year><volume>18</volume><issue>5</issue><fpage>369</fpage><lpage>375</lpage>
<author><surname>Steiger</surname> <given-names>MJ</given-names> </author><author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Carta</surname> <given-names>A</given-names> </author><title>The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon &#8220;off &#8221; periods in Parkinson&#8217;s disease</title><source>Clin Neuropharmacol</source><year>1991</year><volume>14</volume><issue>3</issue><fpage>241</fpage><lpage>244</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Fabbri</surname> <given-names>L</given-names> </author><author><surname>Vecsei</surname> <given-names>L</given-names> </author><author><surname>Krygowska-Wajs</surname> <given-names>A</given-names> </author><author><surname>Monici Preti</surname> <given-names>PA</given-names> </author><author><surname>Ruggieri</surname> <given-names>SA</given-names> </author><title>Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease</title><source>Clin Neuropharmacol</source><year>2007</year><volume>30</volume><issue>1</issue><fpage>18</fpage><lpage>24</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Zappia</surname> <given-names>M</given-names> </author><author><surname>Dall&#8217;Armi</surname> <given-names>V</given-names> </author><author><surname>Kulisevsky</surname> <given-names>J</given-names> </author><author><surname>Lamberti</surname> <given-names>P</given-names> </author><author><surname>Obeso</surname> <given-names>JA</given-names> </author><title>Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>12</issue><fpage>1881</fpage><lpage>1887</lpage>
<author><surname>Chen</surname> <given-names>D</given-names> </author><title>An exploratory study of XP21279 (with Lodosyn&#174;) and Sinemet&#174; in Parkinson&#8217;s disease subjects</title>Available from:
<title>Product candidates, XP21279</title>Available from:
<author><surname>Hsu</surname> <given-names>A</given-names> </author><author><surname>Verhagen Metman</surname> <given-names>L</given-names> </author><author><surname>Ellenbogen</surname> <given-names>A</given-names> </author><title>Comparison of IPX066, a novel extended-release oral carbidopa-levodopa formulation, to immediate-release carbidopa-levodopa in patients with advanced Parkinson&#8217;s disease</title><source>Am Acad Neurol</source><year>2010</year><volume>74</volume><issue>Suppl 2</issue><fpage>A350</fpage>
<title>A study to evaluate the safety and efficacy of IPX066 in subjects with Parkinson&#8217;s disease (APEX-PD)</title>Available from:
<author><surname>Ferr&#233;</surname> <given-names>S</given-names> </author><author><surname>O&#8217;Connor</surname> <given-names>WT</given-names> </author><author><surname>Fuxe</surname> <given-names>K</given-names> </author><author><surname>Ungerstedt</surname> <given-names>U</given-names> </author><title>The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain</title><source>J Neurosci</source><year>1993</year><volume>13</volume><issue>12</issue><fpage>5402</fpage><lpage>5406</lpage>
<author><surname>Svenningsson</surname> <given-names>P</given-names> </author><author><surname>Le Moine</surname> <given-names>C</given-names> </author><author><surname>Aubert</surname> <given-names>I</given-names> </author><author><surname>Burbaud</surname> <given-names>P</given-names> </author><author><surname>Fredholm</surname> <given-names>BB</given-names> </author><author><surname>Bloch</surname> <given-names>B</given-names> </author><title>Cellular distribution of adenosine A2A receptor mRNA in the primate striatum</title><source>J Comp Neurol</source><year>1998</year><volume>399</volume><issue>2</issue><fpage>229</fpage><lpage>240</lpage>
<author><surname>Ferr&#233;</surname> <given-names>S</given-names> </author><author><surname>Fredholm</surname> <given-names>BB</given-names> </author><author><surname>Morelli</surname> <given-names>M</given-names> </author><author><surname>Popoli</surname> <given-names>P</given-names> </author><author><surname>Fuxe</surname> <given-names>K</given-names> </author><title>Adenosine&#8211;dopamine receptor&#8211;receptor interactions as an integrative mechanism in the basal ganglia</title><source>Trends Neurosci</source><year>1997</year><volume>20</volume><issue>10</issue><fpage>482</fpage><lpage>487</lpage>
<author><surname>Mori</surname> <given-names>A</given-names> </author><author><surname>Shindou</surname> <given-names>T</given-names> </author><title>Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists</title><source>Neurology</source><year>2003</year><volume>61</volume><issue>11 Suppl 6</issue><fpage>S44</fpage><lpage>S48</lpage>
<author><surname>Fenu</surname> <given-names>S</given-names> </author><author><surname>Pinna</surname> <given-names>A</given-names> </author><author><surname>Ongini</surname> <given-names>E</given-names> </author><author><surname>Morelli</surname> <given-names>M</given-names> </author><title>Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats</title><source>Eur J Pharmacol</source><year>1997</year><volume>321</volume><issue>2</issue><fpage>143</fpage><lpage>147</lpage>
<author><surname>Rose</surname> <given-names>S</given-names> </author><author><surname>Ramsay Croft</surname> <given-names>N</given-names> </author><author><surname>Jenner</surname> <given-names>P</given-names> </author><title>The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats</title><source>Brain Res</source><year>2007</year><volume>1133</volume><issue>1</issue><fpage>110</fpage><lpage>114</lpage>
<author><surname>Kanda</surname> <given-names>T</given-names> </author><author><surname>Jackson</surname> <given-names>MJ</given-names> </author><author><surname>Smith</surname> <given-names>LA</given-names> </author><title>Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys</title><source>Ann Neurol</source><year>1998</year><volume>43</volume><issue>4</issue><fpage>507</fpage><lpage>513</lpage>
<author><surname>Lundblad</surname> <given-names>M</given-names> </author><author><surname>Vaudano</surname> <given-names>E</given-names> </author><author><surname>Cenci</surname> <given-names>MA</given-names> </author><title>Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia</title><source>J Neurochem</source><year>2003</year><volume>84</volume><issue>6</issue><fpage>1398</fpage><lpage>1410</lpage>
<author><surname>Kanda</surname> <given-names>T</given-names> </author><author><surname>Jackson</surname> <given-names>MJ</given-names> </author><author><surname>Smith</surname> <given-names>LA</given-names> </author><title>Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys</title><source>Exp Neurol</source><year>2000</year><volume>162</volume><issue>2</issue><fpage>321</fpage><lpage>327</lpage>
<author><surname>Bara-Jimenez</surname> <given-names>W</given-names> </author><author><surname>Sherzai</surname> <given-names>A</given-names> </author><author><surname>Dimitrova</surname> <given-names>T</given-names> </author><title>Adenosine A(2A) receptor antagonist treatment of Parkinson&#8217;s disease</title><source>Neurology</source><year>2003</year><volume>61</volume><issue>3</issue><fpage>293</fpage><lpage>296</lpage>
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Hubble</surname> <given-names>JP</given-names> </author><author><surname>Truong</surname> <given-names>DD</given-names> </author><title>Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD</title><source>Neurology</source><year>2003</year><volume>61</volume><issue>3</issue><fpage>297</fpage><lpage>303</lpage>
<author><surname>Lewitt</surname> <given-names>PA</given-names> </author><author><surname>Guttman</surname> <given-names>M</given-names> </author><author><surname>Tetrud</surname> <given-names>JW</given-names> </author><title>Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces &#8220;off &#8221; time in Parkinson&#8217;s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)</title><source>Ann Neurol</source><year>2008</year><volume>63</volume><issue>3</issue><fpage>295</fpage><lpage>302</lpage>
<author><surname>Stacy</surname> <given-names>M</given-names> </author><author><surname>Silver</surname> <given-names>D</given-names> </author><author><surname>Mendis</surname> <given-names>T</given-names> </author><title>A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease</title><source>Neurology</source><year>2008</year><volume>70</volume><issue>23</issue><fpage>2233</fpage><lpage>2240</lpage>
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Shulman</surname> <given-names>LM</given-names> </author><author><surname>Trugman</surname> <given-names>JM</given-names> </author><title>Study of istradefylline in patients with Parkinson&#8217;s disease on levodopa with motor fluctuations</title><source>Mov Disord</source><year>2008</year><volume>23</volume><issue>15</issue><fpage>2177</fpage><lpage>2185</lpage>
<author><surname>Guttman</surname> <given-names>M</given-names> </author><title>Efficacy of istradefylline in Parkinson&#8217;s disease patients treated with levodopa with motor response complications: primary efficacy results of the KW-6002 US-018 study</title><source>Mov Disord</source><year>2006</year><volume>21</volume><issue>Suppl 15</issue><fpage>S585</fpage>
<title>KW-6002 to treat Parkinson&#8217;s disease. NCT00006337</title>Available from:
<title>2nd generation A2A antagonist</title>Available from:
<title>A phase 2, 12-week, double-blind, dose-finding, placebo-controlled study to assess the efficacy and safety of a range of SCH 420814 doses in subjects with moderate to severe Parkinson&#8217;s disease experiencing motor fluctuations and dyskinesias</title>Available from:
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Pourcher</surname> <given-names>E</given-names> </author><author><surname>Micheli</surname> <given-names>F</given-names> </author><title>Efficacy of preladenant, a novel A2A antagonist, as an adjunct to levodopa for the treatment of Parkinson&#8217;s disease</title><source>Presented at Movement Disorder Society&#8217;s 13th International Congress of Parkinson&#8217;s Disease and Movements Disorders</source><other>Paris, France</other><other>7&#8211;11 Jun 2009</other>Abstract Tu-185.
<author><surname>Huyck</surname> <given-names>SB</given-names> </author><author><surname>Wolski</surname> <given-names>K</given-names> </author><author><surname>Cantillon</surname> <given-names>M</given-names> </author><title>Impact of A2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson&;s disease: post hoc analysis of dose-finding study</title><other>Presented at Movement Disorder Societys 13th International Congress of Parkinson&;s Disease and Movements Disorders</other><other>Paris, France</other><other>7&;11 Jun 2009</other><other>Abstract Tu-187.</other>
<title>A placebo- and active-controlled study of preladenant in early Parkinson&#8216;s disease (study P05664 AM2)</title><other>Available from:</other>
<title>A placebo- and active controlled study of preladenant in subjects with moderate to severe Parkinson&#8216;s disease (study P04938 AM2)</title><other>Available from:</other>
<title>Synosia Therapeutics Pipeline</title><other>Available from:</other>
<title>Sigma-Tau. Research development stages</title><other>Available from:</other>
<author><surname>Ross</surname> <given-names>GW</given-names> </author><author><surname>Abbott</surname> <given-names>RD</given-names> </author><author><surname>Petrovitch</surname> <given-names>H</given-names> </author><title>Association of coffee and caffeine intake with the risk of Parkinson disease</title><source>JAMA</source><year>2000</year><volume>283</volume><issue>20</issue><fpage>2674</fpage><lpage>2679</lpage>
<author><surname>Ascherio</surname> <given-names>A</given-names> </author><author><surname>Zhang</surname> <given-names>SM</given-names> </author><author><surname>Hern&#225;n</surname> <given-names>MA</given-names> </author><title>Prospective study of caffeine consumption and risk of Parkinson&#8217;s disease in men and women</title><source>Ann Neurol</source><year>2001</year><volume>50</volume><issue>1</issue><fpage>56</fpage><lpage>63</lpage>
<author><surname>Tan</surname> <given-names>EK</given-names> </author><author><surname>Tan</surname> <given-names>C</given-names> </author><author><surname>Fook-Chong</surname> <given-names>SM</given-names> </author><title>Dose-dependent protective effect of coffee, tea, and smoking in Parkinson&#8217;s disease: a study in ethnic Chinese</title><source>J Neurol Sci</source><year>2003</year><volume>216</volume><issue>1</issue><fpage>163</fpage><lpage>167</lpage>
<author><surname>Hu</surname> <given-names>G</given-names> </author><author><surname>Bidel</surname> <given-names>S</given-names> </author><author><surname>Jousilahti</surname> <given-names>P</given-names> </author><author><surname>Antikainen</surname> <given-names>R</given-names> </author><author><surname>Tuomilehto</surname> <given-names>J</given-names> </author><title>Coffee and tea consumption and the risk of Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2007</year><volume>22</volume><issue>15</issue><fpage>2242</fpage><lpage>2248</lpage>
<author><surname>Chen</surname> <given-names>JF</given-names> </author><author><surname>Xu</surname> <given-names>K</given-names> </author><author><surname>Petzer</surname> <given-names>JP</given-names> </author><title>Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson&#8217;s disease</title><source>J Neurosci</source><year>2001</year><volume>21</volume><issue>10</issue><fpage>RC143</fpage>
<author><surname>Ikeda</surname> <given-names>K</given-names> </author><author><surname>Kurokawa</surname> <given-names>M</given-names> </author><author><surname>Aoyama</surname> <given-names>S</given-names> </author><author><surname>Kuwana</surname> <given-names>Y</given-names> </author><title>Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson&#8217;s disease</title><source>J Neurochem</source><year>2002</year><volume>80</volume><issue>2</issue><fpage>262</fpage><lpage>270</lpage>
<author><surname>Pierri</surname> <given-names>M</given-names> </author><author><surname>Vaudano</surname> <given-names>E</given-names> </author><author><surname>Sager</surname> <given-names>T</given-names> </author><author><surname>Englund</surname> <given-names>U</given-names> </author><title>KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse</title><source>Neuropharmacology</source><year>2005</year><volume>48</volume><issue>4</issue><fpage>517</fpage><lpage>524</lpage>
<author><surname>Jenner</surname> <given-names>P</given-names> </author><author><surname>Mori</surname> <given-names>A</given-names> </author><author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Morelli</surname> <given-names>M</given-names> </author><author><surname>Fredholm</surname> <given-names>BB</given-names> </author><author><surname>Chen</surname> <given-names>JF</given-names> </author><title>Adenosine, adenosine A2A antagonists, and Parkinson&#8217;s disease</title><source>Parkinsonism Relat Disord</source><year>2009</year><volume>15</volume><issue>6</issue><fpage>406</fpage><lpage>413</lpage>
<author><surname>Blandini</surname> <given-names>F</given-names> </author><author><surname>Armentero</surname> <given-names>MT</given-names> </author><author><surname>Fancellu</surname> <given-names>R</given-names> </author><author><surname>Blaugrund</surname> <given-names>E</given-names> </author><author><surname>Nappi</surname> <given-names>G</given-names> </author><title>Neuroprotective effect of rasagiline in a rodent model of Parkinson&#8217;s disease</title><source>Exp Neurol</source><year>2004</year><volume>187</volume><issue>2</issue><fpage>455</fpage><lpage>459</lpage>
<author><surname>Kupsch</surname> <given-names>A</given-names> </author><author><surname>Sautter</surname> <given-names>J</given-names> </author><author><surname>G&#246;tz</surname> <given-names>ME</given-names> </author><title>Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline</title><source>J Neural Transm</source><year>2001</year><volume>108</volume><issue>8&#8211;9</issue><fpage>985</fpage><lpage>1009</lpage>
<title>A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease</title><source>Arch Neurol</source><year>2004</year><volume>61</volume><issue>4</issue><fpage>561</fpage><lpage>566</lpage>
<author><surname>Olanow</surname> <given-names>CW</given-names> </author><author><surname>Rascol</surname> <given-names>O</given-names> </author><author><surname>Hauser</surname> <given-names>RA</given-names> </author><title>A double-blind, delayed-start trial of rasagiline in Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>13</issue><fpage>1268</fpage><lpage>1278</lpage>
<author><surname>Kieburtz</surname> <given-names>K</given-names> </author><title>ADAGIO misses a beat?</title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><issue>12</issue><fpage>1081</fpage><lpage>1082</lpage>
<author><surname>Ahlskog</surname> <given-names>JE</given-names> </author><author><surname>Uitti</surname> <given-names>RJ</given-names> </author><title>Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?</title><source>Neurology</source><year>2010</year><volume>74</volume><issue>14</issue><fpage>1143</fpage><lpage>1148</lpage>
<author><surname>Marzo</surname> <given-names>A</given-names> </author><author><surname>Dal Bo</surname> <given-names>L</given-names> </author><author><surname>Monti</surname> <given-names>NC</given-names> </author><title>Pharmacokinetics and pharmacodynamics of saf inamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity</title><source>Pharmacol Res</source><year>2004</year><volume>50</volume><issue>1</issue><fpage>77</fpage><lpage>85</lpage>
<author><surname>Caccia</surname> <given-names>C</given-names> </author><author><surname>Maj</surname> <given-names>R</given-names> </author><author><surname>Calabresi</surname> <given-names>M</given-names> </author><title>Safinamide: from molecular targets to a new anti-Parkinson drug</title><source>Neurology</source><year>2006</year><volume>67</volume><issue>7 Suppl 2</issue><fpage>S18</fpage><lpage>S23</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Arnold</surname> <given-names>G</given-names> </author><author><surname>Onofrj</surname> <given-names>M</given-names> </author><title>Improvement of motor function in early Parkinson disease by safinamide</title><source>Neurology</source><year>2004</year><volume>63</volume><issue>4</issue><fpage>746</fpage><lpage>748</lpage>
<author><surname>Borgohain</surname> <given-names>R</given-names> </author><author><surname>Szasz</surname> <given-names>J</given-names> </author><author><surname>Bhatt</surname> <given-names>M</given-names> </author><title>Efficacy and safety of safinamide in patients with Parkinson&#8217;s disease experiencing motor fluctuations: results of a 6-month phase III, randomized, double-blind, placebo-controlled study</title><year>2009</year>Available from:
<author><surname>Willmer</surname> <given-names>J</given-names> </author><title>Safinamide in levodopa induced dyskinesia in Parkinson&#8217;s disease subjects (safinamide-LID)</title>Available from:
<author><surname>Schapira</surname> <given-names>AH</given-names> </author><title>Safinamide in the treatment of Parkinson&#8217;s disease</title><source>Expert Opin Pharmacother</source><year>2010</year><volume>11</volume><issue>13</issue><fpage>2261</fpage><lpage>2268</lpage>
<author><surname>Stacy</surname> <given-names>M</given-names> </author><author><surname>Galbreath</surname> <given-names>A</given-names> </author><title>Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia</title><source>Clin Neuropharmacol</source><year>2008</year><volume>31</volume><issue>1</issue><fpage>51</fpage><lpage>56</lpage>
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Rascol</surname> <given-names>O</given-names> </author><author><surname>Korczyn</surname> <given-names>AD</given-names> </author><title>Ten-year follow-up of Parkinson&#8217;s disease patients randomized to initial therapy with ropinirole or levodopa</title><source>Mov Disord</source><year>2007</year><volume>22</volume><issue>16</issue><fpage>2409</fpage><lpage>2417</lpage>
<author><surname>Holloway</surname> <given-names>R</given-names> </author><author><surname>Marek</surname> <given-names>K</given-names> </author><author><surname>Biglan</surname> <given-names>K</given-names> </author><title>Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease</title><source>Arch Neurol</source><year>2009</year><volume>66</volume><issue>5</issue><fpage>563</fpage><lpage>570</lpage>
<title>Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression</title><source>JAMA</source><year>2002</year><volume>287</volume><issue>13</issue><fpage>1653</fpage><lpage>1661</lpage>
<author><surname>Whone</surname> <given-names>AL</given-names> </author><author><surname>Watts</surname> <given-names>RL</given-names> </author><author><surname>Stoessl</surname> <given-names>AJ</given-names> </author><title>Slower progression of Parkinson&#8217;s disease with ropinirole versus levodopa: the REAL-PET study</title><source>Ann Neurol</source><year>2003</year><volume>54</volume><issue>1</issue><fpage>93</fpage><lpage>101</lpage>
<author><surname>Schapira</surname> <given-names>AH</given-names> </author><author><surname>Albrecht</surname> <given-names>S</given-names> </author><author><surname>Barone</surname> <given-names>P</given-names> </author><title>Immediate vs delayed-start pramipexole in early Parkinson&#8217;s disease: the PROUD study</title><source>Parkinsonism Relat Disord</source><year>2009</year><volume>15</volume><issue>Suppl 2</issue><fpage>S81</fpage>
<author><surname>Schapira</surname> <given-names>AH</given-names> </author><author><surname>Albrecht</surname> <given-names>S</given-names> </author><author><surname>Barone</surname> <given-names>P</given-names> </author><title>Rationale for delayed-start study of pramipexole in Parkinson&#8217;s disease: the PROUD study</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>11</issue><fpage>1627</fpage><lpage>1632</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Hersh</surname> <given-names>BP</given-names> </author><author><surname>Scott</surname> <given-names>BL</given-names> </author><author><surname>Nausieda</surname> <given-names>PA</given-names> </author><author><surname>Giorgi</surname> <given-names>L</given-names> </author><title>Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson&#8217;s disease: a randomized, double-blind, non-inferiority crossover study</title><source>Curr Med Res Opin</source><year>2008</year><volume>24</volume><issue>10</issue><fpage>2883</fpage><lpage>2895</lpage>
<author><surname>Pahwa</surname> <given-names>R</given-names> </author><author><surname>Stacy</surname> <given-names>MA</given-names> </author><author><surname>Factor</surname> <given-names>SA</given-names> </author><title>Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease</title><source>Neurology</source><year>2007</year><volume>68</volume><issue>14</issue><fpage>1108</fpage><lpage>1115</lpage>
<author><surname>Hersh</surname> <given-names>BP</given-names> </author><author><surname>Earl</surname> <given-names>NL</given-names> </author><author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Stacy</surname> <given-names>M</given-names> </author><title>Early treatment benefits of ropinirole prolonged release in Parkinson&#8217;s disease patients with motor fluctuations</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>7</issue><fpage>927</fpage><lpage>931</lpage>
<author><surname>Hauser</surname> <given-names>RA</given-names> </author><author><surname>Schapira</surname> <given-names>AH</given-names> </author><author><surname>Rascol</surname> <given-names>O</given-names> </author><title>Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>15</issue><fpage>2542</fpage><lpage>2549</lpage>
<author><surname>Driver-Dunckley</surname> <given-names>E</given-names> </author><author><surname>Samanta</surname> <given-names>J</given-names> </author><author><surname>Stacy</surname> <given-names>M</given-names> </author><title>Pathological gambling associated with dopamine agonist therapy in Parkinson&#8217;s disease</title><source>Neurology</source><year>2003</year><volume>61</volume><issue>3</issue><fpage>422</fpage><lpage>423</lpage>
<author><surname>Weintraub</surname> <given-names>D</given-names> </author><author><surname>Siderowf</surname> <given-names>AD</given-names> </author><author><surname>Potenza</surname> <given-names>MN</given-names> </author><title>Association of dopamine agonist use with impulse control disorders in Parkinson disease</title><source>Arch Neurol</source><year>2006</year><volume>63</volume><issue>7</issue><fpage>969</fpage><lpage>973</lpage>
<author><surname>Voon</surname> <given-names>V</given-names> </author><author><surname>Hassan</surname> <given-names>K</given-names> </author><author><surname>Zurowski</surname> <given-names>M</given-names> </author><title>Prevalence of repetitive and reward-seeking behaviors in Parkinson disease</title><source>Neurology</source><year>2006</year><volume>67</volume><issue>7</issue><fpage>1254</fpage><lpage>1257</lpage>
<author><surname>Evans</surname> <given-names>AH</given-names> </author><author><surname>Strafella</surname> <given-names>AP</given-names> </author><author><surname>Weintraub</surname> <given-names>D</given-names> </author><author><surname>Stacy</surname> <given-names>M</given-names> </author><title>Impulsive and compulsive behaviors in Parkinson&#8217;s disease</title><source>Mov Disord</source><year>2009</year><volume>24</volume><issue>11</issue><fpage>1561</fpage><lpage>1570</lpage>
<author><surname>Weintraub</surname> <given-names>D</given-names> </author><author><surname>Koester</surname> <given-names>J</given-names> </author><author><surname>Potenza</surname> <given-names>MN</given-names> </author><title>Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients</title><source>Arch Neurol</source><year>2010</year><volume>67</volume><issue>5</issue><fpage>589</fpage><lpage>595</lpage>
<author><surname>Thomas</surname> <given-names>A</given-names> </author><author><surname>Bonanni</surname> <given-names>L</given-names> </author><author><surname>Gambi</surname> <given-names>F</given-names> </author><author><surname>di Iorio</surname> <given-names>A</given-names> </author><author><surname>Onofrj</surname> <given-names>M</given-names> </author><title>Pathological gambling in Parkinson disease is reduced by amantadine</title><source>Ann Neurol</source><year>2010</year><volume>68</volume><issue>3</issue><fpage>400</fpage><lpage>404</lpage>
<author><surname>Weintraub</surname> <given-names>D</given-names> </author><author><surname>Sohr</surname> <given-names>M</given-names> </author><author><surname>Potenza</surname> <given-names>MN</given-names> </author><title>Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study</title><source>Ann Neurol</source><year>2010</year><volume>68</volume><issue>6</issue><fpage>963</fpage><lpage>968</lpage>
<author><surname>Weintraub</surname> <given-names>D</given-names> </author><title>Naltrexone for impulse control disorders in Parkinson&#8216;s disease</title>Available from:
<author><surname>Modi</surname> <given-names>G</given-names> </author><author><surname>Pillay</surname> <given-names>V</given-names> </author><author><surname>Choonara</surname> <given-names>YE</given-names> </author><title>Advances in the treatment of neurodegenerative disorders employing nanotechnology</title><source>Ann N Y Acad Sci</source><year>2010</year><volume>1184</volume><fpage>154</fpage><lpage>172</lpage>
<author><surname>Modi</surname> <given-names>G</given-names> </author><author><surname>Pillay</surname> <given-names>V</given-names> </author><author><surname>Choonara</surname> <given-names>YE</given-names> </author><author><surname>Ndesendo</surname> <given-names>VM</given-names> </author><author><surname>du Toit</surname> <given-names>LC</given-names> </author><author><surname>Naidoo</surname> <given-names>D</given-names> </author><title>Nanotechnological applications for the treatment of neurodegenerative disorders</title><source>Prog Neurobiol</source><year>2009</year><volume>88</volume><issue>4</issue><fpage>272</fpage><lpage>285</lpage>
<author><surname>Staples</surname> <given-names>M</given-names> </author><title>Microchips and controlled-release drug reservoirs</title><source>Wiley Interdiscip Rev Nanomed Nanobiotechnol</source><year>2010</year><volume>2</volume><issue>4</issue><fpage>400</fpage><lpage>417</lpage>
<author><surname>Linazasoro</surname> <given-names>G</given-names> </author><title>Potential applications of nanotechnologies to Parkinson&#8217;s disease therapy</title><source>Parkinsonism Relat Disord</source><year>2008</year><volume>14</volume><issue>5</issue><fpage>383</fpage><lpage>392</lpage>
<author><surname>Bergman</surname> <given-names>H</given-names> </author><author><surname>Wichmann</surname> <given-names>T</given-names> </author><author><surname>DeLong</surname> <given-names>MR</given-names> </author><title>Reversal of experimental parkinsonism by lesions of the subthalamic nucleus</title><source>Science</source><year>1990</year><volume>249</volume><issue>4975</issue><fpage>1436</fpage><lpage>1438</lpage>
<author><surname>Aziz</surname> <given-names>TZ</given-names> </author><author><surname>Peggs</surname> <given-names>D</given-names> </author><author><surname>Sambrook</surname> <given-names>MA</given-names> </author><author><surname>Crossman</surname> <given-names>AR</given-names> </author><title>Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate</title><source>Mov Disord</source><year>1991</year><volume>6</volume><issue>4</issue><fpage>288</fpage><lpage>292</lpage>
<author><surname>Benazzouz</surname> <given-names>A</given-names> </author><author><surname>Gross</surname> <given-names>C</given-names> </author><author><surname>F&#233;ger</surname> <given-names>J</given-names> </author><author><surname>Boraud</surname> <given-names>T</given-names> </author><author><surname>Bioulac</surname> <given-names>B</given-names> </author><title>Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys</title><source>Eur J Neurosci</source><year>1993</year><volume>5</volume><issue>4</issue><fpage>382</fpage><lpage>389</lpage>
<author><surname>Wichmann</surname> <given-names>T</given-names> </author><author><surname>Bergman</surname> <given-names>H</given-names> </author><author><surname>DeLong</surname> <given-names>MR</given-names> </author><title>The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism</title><source>J Neurophysiol</source><year>1994</year><volume>72</volume><issue>2</issue><fpage>521</fpage><lpage>530</lpage>
<author><surname>Kleiner-Fisman</surname> <given-names>G</given-names> </author><author><surname>Fisman</surname> <given-names>DN</given-names> </author><author><surname>Sime</surname> <given-names>E</given-names> </author><author><surname>Saint-Cyr</surname> <given-names>JA</given-names> </author><author><surname>Lozano</surname> <given-names>AM</given-names> </author><author><surname>Lang</surname> <given-names>AE</given-names> </author><title>Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease</title><source>J Neurosurg</source><year>2003</year><volume>99</volume><issue>3</issue><fpage>489</fpage><lpage>495</lpage>
<author><surname>Weaver</surname> <given-names>FM</given-names> </author><author><surname>Follett</surname> <given-names>K</given-names> </author><author><surname>Stern</surname> <given-names>M</given-names> </author><title>Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial</title><source>JAMA</source><year>2009</year><volume>301</volume><issue>1</issue><fpage>63</fpage><lpage>73</lpage>
<author><surname>Follett</surname> <given-names>KA</given-names> </author><author><surname>Weaver</surname> <given-names>FM</given-names> </author><author><surname>Stern</surname> <given-names>M</given-names> </author><title>Pallidal versus subthalamic deep-brain stimulation for Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>22</issue><fpage>2077</fpage><lpage>2091</lpage>
<author><surname>Mazzone</surname> <given-names>P</given-names> </author><author><surname>Lozano</surname> <given-names>A</given-names> </author><author><surname>Stanzione</surname> <given-names>P</given-names> </author><title>Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson&#8217;s disease</title><source>Neuroreport</source><year>2005</year><volume>16</volume><issue>17</issue><fpage>1877</fpage><lpage>1881</lpage>
<author><surname>Plaha</surname> <given-names>P</given-names> </author><author><surname>Gill</surname> <given-names>SS</given-names> </author><title>Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson&#8217;s disease</title><source>Neuroreport</source><year>2005</year><volume>16</volume><issue>17</issue><fpage>1883</fpage><lpage>1887</lpage>
<author><surname>Moro</surname> <given-names>E</given-names> </author><author><surname>Hamani</surname> <given-names>C</given-names> </author><author><surname>Poon</surname> <given-names>YY</given-names> </author><title>Unilateral pedunculopontine stimulation improves falls in Parkinson&#8217;s disease</title><source>Brain</source><year>2010</year><volume>133</volume><issue>Pt 1</issue><fpage>215</fpage><lpage>224</lpage>
<author><surname>Ferraye</surname> <given-names>MU</given-names> </author><author><surname>Deb&#251;</surname> <given-names>B</given-names> </author><author><surname>Fraix</surname> <given-names>V</given-names> </author><title>Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson&#8216;s disease</title><source>Brain</source><year>2010</year><volume>133</volume><issue>Pt 1</issue><fpage>205</fpage><lpage>214</lpage>
<author><surname>Benabid</surname> <given-names>AL</given-names> </author><author><surname>Chabardes</surname> <given-names>S</given-names> </author><author><surname>Mitrofanis</surname> <given-names>J</given-names> </author><author><surname>Pollak</surname> <given-names>P</given-names> </author><title>Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson&#8217;s disease</title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><issue>1</issue><fpage>67</fpage><lpage>81</lpage>
<author><surname>Benabid</surname> <given-names>AL</given-names> </author><author><surname>Pollak</surname> <given-names>P</given-names> </author><author><surname>Gao</surname> <given-names>D</given-names> </author><title>Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders</title><source>J Neurosurg</source><year>1996</year><volume>84</volume><issue>2</issue><fpage>203</fpage><lpage>214</lpage>
<author><surname>Meissner</surname> <given-names>W</given-names> </author><author><surname>Leblois</surname> <given-names>A</given-names> </author><author><surname>Hansel</surname> <given-names>D</given-names> </author><title>Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations</title><source>Brain</source><year>2005</year><volume>128</volume><issue>Pt 10</issue><fpage>2372</fpage><lpage>2382</lpage>
<author><surname>Welter</surname> <given-names>ML</given-names> </author><author><surname>Houeto</surname> <given-names>JL</given-names> </author><author><surname>Bonnet</surname> <given-names>AM</given-names> </author><title>Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients</title><source>Arch Neurol</source><year>2004</year><volume>61</volume><issue>1</issue><fpage>89</fpage><lpage>96</lpage>
<author><surname>Xia</surname> <given-names>R</given-names> </author><author><surname>Berger</surname> <given-names>F</given-names> </author><author><surname>Piallat</surname> <given-names>B</given-names> </author><author><surname>Benabid</surname> <given-names>AL</given-names> </author><title>Alteration of hormone and neurotransmitter production in cultured cells by high and low frequency electrical stimulation</title><source>Acta Neurochir (Wien)</source><year>2007</year><volume>149</volume><issue>1</issue><fpage>67</fpage><lpage>73</lpage>
<author><surname>Harnack</surname> <given-names>D</given-names> </author><author><surname>Meissner</surname> <given-names>W</given-names> </author><author><surname>Jira</surname> <given-names>JA</given-names> </author><author><surname>Winter</surname> <given-names>C</given-names> </author><author><surname>Morgenstern</surname> <given-names>R</given-names> </author><author><surname>Kupsch</surname> <given-names>A</given-names> </author><title>Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism</title><source>Exp Neurol</source><year>2008</year><volume>210</volume><issue>1</issue><fpage>257</fpage><lpage>260</lpage>
<author><surname>Maesawa</surname> <given-names>S</given-names> </author><author><surname>Kaneoke</surname> <given-names>Y</given-names> </author><author><surname>Kajita</surname> <given-names>Y</given-names> </author><title>Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons</title><source>J Neurosurg</source><year>2004</year><volume>100</volume><issue>4</issue><fpage>679</fpage><lpage>687</lpage>
<author><surname>Temel</surname> <given-names>Y</given-names> </author><author><surname>Visser-Vandewalle</surname> <given-names>V</given-names> </author><author><surname>Kaplan</surname> <given-names>S</given-names> </author><title>Protection of nigral cell death by bilateral subthalamic nucleus stimulation</title><source>Brain Res</source><year>2006</year><volume>1120</volume><issue>1</issue><fpage>100</fpage><lpage>105</lpage>
<author><surname>Wallace</surname> <given-names>BA</given-names> </author><author><surname>Ashkan</surname> <given-names>K</given-names> </author><author><surname>Heise</surname> <given-names>CE</given-names> </author><title>Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys</title><source>Brain</source><year>2007</year><volume>130</volume><issue>Pt 8</issue><fpage>2129</fpage><lpage>2145</lpage>
<author><surname>Spieles-Engemann</surname> <given-names>AL</given-names> </author><author><surname>Behbehani</surname> <given-names>MM</given-names> </author><author><surname>Collier</surname> <given-names>TJ</given-names> </author><title>Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss</title><source>Neurobiol Dis</source><year>2010</year><volume>39</volume><issue>1</issue><fpage>105</fpage><lpage>115</lpage>
<author><surname>Bergman</surname> <given-names>H</given-names> </author><author><surname>Wichmann</surname> <given-names>T</given-names> </author><author><surname>Karmon</surname> <given-names>B</given-names> </author><author><surname>DeLong</surname> <given-names>MR</given-names> </author><title>The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism</title><source>J Neurophysiol</source><year>1994</year><volume>72</volume><issue>2</issue><fpage>507</fpage><lpage>520</lpage>
<author><surname>Crossman</surname> <given-names>AR</given-names> </author><author><surname>Mitchell</surname> <given-names>IJ</given-names> </author><author><surname>Sambrook</surname> <given-names>MA</given-names> </author><title>Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey</title><source>Neuropharmacology</source><year>1985</year><volume>24</volume><issue>6</issue><fpage>587</fpage><lpage>591</lpage>
<author><surname>Eidelberg</surname> <given-names>D</given-names> </author><author><surname>Moeller</surname> <given-names>JR</given-names> </author><author><surname>Dhawan</surname> <given-names>V</given-names> </author><title>The metabolic topography of parkinsonism</title><source>J Cereb Blood Flow Metab</source><year>1994</year><volume>14</volume><issue>5</issue><fpage>783</fpage><lpage>801</lpage>
<title>Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>13</issue><fpage>956</fpage><lpage>963</lpage>
<author><surname>Charles</surname> <given-names>PD</given-names> </author><author><surname>van Blercom</surname> <given-names>N</given-names> </author><author><surname>Krack</surname> <given-names>P</given-names> </author><title>Predictors of effective bilateral subthalamic nucleus stimulation for PD</title><source>Neurology</source><year>2002</year><volume>59</volume><issue>6</issue><fpage>932</fpage><lpage>934</lpage>
<author><surname>Deuschl</surname> <given-names>G</given-names> </author><author><surname>Schade-Brittinger</surname> <given-names>C</given-names> </author><author><surname>Krack</surname> <given-names>P</given-names> </author><title>A randomized trial of deep-brain stimulation for Parkinson&#8217;s disease</title><source>N Engl J Med</source><year>2006</year><volume>355</volume><issue>9</issue><fpage>896</fpage><lpage>908</lpage>
<author><surname>Volkmann</surname> <given-names>J</given-names> </author><title>Deep brain stimulation for the treatment of Parkinson&#8217;s disease</title><source>J Clin Neurophysiol</source><year>2004</year><volume>21</volume><issue>1</issue><fpage>6</fpage><lpage>17</lpage>
<author><surname>Morgante</surname> <given-names>L</given-names> </author><author><surname>Morgante</surname> <given-names>F</given-names> </author><author><surname>Moro</surname> <given-names>E</given-names> </author><title>How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire</title><source>Parkinsonism Relat Disord</source><year>2007</year><volume>13</volume><issue>8</issue><fpage>528</fpage><lpage>531</lpage>
<author><surname>Espay</surname> <given-names>AJ</given-names> </author><author><surname>Vaughan</surname> <given-names>JE</given-names> </author><author><surname>Marras</surname> <given-names>C</given-names> </author><author><surname>Fowler</surname> <given-names>R</given-names> </author><author><surname>Eckman</surname> <given-names>MH</given-names> </author><title>Early versus delayed bilateral subthalamic deep brain stimulation for parkinson&#8217;s disease: a decision analysis</title><source>Mov Disord</source><year>2010</year><volume>25</volume><issue>10</issue><fpage>1456</fpage><lpage>1463</lpage>
<author><surname>Deuschl</surname> <given-names>G</given-names> </author><title>Controlled trial of deep brain stimulation in early patients with Parkinson&#8217;s disease</title>Available from:
<author><surname>Charles</surname> <given-names>PD</given-names> </author><title>Deep brain stimulation (DBS) for early stage Parkinson&#8217;s disease (PD)</title>Available from:
<author><surname>Keeler</surname> <given-names>CE</given-names> </author><title>Gene therapy</title><source>J Hered</source><year>1947</year><volume>38</volume><issue>10</issue><fpage>294</fpage><lpage>298</lpage>
<author><surname>Morrow</surname> <given-names>JF</given-names> </author><title>The prospects for gene therapy in humans</title><source>Ann N Y Acad Sci</source><year>1976</year><volume>265</volume><fpage>13</fpage><lpage>21</lpage>
<author><surname>Nagatsu</surname> <given-names>T</given-names> </author><author><surname>Sawada</surname> <given-names>M</given-names> </author><title>Biochemistry of postmortem brains in Parkinson&#8217;s disease: historical overview and future prospects</title><source>J Neural Transm Suppl</source><year>2007</year><issue>72</issue><fpage>113</fpage><lpage>120</lpage>
<author><surname>Bankiewicz</surname> <given-names>KS</given-names> </author><author><surname>Forsayeth</surname> <given-names>J</given-names> </author><author><surname>Eberling</surname> <given-names>JL</given-names> </author><title>Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC</title><source>Mol Ther</source><year>2006</year><volume>14</volume><issue>4</issue><fpage>564</fpage><lpage>570</lpage>
<author><surname>Shen</surname> <given-names>Y</given-names> </author><author><surname>Muramatsu</surname> <given-names>S</given-names> </author><author><surname>Ikeguchi</surname> <given-names>K</given-names> </author><title>Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson&#8217;s disease</title><source>Hum Gene Ther</source><year>2000</year><volume>11</volume><issue>11</issue><fpage>1509</fpage><lpage>1519</lpage>
<author><surname>Muramatsu</surname> <given-names>S</given-names> </author><author><surname>Fujimoto</surname> <given-names>K</given-names> </author><author><surname>Ikeguchi</surname> <given-names>K</given-names> </author><title>Behavioral recovery in a primate model of Parkinson&#8217;s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes</title><source>Hum Gene Ther</source><year>2002</year><volume>13</volume><issue>3</issue><fpage>345</fpage><lpage>354</lpage>
<author><surname>Jarraya</surname> <given-names>B</given-names> </author><author><surname>Boulet</surname> <given-names>S</given-names> </author><author><surname>Ralph</surname> <given-names>GS</given-names> </author><title>Dopamine gene therapy for Parkinson&#8217;s disease in a nonhuman primate without associated dyskinesia</title><source>Sci Transl Med</source><year>2009</year><volume>1</volume><issue>2</issue><fpage>2ra4</fpage>
<title>Oxford BioMedica announces two-year phase I/II results of ProSavin&#174; in Parkinson&#8217;s disease &#8211; 6/14/2010</title>Available from:
<author><surname>Palfi</surname> <given-names>S</given-names> </author><title>Phase I/II study of the safety, efficacy and dose evaluation of ProSavin for the treatment of bilateral idiopathic Parkinson&#8217;s disease</title>Available from:
<author><surname>Bankiewicz</surname> <given-names>KS</given-names> </author><author><surname>Eberling</surname> <given-names>JL</given-names> </author><author><surname>Kohutnicka</surname> <given-names>M</given-names> </author><title>Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach</title><source>Exp Neurol</source><year>2000</year><volume>164</volume><issue>1</issue><fpage>2</fpage><lpage>14</lpage>
<author><surname>Eberling</surname> <given-names>JL</given-names> </author><author><surname>Jagust</surname> <given-names>WJ</given-names> </author><author><surname>Christine</surname> <given-names>CW</given-names> </author><title>Results from a phase I safety trial of hAADC gene therapy for Parkinson disease</title><source>Neurology</source><year>2008</year><volume>70</volume><issue>21</issue><fpage>1980</fpage><lpage>1983</lpage>
<author><surname>Muramatsu</surname> <given-names>S</given-names> </author><author><surname>Fujimoto</surname> <given-names>K</given-names> </author><author><surname>Kato</surname> <given-names>S</given-names> </author><title>A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson&#8217;s disease</title><source>Mol Ther</source><year>2010</year><volume>18</volume><issue>9</issue><fpage>1731</fpage><lpage>1735</lpage>
<author><surname>Stocchi</surname> <given-names>F</given-names> </author><author><surname>Ruggieri</surname> <given-names>S</given-names> </author><author><surname>Vacca</surname> <given-names>L</given-names> </author><author><surname>Olanow</surname> <given-names>CW</given-names> </author><title>Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson&#8217;s disease</title><source>Brain</source><year>2002</year><volume>125</volume><issue>Pt 9</issue><fpage>2058</fpage><lpage>2066</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><author><surname>Obeso</surname> <given-names>JA</given-names> </author><author><surname>Stocchi</surname> <given-names>F</given-names> </author><title>Continuous dopamine-receptor stimulation in advanced Parkinson&#8217;s disease</title><source>Trends Neurosci</source><year>2000</year><volume>23</volume><issue>10 Suppl</issue><fpage>S109</fpage><lpage>S115</lpage>
<author><surname>Chase</surname> <given-names>TN</given-names> </author><title>Levodopa therapy: consequences of the nonphysiologic replacement of dopamine</title><source>Neurology</source><year>1998</year><volume>50</volume><issue>5 Suppl 5</issue><fpage>S17</fpage><lpage>S25</lpage>
<author><surname>Carlsson</surname> <given-names>T</given-names> </author><author><surname>Winkler</surname> <given-names>C</given-names> </author><author><surname>Burger</surname> <given-names>C</given-names> </author><title>Reversal of dyskinesias in an animal model of Parkinson&#8217;s disease by continuous L-DOPA delivery using rAAV vectors</title><source>Brain</source><year>2005</year><volume>128</volume><issue>Pt 3</issue><fpage>559</fpage><lpage>569</lpage>
<author><surname>Kaplitt</surname> <given-names>MG</given-names> </author><author><surname>Feigin</surname> <given-names>A</given-names> </author><author><surname>Tang</surname> <given-names>C</given-names> </author><title>Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson&#8217;s disease: an open label, phase I trial</title><source>Lancet</source><year>2007</year><volume>369</volume><issue>9579</issue><fpage>2097</fpage><lpage>2105</lpage>
<author><surname>Stoessl</surname> <given-names>AJ</given-names> </author><title>Gene therapy for Parkinson&#8217;s disease: early data</title><source>Lancet</source><year>2007</year><volume>369</volume><issue>9579</issue><fpage>2056</fpage><lpage>2058</lpage>
<author><surname>Schapira</surname> <given-names>AH</given-names> </author><author><surname>Olanow</surname> <given-names>CW</given-names> </author><title>Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions</title><source>JAMA</source><year>2004</year><volume>291</volume><issue>3</issue><fpage>358</fpage><lpage>364</lpage>
<author><surname>Lin</surname> <given-names>LF</given-names> </author><author><surname>Doherty</surname> <given-names>DH</given-names> </author><author><surname>Lile</surname> <given-names>JD</given-names> </author><author><surname>Bektesh</surname> <given-names>S</given-names> </author><author><surname>Collins</surname> <given-names>F</given-names> </author><title>GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons</title><source>Science</source><year>1993</year><volume>260</volume><issue>5111</issue><fpage>1130</fpage><lpage>1132</lpage>
<author><surname>Nutt</surname> <given-names>JG</given-names> </author><author><surname>Burchiel</surname> <given-names>KJ</given-names> </author><author><surname>Comella</surname> <given-names>CL</given-names> </author><title>Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD</title><source>Neurology</source><year>2003</year><volume>60</volume><issue>1</issue><fpage>69</fpage><lpage>73</lpage>
<author><surname>Kordower</surname> <given-names>JH</given-names> </author><author><surname>Palfi</surname> <given-names>S</given-names> </author><author><surname>Chen</surname> <given-names>EY</given-names> </author><title>Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson&#8217;s disease</title><source>Ann Neurol</source><year>1999</year><volume>46</volume><issue>3</issue><fpage>419</fpage><lpage>424</lpage>
<author><surname>Kirik</surname> <given-names>D</given-names> </author><author><surname>Rosenblad</surname> <given-names>C</given-names> </author><author><surname>Bjorklund</surname> <given-names>A</given-names> </author><author><surname>Mandel</surname> <given-names>RJ</given-names> </author><title>Long-term rAA V-mediated gene transfer of GDNF in the rat Parkinson&#8217;s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system</title><source>J Neurosci</source><year>2000</year><volume>20</volume><issue>12</issue><fpage>4686</fpage><lpage>4700</lpage>
<author><surname>Wang</surname> <given-names>L</given-names> </author><author><surname>Muramatsu</surname> <given-names>S</given-names> </author><author><surname>Lu</surname> <given-names>Y</given-names> </author><title>Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson&#8217;s disease</title><source>Gene Ther</source><year>2002</year><volume>9</volume><issue>6</issue><fpage>381</fpage><lpage>389</lpage>
<author><surname>Kordower</surname> <given-names>JH</given-names> </author><author><surname>Emborg</surname> <given-names>ME</given-names> </author><author><surname>Bloch</surname> <given-names>J</given-names> </author><title>Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson&#8217;s disease</title><source>Science</source><year>2000</year><volume>290</volume><issue>5492</issue><fpage>767</fpage><lpage>773</lpage>
<author><surname>Lo Bianco</surname> <given-names>C</given-names> </author><author><surname>D&#233;glon</surname> <given-names>N</given-names> </author><author><surname>Pralong</surname> <given-names>W</given-names> </author><author><surname>Aebischer</surname> <given-names>P</given-names> </author><title>Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson&#8217;s disease</title><source>Neurobiol Dis</source><year>2004</year><volume>17</volume><issue>2</issue><fpage>283</fpage><lpage>289</lpage>
<author><surname>Gill</surname> <given-names>SS</given-names> </author><author><surname>Patel</surname> <given-names>NK</given-names> </author><author><surname>Hotton</surname> <given-names>GR</given-names> </author><title>Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease</title><source>Nat Med</source><year>2003</year><volume>9</volume><issue>5</issue><fpage>589</fpage><lpage>595</lpage>
<author><surname>Patel</surname> <given-names>NK</given-names> </author><author><surname>Bunnage</surname> <given-names>M</given-names> </author><author><surname>Plaha</surname> <given-names>P</given-names> </author><author><surname>Svendsen</surname> <given-names>CN</given-names> </author><author><surname>Heywood</surname> <given-names>P</given-names> </author><author><surname>Gill</surname> <given-names>SS</given-names> </author><title>Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study</title><source>Ann Neurol</source><year>2005</year><volume>57</volume><issue>2</issue><fpage>298</fpage><lpage>302</lpage>
<author><surname>Lang</surname> <given-names>AE</given-names> </author><author><surname>Gill</surname> <given-names>S</given-names> </author><author><surname>Patel</surname> <given-names>NK</given-names> </author><title>Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease [Erratum in: Ann Neurol. 2006;60(6):747]</title><source>Ann Neurol</source><year>2006</year><volume>59</volume><issue>3</issue><fpage>459</fpage><lpage>466</lpage>
<author><surname>Gasmi</surname> <given-names>M</given-names> </author><author><surname>Herzog</surname> <given-names>CD</given-names> </author><author><surname>Brandon</surname> <given-names>EP</given-names> </author><title>Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson&#8217;s disease</title><source>Mol Ther</source><year>2007</year><volume>15</volume><issue>1</issue><fpage>62</fpage><lpage>68</lpage>
<author><surname>Gasmi</surname> <given-names>M</given-names> </author><author><surname>Brandon</surname> <given-names>EP</given-names> </author><author><surname>Herzog</surname> <given-names>CD</given-names> </author><title>AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson&#8217;s disease</title><source>Neurobiol Dis</source><year>2007</year><volume>27</volume><issue>1</issue><fpage>67</fpage><lpage>76</lpage>
<author><surname>Kordower</surname> <given-names>JH</given-names> </author><author><surname>Herzog</surname> <given-names>CD</given-names> </author><author><surname>Dass</surname> <given-names>B</given-names> </author><title>Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys</title><source>Ann Neurol</source><year>2006</year><volume>60</volume><issue>6</issue><fpage>706</fpage><lpage>715</lpage>
<author><surname>Marks</surname> <given-names>WJ</given-names> <suffix>Jr</suffix> </author><author><surname>Ostrem</surname> <given-names>JL</given-names> </author><author><surname>Verhagen</surname> <given-names>L</given-names> </author><title>Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson&#8217;s disease: an open-label, phase I trial</title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><issue>5</issue><fpage>400</fpage><lpage>408</lpage>
<author><surname>Siffert</surname> <given-names>J</given-names> </author><title>Double-blind, multicenter, sham surgery controlled study of CERE-120 in subjects with idiopathic Parkinson&#8217;s disease</title>Available from:
<author><surname>Klejbor</surname> <given-names>I</given-names> </author><author><surname>Stachowiak</surname> <given-names>EK</given-names> </author><author><surname>Bharali</surname> <given-names>DJ</given-names> </author><title>ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology</title><source>J Neurosci Methods</source><year>2007</year><volume>165</volume><issue>2</issue><fpage>230</fpage><lpage>243</lpage>
<author><surname>Parkinson</surname> <given-names>J</given-names> </author><source>An Essay on the Shaking Palsy</source><other>London</other><publisher>Sherwood, Neely and Jones</publisher><year>1817</year>
